# Patent

## Title
Antisense modulation of fibroblast growth factor receptor 4 expression

## Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.

## Background
FIELD OF THE INVENTION
The present invention provides compositions and methods for modulating the expression of fibroblast growth factor receptor 4. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding fibroblast growth factor receptor 4. Such compounds have been shown to modulate the expression of fibroblast growth factor receptor 4 (FGFR4).
BACKGROUND OF THE INVENTION
Obesity is considered a long-term metabolic disease. There are several serious medical sequelae related to obesity. There are over 1 billion overweight individuals worldwide with 100 million clinically obese. The increasing health care costs of treating obesity related diseases in the US alone are estimated at over $100 billion annually. Current methods for treating obesity include behavioral modification, diet, surgery (gastroplasty), administering pharmaceutical agents that block appetite stimulating signals or absorption of nutrients (fat), and administering agents that increase thermogenesis or fat metabolism. Some of these methods have disadvantages in that they rely on patient resolve, are invasive, or have unwanted side effects. An understanding of the mechanisms by which obesity is regulated may provide important therapeutic information.
Obesity is frequently associated with insulin resistance and together constitutes risk factors for later development of type 2 diabetes and cardiovascular diseases. Insulin resistance occurs well before development of type 2 diabetes, and insulin is overproduced to compensate for the insulin resistance and to maintain normal glucose levels. Type 2 diabetes ensues, as the pancreas can no longer produce enough insulin to maintain normal glucose levels. Early stages of type 2 diabetes are associated with elevated levels of insulin but as the disease progresses the pancreas may fail to produce insulin, resulting in increased blood glucose levels. Diabetes is a significant risk factor for both heart disease and stroke and is the leading cause of blindness and end-stage renal failure.
Diabetes is a disorder characterized by hyperglycemia due to deficient insulin action that may result from reduced insulin production or insulin resistance or both. Diabetes mellitus is a polygenic disorder affecting a significant portion of the people in the world. It is divided into two types. In type I diabetes, or insulin-dependent diabetes mellitus (IDDM), patients produce little or no insulin, the hormone that regulates glucose utilization. In type 2 diabetes, or noninsulin-dependent diabetes mellitus (NIDDM), patients often have plasma insulin levels that are the same compared to nondiabetic humans; however, these patients have developed a resistance to the insulin stimulating effect of glucose and lipid metabolism in the main insulin-sensitive tissues, i.e., muscle, liver and adipose tissues, and the plasma insulin levels are insufficient to overcome the pronounced insulin resistance. Additionally, glucotoxicity, which results from long-term hyperglycemia, induces tissue-dependent insulin resistance (Nawano et al., Am. J. Physiol. Endocrinol. Metab., 278, E535-543) exacerbating the disease.
Type 2 diabetes accounts for over 90% of all diabetes cases. It is a metabolic disorder characterized by hyperglycemia leading to secondary complications such as neuropathy, nephropathy, retinopathy, hypertriglyceridemia, obesity, and other cardiovascular diseases generally referred to as metabolic syndrome.
Metabolic syndrome is a combination of medical disorders that increase one's risk for cardiovascular disease and diabetes. The symptoms, including high blood pressure, high triglycerides, decreased HDL and obesity, tend to appear together in some individuals. Metabolic syndrome is known under various other names, such as (metabolic) syndrome X, insulin resistance syndrome or Reaven's syndrome.
Diabetes and obesity (sometimes now collectively referred to as “diabesity”) are interrelated in that obesity is known to exacerbate the pathology of diabetes and greater than 60% of diabetics are obese. Most human obesity is associated with insulin resistance and leptin resistance. In fact, it has been suggested that obesity may have an even greater impact on insulin action than diabetes itself (Sindelka et al., Physiol Res., 51, 85-91). Additionally, several compounds on the market for the treatment of diabetes are known to induce weight gain, a very undesirable side effect to the treatment of this disease. Therefore, a compound that has the potential to treat both diabetes and obesity would provide a significant improvement over current treatments.
The fibroblast growth factor (FGF) family of signaling polypeptides regulates a diverse array of physiologic functions including mitogenesis, wound healing, cell differentiation and angiogenesis, and development. Both normal and malignant cell growth as well as proliferation are affected by changes in local concentration of these extracellular signaling molecules, which act as autocrine as well as paracrine factors. Autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers and to a hormone independent state (Powers et al., Endocr. Relat. Cancer, 7, 165-197). FGFs and their receptors are expressed at increased levels in several tissues and cell lines and overexpression is believed to contribute to the malignant phenotype. Furthermore, a number of oncogenes are homologues of genes encoding growth factor receptors, and there is a potential for aberrant activation of FGF-dependent signaling in human pancreatic cancer (Ozawa et al., Teratog. Carcinog. Mutagen., 21, 27-44).
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are critical for the development of most cell types. The cellular response to FGFs is transmitted via four types of high affinity transmembrane tyrosine-kinase fibroblast growth factor receptors numbered 1 to 4 (FGFR1 to FGFR4). There are at least 22 distinct FGF ligands and, as indicated above, four receptors (FGFR1-4). Different ligand/receptor pairs regulate cell growth in either a positive or negative manner, depending on the cell type and stage of development (Dailey et al., Cytokine Growth Factor Rev. 16, 233-247; Eswarakumar et al. Cytokine Growth Factor Rev., 16, 139-149) Upon ligand binding, the receptors dimerize and auto- or trans-phosphorylate specific cytoplasmic tyrosine residues to transmit an intracellular signal that ultimately reaches nuclear transcription factor effectors. Mitogenic signaling by these FGFRs is subsequently mediated via a number of pathways, including the ras/raf/MAP kinase cascade (Ozawa et al., Teratog. Carcinog. Mutagen., 21, 27-44).
Alternative splicing of the mRNA for the FGFRs 1, 2, 3 and 4 results in a wide range of receptor isoforms with varying ligand-binding properties and specificities. (Klagsbrun et al., Cell, 67, 229-231; Jaye et al., Biochim Biophys acta, 1135, 185-199). With different receptor possibilities and at least 22 ligands in the FGF family, there is a great deal of diversity in the FGF signaling pathway (Powers et al., Endocr. Relat. Cancer, 7, 165-197). Furthermore, expression and localization of the receptor isoforms is regulated in a tissue specific manner. Thus, the various FGFs may exert different influences upon different cell types by interacting with different receptor splice variants to initiate unique intracellular signaling cascades, leading to a panoply of cellular responses (Ozawa et al., Teratog. Carcinog. Mutagen., 21, 27-44).
Fibroblast growth factor receptor 4 (also known as FGF receptor-4, TKF; tyrosine kinase related to fibroblast growth factor receptor; hydroxyaryl-protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-4; FGFR4; CD334, FGFR4_HUMAN and JTK2) has high affinity for the acidic and/or basic fibroblast growth factors. (Armstrong et al., Genes Chromosomes Cancer, 4, 94-98).
The FGFR4 gene was mapped to 5q35.1-qter, the long (q) arm of chromosome 5 between position 35.1 and the end (terminus) of the arm, an area involved in leukemias and lymphomas. (Armstrong et al., Genes Chromosomes Cancer, 4, 94-98). More precisely, the FGFR4 gene is located from base pair 176,446,526 to base pair 176,457,732 on chromosome 5. The mouse Fgfr4 gene was mapped to mouse chromosome 13 located from base pair 54,235,030 to base pair to 54,251,130, in a region of homology of synteny with distal human 5q. (Avraham et al., Genomics, 21, 656-658).
The FGFR4 gene spans approximately 11.3 kb and is composed of 18 exons ranging in size from 17 to 600 bp. Exon 1 is untranslated and preceded by structural elements characteristic of a TATA-free promoter. Short tandem repeat polymorphisms were identified in introns 2 and 16 of FGFR4. (Kostrzewa et al., Mammalian Genome, 9, 131-135)
Although FGFRs generally have been shown to have wide distribution throughout the body. To date, FGFR4 has only been found in a few tissues. Among a wide variety of cells and tissues tested, including human lymphocytes and macrophages, FGFR4 was found to be expressed in the lung and in some tumors of lung origin as well as in malignancies not derived from lung tissues. (Holtrich et al., Proc. Nat. Acad. Sci., 88, 10411-10415). FGFR4 has also been found to be expressed in the liver and in adipose tissues. (Patel et al., JCEM, 90(2), 1226-1232).
FGFR4 has also been found to be expressed in certain carcinoma cell lines. In the FGFR4 gene transcript from a mammary carcinoma cell line, a G-to-A transition was discovered that resulted in the substitution of glycine by arginine at position 388 in the transmembrane domain of the receptor. The arg388 allele was also found in cell lines derived from a variety of other tumor types as well as in the germline of cancer patients and healthy individuals. Analysis of 3 geographically separated groups indicated that it occurs in approximately 50% of humans. Investigation of the clinical data of 84 breast cancer patients revealed that homo- or heterozygous carriers of the arg388 allele had a significantly reduced disease-free survival time (P=0.01) within a median follow-up of 62 months. Moreover, the FGFR4 arg388 allele was associated with early metastasis and advanced tumor-node metastasis stage in 82 colon cancer patients. Consistent with this finding, the mammary tumor cell line expressing FGFR4 arg388 exhibited increased motility relative to cells expressing the FGFR4 gly388 isotype. The results supported the conclusion that the FGFR4 arg388 allele represents a determinant that is innocuous in healthy individuals but predisposes cancer patients for significantly accelerated disease progression. (Bange et al., Cancer Res., 62, 840-847).
Fibroblast growth factor 1 (FGF1) plays an important role in adipogenesis. (Hutley et al., Diabetes, 53, 3097-3106). Further, FGF1 has been shown to bind FGFR4 which is also expressed in adipose tissue, (Patel et al., JCEM, 90(2), 1226-1232).
Additionally, FGFR4 has been shown to play a role in systemic lipid and glucose homeostasis. FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increase mass of insulin resistance, in addition to hypercholesterolemia. FGFR4 deficiency was shown to alleviate high-fat diet-induced fatty liver in a certain obese mouse model, which is also a correlate of metabolic syndrome. Restoration of FGFR4, specifically in hepatocytes of FGFR4 deficient mice, decrease plasma lipid level and restored the high fat diet-induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin. (Huang et al., Diabetes, 56, 2501-2510).
Effective treatments are needed for diabetes, obesity, metabolic syndrome and other diseases and conditions thereof. Provided herein is data establishing a role for FGFR4 in both diabetes and obesity. The data supports targeting of FGFR4 for treatment of a range of metabolic conditions, including diabetes, obesity and metabolic syndrome. Therefore, among the objectives herein, it is an object to provide compounds, compositions and methods for the treatment of such diseases and conditions.
Antisense technology is emerging as an effective means for reducing the expression of specific gene products and therefore may prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of FGFR4 expression.
The present invention provides compositions and methods for modulating FGFR4 expression, including modulation of the truncated mutants and alternatively spliced forms of FGFR4.
There remains a need for non-invasive therapies to promote weight loss in obese individuals with improved specificity to avoid side-effects and the present invention meets this need.
SUMMARY OF THE INVENTION
The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding fibroblast growth factor receptor 4 (FGFR4), and which modulate the expression of FGFR4. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of FGFR4 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of FGFR4 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.
Methods of reducing FGFR4 expression, activity and/or nucleic acid levels include administering to an individual a compound targeted to a nucleic acid encoding FGFR4. In certain embodiments, the compound is administered in a composition. Compounds targeted to a FGFR4 nucleic acid may be targeted to sequences as set forth in GENBANK® Accession Nos. AY493377.2, BC033313.1, BQ567109.1, NM—008011.1, nucleotides 790799 to 800614 of GENBANK® Accession No NT—039586.1, nucleotides 792000 to 811000 of GENBANK® Accession No. NT—039586.5, AF202063.1, AF359241.1, BF305431.1, BM803172.1, NM—002011.3, NM—022963.1, nucleotides 21323018 to 21335213 of GENBANK® Accession No. NT—023133.11; and nucleotides 8583892 to 8595932 of GENBANK® Accession No. NT—023132.9. All of the in GENBANK® Accession Nos. along with their associated sequence and structural data pertaining to such sequences including gene organization and structural elements that may be found in sequence databases such as the National Center for Biotechnology Information (NCBI) are incorporated herein by reference in their entirety.
In certain embodiments, the compounds are antisense compounds. In certain embodiments, the antisense compounds are oligomeric antisense compounds. In certain embodiment the oligomeric antisense compounds are or include modified or unmodified oligonucleotides. In certain embodiments, the antisense compounds are single stranded modified oligonucleotides.
Provided herein are methods, compounds and compositions for the treatment, prevention, slowed progression of and/or amelioration of diabetes, obesity, metabolic syndrome or related diseases or conditions thereof.
Provided herein are methods, compounds and compositions for lowering body fat content and improving blood glucose control or tolerance. In certain embodiments, the methods, compounds and compositions are for improving insulin sensitivity. Also provided are methods, compounds and compositions for the reduction of glucose levels. In certain embodiments, such glucose levels can be blood, plasma and/or serum glucose levels. In certain embodiments, such glucose levels can be fed or fasting glucose levels. In certain embodiments, such glucose levels are fed or fasting blood glucose levels. In certain embodiments, such methods include administering to a subject an antisense compound targeted to a nucleic acid encoding fibroblast growth factor receptor 4.
Further provided are methods for treating, preventing and/or ameliorating diabetes, obesity or metabolic syndrome, or another disease or condition thereof in an individual. Such method includes selecting an individual diagnosed with diabetes, obesity or metabolic syndrome or other disease or condition, administering to the individual a therapeutically effective amount of an antisense compound targeted to an fibroblast growth factor receptor 4 nucleic acid, and monitoring factors related to diabetes, obesity or metabolic syndrome or other related disease or condition.
Further provided are methods of increasing metabolic rate. Also provided are methods for lowering body weight gain. Also provided are methods for lowering abdominal fat. Abdominal fat can include perirenal and/or epididymal fat pad weight. Also provided are methods for lowering whole body fat content. Such methods include administering to a subject an antisense compound targeted to a nucleic acid encoding fibroblast growth factor receptor 4. In certain embodiments, such methods include the administration of a therapeutically effective amount of an antisense compound targeted to an fibroblast growth factor receptor 4 nucleic acid. In certain embodiments, the compound is administered in a composition. In certain embodiments the subject is an animal. In certain embodiments the animal is a human. In certain embodiments, the subject to which the antisense compound is administered and in which metabolic rate is increased and/or weight or fat content is lowered has one or more of the diseases or disorders listed above. In certain embodiments, the subject to which the antisense compound is administered and in which metabolic rate is increased and/or weight or fat content is lowered has obesity, diabetes or metabolic syndrome.
In certain embodiments, the methods, compounds and compositions are for the treatment, prevention and/or amelioration of diabetes, obesity and metabolic syndrome. In certain embodiments, the methods, compounds and compositions are for the treatment, prevention and/or amelioration of type 2 diabetes, and type 2 diabetes with dyslipidemia. In certain embodiments, such methods, compounds and compositions are used to treat, slow, prevent, delay or ameliorate the sequelae of diabetes including, but not limited to, retinopathy, neuropathy, cardiovascular complications and nephropathy.
It is understood that the terms individual and subject are used interchangeably herein and that any of the methods provided herein may be useful for a subject or an individual and that subject or individual can be an animal and particularly a human.
In any of the methods provided, an fibroblast growth factor receptor 4 nucleic acid may be the sequence set forth in SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14. Thus, the antisense compound may be targeted to an fibroblast growth factor receptor 4 nucleic acid as set forth in SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
In any of the aforementioned methods, administration of the antisense compound may comprise parenteral administration. The parenteral administration may further comprise subcutaneous or intravenous administration.
In any of the compounds, compositions or methods provided herein, the antisense compound may have least 80%, at least 90%, or at least 95% complementarity to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14. Alternatively, the antisense compound may have 100% complementarity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
The antisense compounds provided herein and employed in any of the described methods may be 8 to 80 subunits in length, 12 to 50 subunits in length, 12 to 30 subunits in length, 15 to 30 subunits in length, 18 to 24 subunits in length, 19 to 22 subunits in length, or 20 subunits in length. Further, the antisense compounds employed in any of the described methods may be antisense oligonucleotides 8 to 80 nucleotides in length, 12 to 50 nucleotides in length, 12 to 30 nucleotides in length 15 to 30 nucleotides in length, 18 to 24 nucleotides in length, 19 to 22 nucleotides in length, or 20 nucleotides in length.
In any of the compounds, compositions and methods provided, the antisense compound may be an antisense oligonucleotide. Moreover, the antisense oligonucleotide may be chimeric. The chimeric antisense oligonucleotide may be a gapmer antisense oligonucleotide. The gapmer antisense oligonucleotide may comprise a gap segment of ten 2′-deoxynucleotides positioned between wing segments of five 2′-MOE nucleotides.
In any of the compounds, compositions and methods provided, the antisense compounds may have at least one modified internucleoside linkage. Additionally, each internucleoside linkage may be a phosphorothioate internucleoside linkage. Each cytosine may be a 5-methyl cytosine.
A compound for treatment of obesity and metabolic syndrome may be an antisense compound 12 to 30 nucleobases targeted to an fibroblast growth factor receptor 4 nucleic acid. The compound may have at least 70% to 100% complementarity to any of SEQ ID NOSEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14. The antisense oligonucleotide may be a gapmer antisense oligonucleotide. The gapmer antisense oligonucleotide may comprise a gap segment of ten 2′-deoxynucleotides positioned between wing segments of five 2′-MOE nucleotides.
The antisense compounds may have at least one modified internucleoside linkage. Additionally, each internucleoside linkage may be a phosphorothioate internucleoside linkage. Each cytosine may be a 5-methyl cytosine.


DETAILED DESCRIPTION OF THE INVENTION
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by on of skill in the art to which the invention(s) belong. Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of subjects. Certain such techniques and procedures may be found for example in “Antisense Drug Technology: Principles, Strategies, and Applications.” by Stanley Crooke, Boca Raton: Taylor & Francis Group, 2008; “Carbohydrate Modifications in Antisense Research” Edited by Sangvi and Cook, American Chemical Society, Washington D.C., 1994; and “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., 18th edition, 1990; and which is hereby incorporated by reference for any purpose. Where permitted, all patents, patent applications, published applications and publications, GENBANK sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. All of the in GENBANK® Accession Nos. along with their associated sequence and structural data pertaining to such sequences including gene organization and structural elements that may be found in sequence databases such as the National Center for Biotechnology Information (NCBI) are incorporated herein by reference in their entirety. In the event that there is a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.
“FGFR4” means fibroblast growth factor receptor 4.
“Obesity” is defined as an excessively high amount of body fat or adipose tissue in relation to lean body mass. The amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits. Body fat distribution can be estimated by skin-fold measures, waist-to-hip circumference ratios, or techniques such as ultrasound, computed tomography, or magnetic resonance imaging. According to the Center for Disease Control and Prevention, individuals with a body mass index (BMI) of 30 or more are considered obese.
“Insulin resistance” is defined as the condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells results in hydrolysis of stored triglycerides, which elevates free fatty acids in the blood plasma. Insulin resistance in muscle reduces glucose uptake whereas insulin resistance in liver reduces glucose storage, with both effects serving to elevate blood glucose. High plasma levels of insulin and glucose due to insulin resistance often leads to metabolic syndrome and type 2 diabetes.
“Diabetes” is (also called diabetes mellitus), is a metabolic disorder typically characterized by high levels of blood glucose. Diabetes mellitus can take one of two forms: type I or type 2.
“Type I diabetes” (also known as insulin-dependent diabetes mellitus or IDDM—strikes people under age 35, typically appearing suddenly between the ages of 10 and 16. In this form of the illness, which affects 10 percent of diabetics, a virus or autoimmune reaction probably destroys the insulin-producing cells. Insulin normally enables sugar to pass from the blood into the body's cells. Since a person with type I diabetes has completely stopped producing insulin, lifelong treatment means taking insulin several times daily.
“Type 2 diabetes,” (also known as diabetes mellitus type 2, and formerly called diabetes mellitus type 2, non-insulin-dependent diabetes (NIDDM), obesity related diabetes, or adult-onset diabetes) is a metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency, and hyperglycemia.
“Diabetic dyslipidemia” or “Type 2 diabetes with dyslipidemia” means a condition characterized by Type 2 diabetes, reduced HDL-C, elevated serum triglycerides, and elevated small, dense LDL particles.
“Metabolic disorder” refers to a condition characterized by an alteration or disturbance in metabolic function. “Metabolic” and “metabolism” are terms well know in the art and generally include the whole range of biochemical processes that occur within a living organism. Metabolic disorders include, but are not limited to, hyperglycemia, prediabetes, diabetes (type I and type 2), obesity, insulin resistance and metabolic syndrome.
“Metabolic syndrome” means a condition characterized by a clustering of lipid and non-lipid risk factors of metabolic origin. In certain embodiments, metabolic syndrome is identified by the presence of any 3 of the following factors: waist circumference of greater than 102 cm in men or greater than 88 cm in women; serum triglyceride of at least 150 mg/dL; HDL-C less than 40 mg/dL in men or less than 50 mg/dL in women; blood pressure of at least 130/85 mmHg; and fasting glucose of at least 110 mg/dL. These determinants can be readily measured in clinical practice (JAMA, 2001, 285: 2486-2497).
“IPGTT” or “Intraperitoneal Glucose Tolerance Testing” in medical practice is defined as the administration of glucose through Intraperitoneal injection to determine how quickly it is cleared from the blood. The test is usually used to test for diabetes, insulin resistance, and sometimes reactive hypoglycemia.
“ITT” or “Insulin Tolerance Test” in medical practice is defined as a test to measure insulin sensitivity through the hormone response to the stress of a low blood sugar level. The test is usually used to test for diabetes, insulin resistance, and sometimes reactive hypoglycemia.
“Metabolic rate” means the rate of metabolism or the amount of energy expended in a give period. Metabolic rate also is the amount of energy expended while at rest in a neutrally temperate environment, in the post-absorptive state (meaning that the digestive system is inactive, which requires about twelve hours of fasting in humans). The release of energy in this state is sufficient only for the functioning of the vital organs, such as the heart, lungs, brain and the rest of the nervous system, liver, kidneys, sex organs, muscles and skin. Metabolic rate decreases with age and with the loss of lean body mass. Increased cardiovascular exercise and muscle mass can increase metabolic rate. Illness, previously consumed food and beverages, environmental temperature, and stress levels can affect one's overall energy expenditure, and can affect one's metabolic rate as revealed by gas analysis. It is measured when the person is at complete rest, but awake.
“Prevention” refers to delaying or forestalling the onset or development of a condition or disease for a period of time from hours to days, preferably weeks to months.
“Amelioration” refers to a lessening of at least one indicator of the severity of a condition or disease. The severity of indicators may be determined by subjective or objective measures which are known to those skilled in the art.
“Treatment” refers to administering a composition of the invention to effect an alteration or improvement of the disease or condition. Prevention, amelioration, and/or treatment may require administration of multiple doses at regular intervals, or prior to onset of the disease or condition to alter the course of the disease or condition. Moreover, a single agent may be used in a single individual for each prevention, amelioration, and treatment of a condition or disease sequentially, or concurrently.
“Slows progression” means decrease in the development of the said disease.
“Cures” means a method or course that restores health or a prescribed treatment for an illness.
“Expression” refers to all the functions and steps by which a gene's coded information is converted into structures present and operating in a cell. Such structures include, but are not limited to the products of transcription and translation.
“Modulation” refers to a perturbation of function or activity when compared to the level of the function or activity prior to modulation. For example, modulation includes the change, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in gene expression. As further example, modulation of expression can include perturbing splice site selection of pre-mRNA processing.
“Animal” refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.
“Subject” refers to an animal, including, but not limited to a human, to whom a pharmaceutical composition is administered.
“Oligonucleotide” means a polymer of linked nucleosides each of which can be modified or unmodified, independent one from another.
“Single-stranded modified oligonucleotide” means a modified oligonucleotide which is not hybridized to a complementary strand.
“Nucleoside” means a nucleobase linked to a sugar.
“Linked nucleosides” means adjacent nucleosides which are bonded together.
“Nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid.
“Contiguous nucleobases” means nucleobases immediately adjacent to each other.
“Modified oligonucleotide” means an oligonucleotide comprising a modified internucleoside linkage, a modified sugar, and/or a modified nucleobase.
“Nucleobase sequence” means the order of contiguous nucleobases independent of any sugar, linkage, and/or nucleobase modification.
“Internucleoside linkage” refers to the chemical bond between nucleosides.
“5-methylcytosine” means a cytosine modified with a methyl group attached to the 5′ position. A 5-methylcytosine is a modified nucleobase
“Modified internucleoside linkage” refers to a substitution and/or any change from a naturally occurring internucleoside bond (i.e. a phosphodiester internucleoside bond).
“Modified nucleobase” refers to any nucleobase other than adenine, cytosine, guanine or thymidine.
“Phosphorothioate linkage” means a linkage between nucleosides where the phosphodiester bond is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom. A phosphorothioate linkage is a modified internucleoside linkage.
“2′-O-methoxyethyl” refers to an O-methoxy-ethyl modification of the 2′ position of a furosyl ring. A 2′-O-methoxyethyl modified sugar is a modified sugar.
“Modified sugar” refers to a substitution and/or any change from a natural sugar.
“Diluent” means an ingredient in a composition that lacks pharmacological activity, but is pharmaceutically necessary or desirable. For example, in drugs that are injected the diluent may be a liquid, e.g. saline solution.
“Salts” mean physiologically and pharmaceutically acceptable salts of antisense compounds, i.e., salts that retain the desired biological activity of the parent oligonucleotide and do not impart undesired toxicological effects thereto.
“Linked deoxynucleoside” means a nucleic acid base (A, G, C, T, U) substituted by deoxyribose linked by a phosphate ester to form a nucleotide.
“Pharmaceutically acceptable carrier “or “excipient” means a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition.
“Bicyclic sugar” means a furosyl ring modified by the bridging of two non-geminal ring atoms. A bicyclic sugar is a modified sugar.
“Pharmaceutical agent” refers to a substance provides a therapeutic benefit when administered to a subject.
“Therapeutically effective amount” refers to an amount of a pharmaceutical agent that provides a therapeutic benefit to an animal. In certain embodiments, a therapeutically effective amount of antisense compound targeted to an FGFR4 nucleic acid is an amount that improves adiposity in the individual.
“Prophylactically effective amount” refers to an amount of a pharmaceutical agent that provides a prophylactic or preventative benefit to an animal. In certain embodiments, a prophylactically effective amount of antisense compound targeted to an FGFR4 nucleic acid is an amount that improves adiposity in the individual.
A “Pharmaceutical composition” means a mixture of substances suitable for administering to an individual. For example, a pharmaceutical composition may comprise an antisense oligonucleotide and a sterile aqueous solution.
“Administering” means providing a pharmaceutical agent or composition to an individual, and includes, but is not limited to administering by a medical professional and self-administering.
“Co-administration” refers to administration of two or more pharmaceutical agents to an animal. The two or more pharmaceutical agents may be in a single pharmaceutical composition, or may be in separate pharmaceutical compositions. Each of the two or more pharmaceutical agents may be administered through the same or different routes of administration. Co-administration encompasses administration in parallel or sequentially.
“Administered concomitantly” refers to the administration of two agents at the same time in any manner in which the pharmacological effects of both are manifest in the patient at the same time. Concomitant administration does not require that both agents be administered in a single pharmaceutical composition, in the same dosage form, or by the same route of administration.
“Individual” means a human or non-human animal selected for treatment or therapy.
“Individual”, “subject”, and “human” may be used interchangeably herein.
“Duration” means the period of time during which an activity or event continues. In certain embodiments, the duration of treatment is the period of time during which doses of a pharmaceutical agent are administered.
“Parenteral administration,” means administration through injection or infusion. Parenteral administration includes, but is not limited to, subcutaneous administration, intravenous administration, or intramuscular administration.
“Subcutaneous administration” means administration just below the skin.
“Intravenous administration” means administration into a vein.
“Intraperitoneal administration” means administration through infusion or injection into the peritoneum.
“Dose” means a specified quantity of a pharmaceutical agent provided in a single administration. In certain embodiments, a dose may be administered in two or more boluses, tablets, or injections. For example, in certain embodiments, where subcutaneous administration is desired, the desired dose requires a volume not easily accommodated by a single injection. In such embodiments, two or more injections may be used to achieve the desired dose. In certain embodiments, a dose may be administered in two or more injections to minimize injection site reaction in an individual.
“Dosage unit” means a form in which a pharmaceutical agent is provided. In certain embodiments, a dosage unit is a vial containing lyophilized antisense oligonucleotide. In certain embodiments, a dosage unit is a vial containing reconstituted antisense oligonucleotide.
“Pharmaceutical agent” means a substance which provides a therapeutic benefit when administered to an individual. For example, in certain embodiments, an antisense oligonucleotide targeted to FGFR4 is a pharmaceutical agent.
“Active pharmaceutical ingredient” means the substance in a pharmaceutical composition that provides a desired effect.
“Major risk factors” refers to factors that contribute to a high risk for a particular disease or condition
“Efficacy” means the ability to produce a desired effect.
“Acceptable safety profile” means a pattern of side effects that is within clinically acceptable limits.
“Side effects” means physiological responses attributable to a treatment other than desired effects. In certain embodiments, side effects include, without limitation, injection site reactions, liver function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system abnormalities, and myopathies. For example, increased aminotransferase levels in serum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver toxicity or liver function abnormality.
“Injection site reaction” means inflammation or abnormal redness of skin at a site of injection in an individual.
“Individual compliance” means adherence to a recommended or prescribed therapy by an individual.
“Therapeutic lifestyle change” means dietary and lifestyle changes intended to lower overall body weight and reduce the risk of developing diabetes and obesity, and includes recommendations for dietary intake of total daily calories, total fat, saturated fat, polyunsaturated fat, monounsaturated fat, carbohydrate, protein, cholesterol, insoluble fiber, as well as recommendations for physical activity.
Overview
Effective treatments are needed for diabetes, obesity, metabolic syndrome and other diseases and conditions thereof. Because of its role in both diabetes and obesity, FGFR4 has been developed as an antisense target. Antisense compounds have been developed which target nucleic acid encoding FGFR4 and which function to reduce FGFR4 levels in a subject.
The antisense compounds provided herein are therefore useful for treating a number of metabolic conditions, including diabetes, obesity and metabolic syndrome. Such treatments encompass a therapeutic regimen that results in a clinically desirable outcome. The clinically desired outcomes may be tied to glucose metabolism. For example, the antisense compounds and methods provided herein are useful for improving blood glucose control or tolerance and for improving insulin sensitivity in a subject in need thereof. The antisense compounds and methods provided herein are also useful for reducing glucose levels in a subject in need thereof. The compounds and methods are particularly useful for reducing blood, plasma and/or serum glucose levels. The compounds and methods are useful for reducing both fed and fasting glucose levels. Such clinical outcomes are desirable in disease and disorders related to glucose metabolism and insulin resistance including, for example, diabetes, particularly type 2 diabetes, obesity and metabolic syndrome. Therefore, the antisense compounds and methods provided herein are useful for the treatment of such diseases and disorders.
The compounds and methods are also particularly useful for increasing metabolic rate and, in turn, lowering body weight gain. The compounds and methods are also particularly useful for lowering epididymal and perirenal fat pad weight and whole body fat content. Such clinical outcomes are desirable in conditions such as metabolic syndrome, obesity, diabetes, in particular type 2 diabetes, type 2 diabetes with dyslipidemia. Therefore, the antisense compounds and methods provided herein are useful for the treatment of such diseases and disorders.
Metabolic syndrome is a condition characterized by a clustering of lipid and non-lipid risk factors of metabolic origin. In certain embodiments, metabolic syndrome is identified by the presence of any 3 of the following factors: waist circumference of greater than 102 cm in men or greater than 88 cm in women; serum triglyceride of at least 150 mg/dL; HDL-C less than 40 mg/dL in men or less than 50 mg/dL in women; blood pressure of at least 130/85 mmHg; and fasting glucose of at least 110 mg/dL. These determinants can be readily measured in clinical practice (JAMA, 2001, 285: 2486-2497). Accordingly, the compounds and methods provided herein may be used to treat individuals exhibiting one or more risk factors for metabolic syndrome. Particularly, the compounds and methods provided herein may be used to reduce body weight, thereby likely reducing waist circumference, and fasting glucose levels.
As illustrated herein, administration of an antisense oligonucleotide targeted to FGFR4 to animals models of diabetes and obesity which exhibit insulin resistance, hyperglycemia and hyperlipidemia, resulted in antisense inhibition of FGFR4, a reduction in body fat weight, percentage body fat content and tissue weight of both epididymal and perirenal fat. Particularly, expression of FGFR4 was reduced. Thus, it is demonstrated that in an experimental model of obesity, antisense inhibition of FGFR4 results in reduced glucose levels and reduced lipogenesis. Accordingly, provided herein are methods of reducing lipogenesis and blood glucose through the administration of an antisense compound targeted to an FGFR4 nucleic acid. Blood glucose and triglyceride levels are considered a risk factor for development of diabetes, obesity and metabolic syndrome. Accordingly, also provided herein are methods for the treatment, prevention and/or amelioration of diabetes, obesity and metabolic syndrome, and for the treatment, prevention and/or amelioration of associated disorders.
Obesity is characterized by an excess of subcutaneous fat in proportion to lean body mass. In obesity, adipose tissue, as opposed to most tissues in the body, will continue to grow. Growth of the adipose tissue results from both the enlargement of mature adipocytes and the formation of new adipocytes from adipocyte precursor cells (preadipocytes). Thus, fat accumulation is associated with increase in the size (hypertrophy) as well as the number (hyperplasia) of adipose tissue cells.
The Examples provided herein show that reduction of FGFR4 by antisense oligonucleotides results in a reduction in body fat content. As indicated by the description of fat accumulation above, the lowered body fat content is partially due to a decrease in adipocyte size (see FIG. 4.) Additionally, due to the function of FGFR4 in cell differentiation and angiogenesis, the lowered body fat content is also achieved by a reduction adipocyte proliferation.
Certain Indications
In certain embodiments, the invention provides methods of treating an individual comprising administering one or more pharmaceutical compositions of the present invention. In certain embodiments, the individual has diabetes, obesity, metabolic syndrome and/or associated disorders including but not limited to type 2 diabetes, type 2 diabetes with dyslipidemia, dyslipidemia, hyperlipidemia, or non-alcoholic fatty liver disease.
In one embodiment are methods for methods for treating obesity or metabolic syndrome, or alternatively methods for decreasing blood glucose levels or triglyceride levels, by administering to an individual suffering from obesity or elevated glucose or triglyceride levels a therapeutically effective amount of an antisense compound targeted to an FGFR4 nucleic acid. In another embodiment, a method of decreasing body fat content comprises selecting an individual in need of a decrease in body fat content, and administering to the individual a therapeutically effective amount of an antisense compound targeted to an FGFR4 nucleic acid. In a further embodiment, a method of reducing risk of development of obesity and metabolic syndrome includes selecting an individual having elevated blood glucose or triglyceride levels and one or more additional indicators risk of development of obesity or metabolic syndrome, and administering to the individual a therapeutically effective amount of an antisense compound targeted to an FGFR4 nucleic acid.
In one embodiment, administration of a therapeutically effective amount of an antisense compound targeted an FGFR4 nucleic acid is accompanied by monitoring of glucose levels in the serum of an individual, to determine an individual's response to administration of the antisense compound. An individual's response to administration of the antisense compound is used by a physician to determine the amount and duration of therapeutic intervention.
A physician may determine the need for therapeutic intervention for individuals in cases where more or less aggressive blood glucose or adiposity therapy is needed. The practice of the methods herein may be applied to any altered guidelines provided by the NCEP, or other entities that establish guidelines for physicians used in treating any of the diseases or conditions listed herein, for determining and diagnosing metabolic syndrome.
In one embodiment, administration of an antisense compound targeted an FGFR4 nucleic acid is parenteral administration. Parenteral administration may be intravenous or subcutaneous administration. Accordingly, in another embodiment, administration of an antisense compound targeted to an FGFR4 nucleic acid is intravenous or subcutaneous administration. Administration may include multiple doses of an antisense compound targeted to an FGFR4 nucleic acid.
In certain embodiments a pharmaceutical composition comprising an antisense compound targeted to FGFR4 is for use in therapy. In certain embodiments, the therapy is the reduction of blood glucose, body fat content, or fat tissue weight in an individual. In certain embodiments, the therapy is the treatment of obesity, metabolic syndrome, mixed dyslipidemia, type 2 diabetes, type 2 diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, or non-alcoholic fatty liver disease.
In certain embodiments pharmaceutical composition comprising an antisense compound targeted to FGFR4 is used for the preparation of a medicament for reduction of blood glucose, blood glucose, body fat content, or fat tissue weight. In certain embodiments pharmaceutical composition comprising an antisense compound targeted to FGFR4 is used for the preparation of a medicament for reducing body fat content and obesity. In certain embodiments an antisense compound targeted to FGFR4 is used for the preparation of a medicament for the treatment of metabolic syndrome disorders. In certain embodiments an antisense compound targeted to FGFR4 is used for the preparation of a medicament of type 2 diabetes, type 2 diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease.
Certain Combination Therapies
In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared separately.
In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising an antisense compound targeted to a FGFR4 nucleic acid include glucose-lowering agents and therapies. In some embodiments, the glucose-lowering agent is a PPAR agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a GLP-1 analog, insulin or an insulin analog, an insulin secretagogue, a SGLT2 inhibitor, a human amylin analog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, or a sulfonylurea.
In some embodiments, the glucose-lowering therapeutic is a GLP-1 analog. In some embodiments, the GLP-1 analog is exendin-4 or liraglutide.
In other embodiments, the glucose-lowering therapeutic is a sulfonylurea. In some embodiments, the sulfonylurea is acetohexamide, chlorpropamide, tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or a gliclazide.
In some embodiments, the glucose lowering drug is a biguanide. In some embodiments, the biguanide is metformin, and in some embodiments, blood glucose levels are decreased without increased lactic acidosis as compared to the lactic acidosis observed after treatment with metformin alone.
In some embodiments, the glucose lowering drug is a meglitinide. In some embodiments, the meglitinide is nateglinide or repaglinide.
In some embodiments, the glucose-lowering drug is a thiazolidinedione. In some embodiments, the thiazolidinedione is pioglitazone, rosiglitazone, or troglitazone. In some embodiments, blood glucose levels are decreased without greater weight gain than observed with rosiglitazone treatment alone.
In some embodiments, the glucose-lowering drug is an alpha-glucosidase inhibitor. In some embodiments, the alpha-glucosidase inhibitor is acarbose or miglitol.
In a certain embodiment, a co-administered glucose-lowering agent is ISIS 113715.
In a certain embodiment, glucose-lowering therapy is therapeutic lifestyle change.
In certain such embodiments, the glucose-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the glucose-lowering agent is administered following administration of a pharmaceutical composition of the present invention. In certain such embodiments the glucose-lowering agent is administered at the same time as a pharmaceutical composition of the present invention. In certain such embodiments the dose of a co-administered glucose-lowering agent is the same as the dose that would be administered if the glucose-lowering agent was administered alone. In certain such embodiments the dose of a co-administered glucose-lowering agent is lower than the dose that would be administered if the glucose-lowering agent was administered alone. In certain such embodiments the dose of a co-administered glucose-lowering agent is greater than the dose that would be administered if the glucose-lowering agent was administered alone.
In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising an antisense compound targeted to a FGFR4 nucleic acid include anti-obesity agents. Such anti-obesity agents include but are not limited to Orlistat, Sibutramine, or Rimonabant, and may be administered as described above as adipose or body weight lowering agents.
In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising an antisense compound targeted to a FGFR4 nucleic acid include antipsychotic agents. Such antipsychotic agents therapeutics may be administered as described above to reduce metabolic abnormalities associated with treatment with antipsychotic agents.
Due to the ability of FGFR4 antisense oligonucleotides to increase metabolic rate and insulin sensitivity and reduce adiposity and weight gain, these compounds can be administered to reduce metabolic abnormalities associated with treatment with antipsychotic agents. In certain embodiments the FGFR4 antisense oligonucleotide is delivered in a method of reducing metabolic abnormalities associated with the therapeutic use of psychotherapeutic agents. Such weight inducing antipsychotic agents include, but are not limited to clozapine, olanzapine, aripiprazole, risperidone and ziprasidone.
In certain embodiments the FGFR4 antisense oligonucleotide is delivered concomitant with delivery of the psychotherapeutic agent. Alternatively, delivery can be in the same formulation or can be administered separately. In certain embodiments, FGFR4 antisense oligonucleotide is administered prior to the treatment with antipsychotic agents. In a certain embodiment, the FGFR4 antisense oligonucleotide is administered after treatment with an obesity inducing drug or agent is ceased. In a particular embodiment administering of the FGFR4 antisense compound results in increased metabolic rate or decreasing adiposity or both without affecting the CNS effects of the psychotherapeutic agent
In certain embodiments, FGFR4 antisense oligonucleotides are administered in combination either in the same formulation or separate formulations with other anti-obesity drugs or agents. In certain embodiment, the anti-obesity agents are CNS based such as, but not limited to, sibutramine or GLP-1 based such as, but not limited to, liraglutide.
Further provided is a method of administering an antisense compound targeted to a FGFR4 nucleic acid via injection and further including administering a topical steroid at the injection site.
Further examples of pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include, but are not limited to, corticosteroids, including but not limited to prednisone; immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti-inflammatory agents, including, but not limited to non-steroidal anti-inflammatory drugs (e.g., ibuprofen, COX-1 inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins, sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines.
In certain embodiments, the pharmaceutical compositions of the present invention may be administered in conjunction with a lipid-lowering therapy. In certain such embodiments, a lipid-lowering therapy is therapeutic lifestyle change. In certain such embodiments, a lipid-lowering therapy is LDL apheresis.
Antisense Compounds
Oligomeric compounds include, but are not limited to, oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics, antisense compounds, antisense oligonucleotides, and siRNAs. An oligomeric compound may be “antisense” to a target nucleic acid, meaning that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.
In certain embodiments, an antisense compound has a nucleobase sequence that, when written in the 5′ to 3′ direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase sequence that, when written in the 5′ to 3′ direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.
In certain embodiments, the present invention provides oligonucleotides of any of a variety of ranges of lengths. In certain embodiments, the invention provides oligonucleotides consisting of X-Y linked oligonucleosides, where X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that X≦Y. For example, in certain embodiments, the invention provides oligonucleotides comprising: 8-9, 8-10, 8-11, 8-12, 8-13, 8-14, 8-15, 8-16, 8-17, 8-18, 8-19, 8-20, 8-21, 8-22, 8-23, 8-24, 8-25, 8-26, 8-27, 8-28, 8-29, 8-30, 9-10, 9-11, 9-12, 9-13, 9-14, 9-15, 9-16, 9-17, 9-18, 9-19, 9-20, 9-21, 9-22, 9-23, 9-24, 9-25, 9-26, 9-27, 9-28, 9-29, 9-30, 10-11, 10-12, 10-13, 10-14, 10-15, 10-16, 10-17, 10-18, 10-19, 10-20, 10-21, 10-22, 10-23, 10-24, 10-25, 10-26, 10-27, 10-28, 10-29, 10-30, 11-12, 11-13, 11-14, 11-15, 11-16, 11-17, 11-18, 11-19, 11-20, 11-21, 11-22, 11-23, 11-24, 11-25, 11-26, 11-27, 11-28, 11-29, 11-30, 12-13, 12-14, 12-15, 12-16, 12-17, 12-18, 12-19, 12-20, 12-21, 12-22, 12-23, 12-24, 12-25, 12-26, 12-27, 12-28, 12-29, 12-30, 13-14, 13-15, 13-16, 13-17, 13-18, 13-19, 13-20, 13-21, 13-22, 13-23, 13-24, 13-25, 13-26, 13-27, 13-28, 13-29, 13-30, 14-15, 14-16, 14-17, 14-18, 14-19, 14-20, 14-21, 14-22, 14-23, 14-24, 14-25, 14-26, 14-27, 14-28, 14-29, 14-30, 15-16, 15-17, 15-18, 15-19, 15-20, 15-21, 15-22, 15-23, 15-24, 15-25, 15-26, 15-27, 15-28, 15-29, 15-30, 16-17, 16-18, 16-19, 16-20, 16-21, 16-22, 16-23, 16-24, 16-25, 16-26, 16-27, 16-28, 16-29, 16-30, 17-18, 17-19, 17-20, 17-21, 17-22, 17-23, 17-24, 17-25, 17-26, 17-27, 17-28, 17-29, 17-30, 18-19, 18-20, 18-21, 18-22, 18-23, 18-24, 18-25, 18-26, 18-27, 18-28, 18-29, 18-30, 19-20, 19-21, 19-22, 19-23, 19-24, 19-25, 19-26, 19-29, 19-28, 19-29, 19-30, 20-21, 20-22, 20-23, 20-24, 20-25, 20-26, 20-27, 20-28, 20-29, 20-30, 21-22, 21-23, 21-24, 21-25, 21-26, 21-27, 21-28, 21-29, 21-30, 22-23, 22-24, 22-25, 22-26, 22-27, 22-28, 22-29, 22-30, 23-24, 23-25, 23-26, 23-27, 23-28, 23-29, 23-30, 24-25, 24-26, 24-27, 24-28, 24-29, 24-30, 25-26, 25-27, 25-28, 25-29, 25-30, 26-27, 26-28, 26-29, 26-30, 27-28, 27-29, 27-30, 28-29, 28-30, or 29-30 liked nucleosides.
In certain embodiments, an antisense compound targeted to an FGFR4 nucleic acid is 8 to 80, 12 to 50, 12 to 30 or 15 to 30 subunits in length. In other words, antisense compounds are from 8 to 80, 12 to 50, 12 to 30 or 15 to 30 linked subunits. In certain such embodiments, the antisense compounds are 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 subunits in length.
In certain embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 12 to 30 nucleotides in length. In certain such embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.
In certain embodiment, an antisense compound targeted to an FGFR4 nucleic acid is 15 to 30 subunits in length. In other words, antisense compounds are from 15 to 30 linked subunits. In certain such embodiments, the antisense compounds are 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 subunits in length.
In certain embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 15 to 30 nucleotides in length. In certain such embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.
In certain embodiments, an antisense compound targeted to an FGFR4 nucleic acid is 18 to 24 subunits in length. In other words, antisense compounds are from 18 to 24 linked subunits. In one embodiment, the antisense compounds are 18, 19, 20, 21, 22, 23, or 24 subunits in length.
In certain embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 18 to 24 nucleotides in length. In certain such embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 18, 19, 20, 21, 22, 23, or 24 nucleotides in length.
In certain embodiments, an antisense compound targeted to an FGFR4 nucleic acid is 19 to 22 subunits in length. In other words, antisense compounds are from 19 to 22 linked subunits. This embodies antisense compounds of 19, 20, 21, or 22 subunits in length.
In certain embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 19 to 22 nucleotides in length. In certain such embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 19, 20, 21, or 22 nucleotides in length.
In certain embodiments, an antisense compound targeted to an FGFR4 nucleic acid is 20 subunits in length. In certain such embodiments, antisense compounds are 20 linked subunits in length.
In certain embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 20 nucleotides in length. In certain such embodiments, an antisense oligonucleotide targeted to an FGFR4 nucleic acid is 20 linked nucleotides in length.
In certain embodiments, a shortened or truncated antisense compound targeted to an FGFR4 nucleic acid has a single subunit deleted from the 5′ end (5′ truncation), or alternatively from the 3′ end (3′ truncation). A shortened or truncated antisense compound targeted to an FGFR4 nucleic acid may have two subunits deleted from the 5′ end, or alternatively may have two subunits deleted from the 3′ end, of the antisense compound. Alternatively, the deleted nucleosides may be dispersed throughout the antisense compound, for example, in an antisense compound having one nucleoside deleted from the 5′ end and one nucleoside deleted from the 3′ end.
When a single additional subunit is present in a lengthened antisense compound, the additional subunit may be located at the 5′ or 3′ end of the antisense compound. When two are more additional subunits are present, the added subunits may be adjacent to each other, for example, in an antisense compound having two subunits added to the 5′ end (5′ addition), or alternatively to the 3′ end (3′ addition), of the antisense compound. Alternatively, the added subunits may be dispersed throughout the antisense compound, for example, in an antisense compound having one subunit added to the 5′ end and one subunit added to the 3′ end.
It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including those with 1 or 3 mismatches.
Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide demonstrated potent anti-tumor activity in vivo.
(Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a series of tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.
Antisense compounds targeted to an FGFR4 nucleic acid are synthesized in vitro and do not include genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. In certain embodiments, the compounds provided herein targeted to an FGFR4 nucleic acid are specific for FGFR4 meaning they are not cross-reactive with other FGF receptor subtypes.
Antisense Compound Motifs
In certain embodiments, antisense compounds targeted to an FGFR4 nucleic acid have chemically modified subunits arranged in patterns, or motifs, to confer to the antisense compounds properties such as enhanced the inhibitory activity, increased binding affinity for a target nucleic acid, or resistance to degradation by in vivo nucleases.
Chimeric antisense compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense compound may serve as a substrate for the cellular endonuclease RNase H, which cleaves the RNA strand of an RNA:DNA duplex.
Antisense compounds having a gapmer motif are considered chimeric antisense compounds. In a gapmer an internal position having a plurality of nucleotides that supports RNase H cleavage is positioned between external regions having a plurality of nucleotides that are chemically distinct from the nucleosides of the internal region. In the case of an antisense oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for endonuclease cleavage, while the wing segments comprise modified nucleosides. The regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may in some embodiments include β-D-ribonucleosides, β-D-deoxyribonucleosides, 2′-modified nucleosides (such 2′-modified nucleosides may include 2′-MOE, and 2′-O—CH3, among others), and bicyclic sugar modified nucleosides (such bicyclic sugar modified nucleosides may include those having a 4′-(CH2)n—O-2′ bridge, where n=1 or n=2). In general, each distinct region comprises uniform sugar moieties. The wing-gap-wing motif is frequently described as “X-Y-Z”, where “X” represents the length of the 5′ wing region, “Y” represents the length of the gap region, and “Z” represents the length of the 3′ wing region.
In one embodiment, antisense compounds targeted to an FGFR4 nucleic acid possess a 5-10-5 gapmer motif.
Target Nucleic Acids, Target Regions and Nucleotide Sequences
Gene Targets
Nucleotide sequences that encode Mus musculus FGFR4 include, without limitation, the following: GENBANK® Accession No. AY493377.2, incorporated herein as SEQ ID NO: 9 GENBANK® Accession No. BC033313.1, incorporated herein as SEQ ID NO: 10; GENBANK® Accession No. BQ567109.1 incorporated herein as SEQ ID NO: 11; GENBANK® Accession No. NM—008011.1 incorporated herein as SEQ ID NO: 12; and nucleotides 790799 to 800614 of GENBANK® Accession No NT—039586. incorporated herein as SEQ ID NO: 13; and nucleotides 792000 to 811000 of GENBANK® Accession No. NT—039586.5 incorporated herein as SEQ ID NO: 14.
Nucleotide sequences that encode human FGFR4 include, without limitation, the following: GENBANK® Accession No. AF202063.1, incorporated herein as SEQ ID NO: 1; GENBANK® Accession No. AF359241.1, incorporated herein as SEQ ID NO: 2; GENBANK® Accession No. BF305431.1, incorporated herein as SEQ ID NO: 3; GENBANK® Accession No. BM803172.1, incorporated herein as SEQ ID NO: 4; GENBANK® Accession No. NM—002011.3, incorporated herein as SEQ ID NO: 5; GENBANK® Accession NM—022963.1 incorporated herein as SEQ ID NO: 6; nucleotides 21323018 to 21335213 of GENBANK® Accession No. NT—023133.11, incorporated herein as SEQ ID NO: 7; and nucleotides 8583892 to 8595932 of GENBANK® Accession No. NT—023132.9, incorporated herein as SEQ ID NO: 8.







TABLE 1







Gene Targets, Synonyms and Regions















SEQ






ID


Target Name
Synonyms
Species
Genbank #
NO














fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
AF202063.1
1


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
AF359241.1
2


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
BF305431.1
3


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
BM803172.1
4


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
NM_002011.3
5


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
NM_022963.1
6


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
nucleotides
7


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-

21323018 to




protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-

21335213 of




4; FGFR4; CD334, FGFR4_HUMAN and JTK2

NT_023133.11



fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Human
nucleotides
8


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-

8583892 to




protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-

8595932 of




4; FGFR4; CD334, FGFR4_HUMAN and JTK2

NT_023132.9



fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Mouse
AY493377.2
9


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Mouse
BC033313.1
10


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Mouse
BQ567109.1
11


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Mouse
NM_008011.1
12


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-






protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-






4; FGFR4; CD334, FGFR4_HUMAN and JTK2





fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Mouse
nucleotides
13


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-

790799 to




protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-

800614 of




4; FGFR4; CD334, FGFR4_HUMAN and JTK2

NT_039586.2



fibroblast growth
FGF receptor-4, TKF; tyrosine kinase related to
Mouse
nucleotides
14


factor receptor 4
fibroblast growth factor receptor; hydroxyaryl-

792000 to




protein kinase; tyrosylprotein kinase; Fgfr4; FGFR-

811000 of




4; FGFR4; CD334, FGFR4_HUMAN and JTK2

NT_039586.5









Mus musculus Nucleotide Sequences Targeted to FGFR4
Nucleotide sequences that encode Mus musculus FGFR4 include, without limitation, the following: GENBANK® Accession No. AY493377.2, incorporated herein as SEQ ID NO: 9 GENBANK® Accession No. BC033313.1, incorporated herein as SEQ ID NO: 10; GENBANK® Accession No. BQ567109.1 incorporated herein as SEQ ID NO: 11; GENBANK® Accession No. NM—008011.1 incorporated herein as SEQ ID NO: 12; and nucleotides 790799 to 800614 of GENBANK® Accession No NT—039586. incorporated herein as SEQ ID NO: 13; and nucleotides 792000 to 811000 of GENBANK® Accession No. NT—039586.5 incorporated herein as SEQ ID NO: 14.
It is noted that some portions of these nucleotide sequences share identical sequence. Examples of such antisense compounds are shown in Table 2. In certain such embodiments, an antisense oligonucleotide targets SEQ ID NO: 9, 10, 11, 12, 13 or 14. In certain such embodiments, an antisense oligonucleotide that is targeted to any of SEQ ID NO: 9, 10, 11, 12, 13 or 14 is at least 90% complementary to the corresponding SEQ ID NO: 9, 10, 11, 12, 13 or 14. In certain such embodiments, an antisense oligonucleotide that is targeted to any of SEQ ID NO: 9, 10, 11, 12, 13 or 14 is at least 95% complementary to the corresponding SEQ ID NO: 9, 10, 11, 12, 13 or 14. In certain such embodiments, an antisense oligonucleotide that is targeted to any of SEQ ID NO: 9, 10, 11, 12, 13 or 14 is 100% complementary to the corresponding SEQ ID NO: 9, 10, 11, 12, 13 or 14. In certain embodiments, an antisense oligonucleotide targeted to any of SEQ ID NO: 9, 10, 11, 12, 13 or 14 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Table 1.
In certain embodiments, gapmer antisense compounds are targeted to an FGFR4 nucleic acid of Mus musculus. In certain such embodiments, gapmer antisense compounds are targeted to SEQ ID NOs: 9, 10, 11, 12, 13 or 14. In certain such embodiments, the nucleotide sequences illustrated in Table 1 have a 5-10-5 gapmer motif Table 2 illustrates gapmer antisense compounds targeted to SEQ ID NO: 10 and 14, having a 5-10-5 motif, where the gap segment comprises 2′-deoxynucleotides and each wing segment comprises nucleotides comprising a 2′-O-methoxyethyl sugar modification. Internucleoside linkages are phosphorthioate, and cytidines are 5-methylcytidines.







TABLE 2







Nucleotide sequences targeted to Mouse (Mus musculus) 


FGFR4 Sequences of SEQ ID NOs: 10 and 14














Target
5′
3′

SEQ
2′MOE



SEQ ID
Target
Target

ID
Gapmer


ISIS #
 NO
Site
Site
Sequence (5′ to 3′)
NO
Motif





393247
10
  228
  247
GGGCTGGCACACTCACCCGC
15
5 10 5


 


393248
10
  238
  257
GATCCCGGCAGGGCTGGCAC
16
5 10 5


 


393249
10
  244
  263
GGTCACGATCCCGGCAGGGC
17
5 10 5


 


393250
10
  337
  356
GCCACATTTCCTTCCAGCTG
18
5 10 5


 


393251
10
  346
  365
CCAAGAGCAGCCACATTTCC
19
5 10 5


 


393252
10
  355
  374
TCAACAGGGCCAAGAGCAGC
20
5 10 5


 


393253
10
  402
  421
TTCCTCAGAGGCCTCAAGGG
21
5 10 5


 


393254
10
  600
  619
AGGAAGGAAGCTGGCGATCT
22
5 10 5


 


393255
10
  610
  629
CAGCATCCTCAGGAAGGAAG
23
5 10 5


 


393256
10
  635
  654
CCACGGGCCAGGCAGAGGTA
24
5 10 5


 


393257
10
  644
  663
GTCATGGAGCCACGGGCCAG
25
5 10 5


 


393258
10
  682
  701
AGGAGTCATCCATAAGCAAC
26
5 10 5


 


393259
10
  687
  706
GGTTAAGGAGTCATCCATAA
27
5 10 5


 


393260
10
  694
  713
TGATGGAGGTTAAGGAGTCA
28
5 10 5


 


393261
10
  773
  792
TGTGTCCAGTAGGGTGCTTG
29
5 10 5


 


393262
10
  873
  892
CCAGTGGATGGTAGGCATGG
30
5 10 5


 


393263
10
  878
  897
TTGAGCCAGTGGATGGTAGG
31
5 10 5


 


393264
10
  996
 1015
AAGGCATGTGTATGTGCCAC
32
5 10 5


 


393265
10
 1001
 1020
TCCACAAGGCATGTGTATGT
33
5 10 5


 


393266
10
 1020
 1039
AATGCTACCCAGAGAGTTCT
34
5 10 5


 


393267
10
 1048
 1067
CCAGCACATCCAGGAGATAG
35
5 10 5


 


299029
10 
 1200
 1219
GCTGCTGCCGTTGATGACGA
36
5 10 5


 


393268
10
 1245
 1264
TGTTGTCTTCAGGACTTGTA
37
5 10 5


 


393269
10
 1364
 1383
AGCCACGCTGACTGGTAGGA
38
5 10 5


 


299036
10
 1380
 1399
CTCTGGCAGCACCGTGAGCC
39
5 10 5


 


393270
10
 1446
 1465
TGATACATACAGGATGATAT
40
5 10 5


 


393271
10
 1466
 1485
ACAAGCAGAACCAGTGAGCC
41
5 10 5


 


393272
10
 1471
 1490
GGAGCACAAGCAGAACCAGT
42
5 10 5


 


393273
10
 1490
 1509
TACACCCCGGCCAGCAGCAG
43
5 10 5


 


393274
10
 1604
 1623
GACTTGCCAGAGGACCTCGA
44
5 10 5


 


393275
10
 1615
 1634
GGGACAAACTTGACTTGCCA
45
5 10 5


 


393276
10
 1625
 1644
CCTCGCACCAGGGACAAACT
46
5 10 5


 


393277
10
 1670
 1689
ACAAGGCCCGTGAGCAAGGG
47
5 10 5


 


393278
10
 1756
 1775
CAAAGCAGCCCTCACCCAGG
48
5 10 5


 


393279
10
 1775
 1794
TCTGCACGAACCACTTGCCC
49
5 10 5


 


393280
10
 1796
 1815
GAGGGATCCATACCAAAGGC
50
5 10 5


 


393281
10
 1850
 1869
GAGGCATTGTCTTTCAGCAT
51
5 10 5


 


393282
10
 1870
 1889
GGTCTGCCAAATCCTTGTCG
52
5 10 5


 


393283
10
 1910
 1929
TGTCTTCCGATTAGCTTCAT
53
5 10 5


 


393284
10
 1939
 1958
AGACACCCAGCAGGTTGATG
54
5 10 5


 


393285
10
 1945
 1964
GAGTGCAGACACCCAGCAGG
55
5 10 5


 


393286
10
 1956
 1975
GGGCCCTTCCTGAGTGCAGA
56
5 10 5


 


393287
10
 2048
 2067
CCATCAGGGCTGAGATCAGG
57
5 10 5


 


322160
10
 2131
 2150
CCAGATACTGCATGCCTCGG
58
5 10 5


 


393288
10
 2150
 2169
TGGATGCACTTCCGAGACTC
59
5 10 5


 


393289
10
 2380
 2399
CCCCGAGGGTGAAGATTTCC
60
5 10 5


 


393290
10
 2440
 2459
TGTGCCCCTCTCGCAGCAGT
61
5 10 5


 


393291
10
 2490
 2509
CCTCATTAGCCCATACAGCT
62
5 10 5


 


393292
10
 2555
 2574
TTGTCCAGAGCTTCCACCAG
63
5 10 5


 


299052
10
 2567
 2586
GCCAGCAGGACCTTGTCCAG
64
5 10 5


 


393293
10
 2580
 2599
CTCTTCAGAGACAGCCAGCA
65
5 10 5


 


393294
10
 2600
 2619
GTCAGGCGGAGGTCAAGGTA
66
5 10 5


 


393295
10
 2616
 2635
AGAAAAGGGTCCAAAGGTCA
67
5 10 5


 


393296
10
 2628
 2647
CCCATTGGAGGGAGAAAAGG
68
5 10 5


 


393297
10
 2635
 2654
TGGCATCCCCATTGGAGGGA
69
5 10 5


 


393298
10
 2641
 2660
TGCTGCTGGCATCCCCATTG
70
5 10 5


 


393299
10
 2880
 2899
CAGGGCCAGAGAGAGGATCT
71
5 10 5


 


393300
10
 2935
 2954
TGGAACAGAAGGCCTCAACT
72
5 10 5


 


393301
10
 2994
 3013
CCAAGGGCAAGGCCATGATC
73
5 10 5


 


393302
10
 3000
 3019
ATGAGTCCAAGGGCAAGGCC
74
5 10 5


 


393303
10
 3005
 3024
TGAGGATGAGTCCAAGGGCA
75
5 10 5


 


393304
10
 3085
 3104
TAGAGCATAAGTTTTGCAGC
76
5 10 5


 


393305
10
 3090
 3109
ATGTTTAGAGCATAAGTTTT
77
5 10 5


 


393306
10
 3095
 3114
TAGAAATGTTTAGAGCATAA
78
5 10 5


 


393307
10
 3120
 3139
AGGCCTCTAGGTTGTTTGGG
79
5 10 5


 


393308
10
 3277
 3296
TTTATAAAAATGCCATGTTC
80
5 10 5


 


393310
14
 3566
 3585
TTCCATGCCCAGTTTGGGAC
81
5 10 5


 


393311
14
 4800
 4819
GGAGTCATTGATACCCATAG
82
5 10 5


 


393312
14
 6049
 6068
GTCAGAGTGGAGGCAGGTTA
83
5 10 5


 


393313
14
 7448
 7467
TTGATTCCCAGCAAATACAT
84
5 10 5


 


393314
14
 7805
 7824
ACCCAGCACATCCAGGAGAT
85
5 10 5


 


393315
14
 8295
 8314
CCCCACAAATGTTGCACCCA
86
5 10 5


 


393316
14
10349
10368
GCCCAGGTTGCCATGTGTAC
87
5 10 5


 


393317
14
12504
12523
GGTTTTGTTATGCATTAGAG
88
5 10 5


 


393318
14
14115
14134
GATCAGGAAGCATAGAAGGA
89
5 10 5


 


393319
14
15655
15674
GACAGTGGTGTGAGTAGTAT
90
5 10 5


 


393320
14
16387
16406
GAACAGGTCAAAGAGGTTTG
91
5 10 5









Human Nucleotide Sequences Targeted to FGFR4

Nucleotide sequences that encode human FGFR4 include, without limitation, the following: GENBANK® Accession No. AF202063.1, incorporated herein as SEQ ID NO: 1; GENBANK® Accession No. AF359241.1, incorporated herein as SEQ ID NO: 2; GENBANK® Accession No. BF305431.1, incorporated herein as SEQ ID NO: 3; GENBANK® Accession No. BM803172.1, incorporated herein as SEQ ID NO: 4; GENBANK® Accession No. NM—002011.3, incorporated herein as SEQ ID NO: 5; GENBANK® Accession NM—022963.1 incorporated herein as SEQ ID NO: 6; nucleotides 21323018 to 21335213 of GENBANK® Accession No. NT—023133.11, incorporated herein as SEQ ID NO: 7; and nucleotides 8583892 to 8595932 of GENBANK® Accession No. NT—023132.9, incorporated herein as SEQ ID NO: 8.
Antisense oligonucleotides with a 5-10-52′-MOE gapmer motif were designed to target human FGFR4 (Table 3). All oligonucleotides of the two series are full phosphorothioate oligonucleotides. GENBANK® Accession No. NM—002011.3 represents the main mRNA which uses exons 1-18. GENBANK® Accession No. NM—022963.1 represents a variant that uses exons 1-8, splices to 10a, and 11-18. Exon 10a starts at the beginning of intron 9 and ends at the end of exon 10. GENBANK® Accession No. AF202063.1 uses exons 3-8, 10a, 10-17, and intron 9. Exon 10a starts 1 nucleotide residue after Exon 8 and ends 219 nucleotide residues after. GENBANK® Accession No. NT—023132.9 (nucleotide residues 8583892-8595932) represents a variant that starts with exon 1, splices to exon 1a, exons 2-4, splices to exon 4a, exons 5-9, splices to exon 10a, exons 10-18 and introns 1, splices to intron 1a, and introns 2-17. Exon 1a starts 10 nucleotide residues before Exon1 ends and ends 44 nucleotide residues after exon1 ends. Exon 4a starts at the beginning of there exon 4 starts and ends 271 nucleotide residues after exon 4. Exon 10a starts 1 nucleotide residue after exon 9 and ends 220 nucleotide residues after. Intron 1a, starts 44 nucleotide residues after the start of intron 1 and ends at the end of intron 1. GENBANK® Accession No. BM803172.1 represents a variant that uses exons 1-2, then splices to exons 4-6. GENBANK® Accession No. BF305431.1 represents a variant that uses and starts with exon 1a (ends in intron 1), splices to and uses exon 2, splices to and uses exons 4-6. GENBANK® Accession No. AF359241.1 represents a variant that begins with and uses exons 2-3, splices to and uses exon 4a (starts at the beginning of exon 4 and ends in exon 5). GENBANK® Accession No. NT—023133.11 (nucleotide residues 21323018-21335213) represents a gene that starts with exon 1, splices to exon 1a, exons 2-4, splices to exon 4a, exons 5-9, splices to exon 10a, exons 10-18 and introns 1, splices to intron 1a, and introns 2-17. Exon 1a starts 10 nucleotide residues before exon1 ends and ends 44 nucleotide residues after exon 1 ends. Exon 4a starts at the beginning of there exon 4 starts and ends 271 nucleotide residues after exon 4. Exon 10a starts 1 nucleotide residue after exon 9 and ends 220 nucleotide residues after. Intron 1a, starts 44 nucleotide residues after the start of intron 1 and ends at the end of intron 1.
GENBANK® Accession No. NM—002011.3 represents the genomic sequence that uses exons 2-18. The antisense oligonucleotides were selected to cover the full genomic human FGFR4 sequence.
In certain embodiments, an antisense oligonucleotide targets SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8. In certain such embodiments, an antisense oligonucleotide that is targeted to any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8 is at least 90% complementary to the corresponding SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8. In certain such embodiments, an antisense oligonucleotide that is targeted to any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8 is at least 95% complementary to the corresponding SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8. In certain such embodiments, an antisense oligonucleotide that is targeted to any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8 is 100% complementary to the corresponding SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, or 8. In certain embodiments, an antisense oligonucleotide targeted to any of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, or 8 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Table 3.
In certain embodiments, gapmer antisense compounds are targeted to an FGFR4 nucleic acid. In certain such embodiments, gapmer antisense compounds are targeted to SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, or 8. In certain such embodiments, the nucleotide sequences illustrated in Table 3 have a 5-10-5 gapmer motif. Table 3 illustrates gapmer antisense compounds targeted to SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, or 8, having a 5-10-5 motif, where the gap segment comprises 2′-deoxynucleotides and each wing segment comprises nucleotides comprising a 2′-O-methoxyethyl sugar modification.
Internucleoside linkages are phosphorothioate, and cytidines are 5-methylcytidines. The following embodiments set forth target regions of Mus musculus and human FGFR4 nucleic acids. Also illustrated are examples of antisense compounds targeted to the target regions. It is understood that the sequence set forth in each SEQ ID NO is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis No) indicate a combination of nucleobase sequence and motif.
Internucleoside linkages are phosphorothioate, and cytidines are 5-methylcytidines.







TABLE 3







Nucleotide sequences targeted to Human FGFR4 


Sequences of SEQ ID NOs: 2, 3, 4, 5, 6 and 8














Target
5′
3′

SEQ
2′-MOE



SEQ ID
Target
Target

ID
Gapmer


ISIS #
 NO
Site
Site
Sequence (5′ to 3′)
NO
Motif





299069
2
  455
  474
CAGCGGGACACAAGTCCTTG
 92
5 10 5


 


299067
3
   46
   65
AACTGCCTTCCTCGAGCCTG
 93
5 10 5


 


299065
4
  306
  325
GTCAAGGAGTCAAGCTCCAC
 94
5 10 5


 


299066
4
  891
  910
GGTAGAGGGATGTCAACCAG
 95
5 10 5


 


299003
5
   26
   45
GGCAGGGTCCGCAGACAGCC
 96
5 10 5


 


299004
5
  160
  179
CAGCAGCCGCATCTCCTTCT
 97
5 10 5


 


299005
5
  192
  211
GGCACACTCAGCAGGACCCC
 98
5 10 5


 


299006
5
  208
  227
CAAGACTGGAGGCCCAGGCA
 99
5 10 5


 


299007
5
  254
  273
GAGCCAGGCAGGGCTCAAGC
100
5 10 5


 


299008
5
  278
  297
CCTGCTCTTGCTGCTCCAGG
101
5 10 5


 


299009
5
  289
  308
TACTGTCAGCTCCTGCTCTT
102
5 10 5


 


299010
5
  304
  323
AGGCTGCCCAAGGGCTACTG
103
5 10 5


 


299012
5
  354
  373
TCCTTGTACCAGTGGCCACC
104
5 10 5


 


299013
5
  380
  399
GGCCAGCAGGTGCCAGGCGA
105
5 10 5


 


299014
5
  412
  431
AATCTCTAGGCGGCCCCTCC
106
5 10 5


 


299015
5
  475
  494
GACGATCATGGAGCCTCGTG
107
5 10 5


 


299016
5
  483
  502
TTCTGCAGGACGATCATGGA
108
5 10 5


 


299017
5
  529
  548
ATCATCGTTGCTGGAGGTCA
109
5 10 5


 


299018
5
  597
  616
GTCCAGTAGGGTGCTTGCTG
110
5 10 5


 


299019
5
  602
  621
GGTGTGTCCAGTAGGGTGCT
111
5 10 5


 


299020
5
  627
  646
TGCAGTTTCTTCTCCATGCG
112
5 10 5


 


299021
5
  711
  730
CCATCCTTAAGCCAGCGGAT
113
5 10 5


 


299022
5
  727
  746
CCCATGAAAGGCCTGTCCAT
114
5 10 5


 


299023
5
  739
  758
AATGCGGTTCTCCCCATGAA
115
5 10 5


 


299024
5
  757
  776
GCGCAGCCGAATGCCTCCAA
116
5 10 5


 


299025
5
  785
  804
TCTCCATCACGAGACTCCAG
117
5 10 5


 


299026
5
  833
  852
CGTTCTCTACCAGGCAGGTG
118
5 10 5


 


299027
5
  964
  983
CTTGCACAGCAGCTCCACGT
119
5 10 5


 


299028
5
  969
  988
TACACCTTGCACAGCAGCTC
120
5 10 5


 


299029
5
 1027
 1046 
GCTGCTGCCGTTGATGACGA
 36
5 10 5


 


299030
5
 1032
 1051 
CCGAAGCTGCTGCCGTTGAT
121
5 10 5


 


299031
5
 1076
 1095 
TGTCTGCAGTCTTTAGGACT
122
5 10 5


 


299032
5
 1090
 1109 
CTCTGAGCTATTGATGTCTG
123
5 10 5


 


299033
5
 1095
 1114 
TCCACCTCTGAGCTATTGAT
124
5 10 5


 


299034
5
 1121
 1140 
CTGACACGTTCCGCAGGTAC
125
5 10 5


 


299035
5
 1181
 1200 
ACTGGTAGGAGAGGCCGATG
126
5 10 5


 


299036
5
 1207
 1226 
CTCTGGCAGCACCGTGAGCC
 39
5 10 5


 


299037
5
 1235
 1254 
GCGCTGCTGCGGTCCATGTG
127
5 10 5


 


299038
5
 1326
 1345 
TGCCCTCGATACAGCCCGGC
128
5 10 5


 


299039
5
 1428
 1447 
TTGCCGGAAGAGCCTGACTC
129
5 10 5


 


299040
5
 1447
 1466 
TACCAGGGATGAGCTTGACT
130
5 10 5


 


299041
5
 1452
 1471 
CCTCGTACCAGGGATGAGCT
131
5 10 5


 


299042
5
 1555
 1574 
AAGCACCAGCCTGTCCCGGG
132
5 10 5


 


299043
5
 1607
 1626 
AGGCCTCTGCACGTACTACC
133
5 10 5


 


299044
5
 1656
 1675 
TTGACGGCCACAGTGCTGGC
134
5 10 5


 


299045
5
 1741
 1760 
CTTGTGTCGGCCGATCAGCT
135
5 10 5


 


299046
5
 1772
 1791 
GGGTGCAGACACCAAGCAGG
136
5 10 5


 


299047
5
 1919
 1938 
AGACCAGGACTGGGAAGGAG
137
5 10 5


 


299048
5
 1968
 1987 
TTCCGGGACTCCAGATACTG
138
5 10 5


 


299049
5
 1979
 1998 
GGTGGATACACTTCCGGGAC
139
5 10 5


 


299050
5
 2268
 2287 
CGATGTCCCTCCCGCAGCAG
140
5 10 5


 


299051
5
 2313
 2332 
ATCAGCCCGTACAGCTCTGG
141
5 10 5


 


299052
5
 2394
 2413 
GCCAGCAGGACCTTGTCCAG
 64
5 10 5


 


299053
5
 2416
 2435 
GTCGAGGTACTCCTCAGAGA
142
5 10 5


 


299054
5
 2481
 2500 
CTGGAGGAGCAGGTGCTGCT
143
5 10 5


 


299055
5
 2497
 2516 
GCTGAAGACAGAATCGCTGG
144
5 10 5


 


299056
5
 2503
 2522 
GTCGTGGCTGAAGACAGAAT
145
5 10 5


 


299057
5
 2557
 2576 
TCATGTCTGCACCCCAGACC
146
5 10 5


 


299058
5
 2565
 2584 
AGCCTTGCTCATGTCTGCAC
147
5 10 5


 


299059
5
 2629
 2648 
TGTGTCAGGCTGTGGCTGAG
148
5 10 5


 


299060
5
 2698
 2717 
AAGGGCACGGCCCTTGGACA
149
5 10 5


 


299061
5
 2738
 2757 
ATTTGGGCCATCAGGACACA
150
5 10 5


 


299062
5
 2752
 2771 
AGCAGAACCCTGACATTTGG
151
5 10 5


 


299063
5
 2851
 2870 
CCTGCTGGTATTGGGAGGCA
152
5 10 5


 


299011
6
  308
  327
ACAGCACAGCCGCACAGGCT
153
5 10 5


 


298992
6
 1204
 1223 
CGCCCAGTACCTGGCAGCAC
154
5 10 5


 


299064
8
  423
  442
GGAGCGAGGAATGTACCCGC
155
5 10 5


 


299003
8
  460
  479
GGCAGGGTCCGCAGACAGCC
 96
5 10 5


 


298994
8
  583
  602
TCCGGCTCACCTCGAGCCTG
156
5 10 5


 


298995
8
 1913
 1932
GGAAACATCCTCTCCCTCGG
157
5 10 5


 


299004
8
 3110
 3129
CAGCAGCCGCATCTCCTTCT
 97
5 10 5


 


299005
8
 3142
 3161
GGCACACTCAGCAGGACCCC
 98
5 10 5


 


299006
8
 3158
 3177
CAAGACTGGAGGCCCAGGCA
 99
5 10 5


 


298996
8
 3199
 3218
GAAGCCATACCAAGCTCCAC
158
5 10 5


 


299008
8
 3924
 3943
CCTGCTCTTGCTGCTCCAGG
101
5 10 5


 


299009
8
 3935
 3954
TACTGTCAGCTCCTGCTCTT
102
5 10 5


 


299010
8
 3950
 3969
AGGCTGCCCAAGGGCTACTG
103
5 10 5


 


299012
8
 4000
 4019
TCCTTGTACCAGTGGCCACC
104
5 10 5


 


299013
8
 4026
 4045
GGCCAGCAGGTGCCAGGCGA
105
5 10 5


 


299014
8
 4058
 4077
AATCTCTAGGCGGCCCCTCC
106
5 10 5


 


299015
8
 4121
 4140
GACGATCATGGAGCCTCGTG
107
5 10 5


 


299016
8
 4129
 4148
TTCTGCAGGACGATCATGGA
108
5 10 5


 


299068
8
 4174
 4193
TTCACTCCCTGCTAGAGTCT
159
5 10 5


 


298997
8
 4250
 4269
GTCAAGGAGTCTACATCAGG
160
5 10 5


 


299017
8
 4266
 4285
ATCATCGTTGCTGGAGGTCA
109
5 10 5


 


299019
8
 4451
 4470
GGTGTGTCCAGTAGGGTGCT
111
5 10 5


 


299020
8
 4476
 4495
TGCAGTTTCTTCTCCATGCG
112
5 10 5


 


299021
8
 4560
 4579
CCATCCTTAAGCCAGCGGAT
113
5 10 5


 


299022
8
 4576
 4595
CCCATGAAAGGCCTGTCCAT
114
5 10 5


 


299023
8
 4588
 4607
AATGCGGTTCTCCCCATGAA
115
5 10 5


 


299025
8
 5214
 5233
TCTCCATCACGAGACTCCAG
117
5 10 5


 


299026
8
 5262
 5281
CGTTCTCTACCAGGCAGGTG
118
5 10 5


 


299027
8
 5905
 5924
CTTGCACAGCAGCTCCACGT
119
5 10 5


 


299028
8
 5910
 5929
TACACCTTGCACAGCAGCTC
120
5 10 5


 


299029
8
 5968
 5987
GCTGCTGCCGTTGATGACGA
 36
5 10 5


 


299030
8
 5973
 5992
CCGAAGCTGCTGCCGTTGAT
121
5 10 5


 


299032
8
 6165
 6184
CTCTGAGCTATTGATGTCTG
123
5 10 5


 


299033
8
 6170
 6189
TCCACCTCTGAGCTATTGAT
124
5 10 5


 


299034
8
 6196
 6215
CTGACACGTTCCGCAGGTAC
125
5 10 5


 


299035
8
 6256
 6275
ACTGGTAGGAGAGGCCGATG
126
5 10 5


 


299037
8
 6663
 6682
GCGCTGCTGCGGTCCATGTG
127
5 10 5


 


299038
8
 6754
 6773
TGCCCTCGATACAGCCCGGC
128
5 10 5


 


298993
8
 6868
 6887
AGTCAGGCTGTCACATGTGA
161
5 10 5


 


299039
8
 6930
 6949
TTGCCGGAAGAGCCTGACTC
129
5 10 5


 


299040
8
 6949
 6968
TACCAGGGATGAGCTTGACT
130
5 10 5


 


299041
8
 6954
 6973
CCTCGTACCAGGGATGAGCT
131
5 10 5


 


299043
8
 7211
 7230
AGGCCTCTGCACGTACTACC
133
5 10 5


 


299044
8
 7260
 7279
TTGACGGCCACAGTGCTGGC
134
5 10 5


 


298998
8
 7654
 7673
GTGAGCCCCTTCTATTAGTC
162
5 10 5


 


298999
8
 8267
 8286
AATGTGCATTTCTCAATCCC
163
5 10 5


 


299045
8
 8899
 8918
CTTGTGTCGGCCGATCAGCT
135
5 10 5


 


299046
8
 8930
 8949
GGGTGCAGACACCAAGCAGG
136
5 10 5


 


299000
8
 8971
 8990
AACGGCCCGTGCAGCCAGCC
164
5 10 5


 


299047
8
 9169
 9188
AGACCAGGACTGGGAAGGAG
137
5 10 5


 


299048
8
 9218
 9237
TTCCGGGACTCCAGATACTG
138
5 10 5


 


299001
8
 9863
 9882
CAGGACTCACACGTCACTCT
165
5 10 5


 


299050
8
10204
10223
CGATGTCCCTCCCGCAGCAG
140
5 10 5


 


299002
8
10797
10816
CAGCCCGTACCTGCGAGAGG
166
5 10 5


 


299052
8
10880
10899
GCCAGCAGGACCTTGTCCAG
 64
5 10 5


 


299054
8
11096
11115
CTGGAGGAGCAGGTGCTGCT
143
5 10 5


 


299055
8
11112
11131
GCTGAAGACAGAATCGCTGG
144
5 10 5


 


299056
8
11118
11137
GTCGTGGCTGAAGACAGAAT
145
5 10 5


 


299057
8
11172
11191
TCATGTCTGCACCCCAGACC
146
5 10 5


 


299058
8
11180
11199
AGCCTTGCTCATGTCTGCAC
147
5 10 5


 


299059
8
11244
11263
TGTGTCAGGCTGTGGCTGAG
148
5 10 5


 


299060
8
11313
11332
AAGGGCACGGCCCTTGGACA
149
5 10 5


 


299061
8
11353
11372
ATTTGGGCCATCAGGACACA
150
5 10 5


 


299062
8
11367
11386
AGCAGAACCCTGACATTTGG
151
5 10 5


 


299063
8
11466
11485
CCTGCTGGTATTGGGAGGCA
152
5 10 5









The following embodiments set forth target regions of human FGFR4 nucleic acids. Also illustrated are examples of antisense compounds targeted to the target regions. It is understood that the sequence set forth in each SEQ ID NO is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis No) indicate a combination of nucleobase sequence and motif.
Target Regions of Human FGFR4
In certain embodiments, a target region is nucleotides 455-474 of SEQ ID NO: 2. In certain embodiments, an antisense compound is targeted to nucleotides 455-474 of SEQ ID NO: 2. In certain such embodiments, an antisense compound targeted to nucleotides 455-474 of SEQ ID NO: 2 is Isis No: 299069. In certain embodiments, an antisense compound targeted to nucleotides 455-474 of SEQ ID NO: 2 has the sequence of SEQ ID NO: 92.
In certain embodiments, a target region is nucleotides 46-65 of SEQ ID NO: 3. In certain embodiments, an antisense compound is targeted to nucleotides 46-65 of SEQ ID NO: 3. In certain such embodiments, an antisense compound targeted to nucleotides 46-65 of SEQ ID NO: 3 is Isis No: 299067. In certain embodiments, an antisense compound targeted to nucleotides 46-65 of SEQ ID NO: 3 has the sequence of SEQ ID NO: 93.
In certain embodiments, a target region is nucleotides 306-325 of SEQ ID NO: 4. In certain embodiments, an antisense compound is targeted to nucleotides 306-325 of SEQ ID NO: 4. In certain such embodiments, an antisense compound targeted to nucleotides 306-325 of SEQ ID NO: 4 is Isis No: 299065. In certain embodiments, an antisense compound targeted to nucleotides 306-325 of SEQ ID NO: 4 has the sequence of SEQ ID NO: 94.
In certain embodiments, a target region is nucleotides 891-910 of SEQ ID NO: 4. In certain embodiments, an antisense compound is targeted to nucleotides 891-910 of SEQ ID NO: 4. In certain such embodiments, an antisense compound targeted to nucleotides 891-910 of SEQ ID NO: 4 is Isis No: 299066. In certain embodiments, an antisense compound targeted to nucleotides 891-910 of SEQ ID NO: 4 has the sequence of SEQ ID NO: 95.
In certain embodiments, a target region is nucleotides 26-45 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 26-45 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 26-45 of SEQ ID NO: 5 is Isis No: 299003. In certain embodiments, an antisense compound targeted to nucleotides 26-45 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 96.
In certain embodiments, a target region is nucleotides 160-179 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 160-179 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 160-179 of SEQ ID NO: 5 is Isis No: 299004. In certain embodiments, an antisense compound targeted to nucleotides 160-179 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 97.
In certain embodiments, a target region is nucleotides 192-211 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 192-211 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 192-211 of SEQ ID NO: 5 is Isis No: 299005. In certain embodiments, an antisense compound targeted to nucleotides 192-211 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 98.
In certain embodiments, a target region is nucleotides 208-227 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 208-227 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 208-227 of SEQ ID NO: 5 is Isis No: 299006. In certain embodiments, an antisense compound targeted to nucleotides 208-227 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 99.
In certain embodiments, a target region is nucleotides 160-211 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 160-211 of SEQ ID NO: 5 is selected from Isis Nos: 299004 and 299005. In certain embodiments, an antisense compound targeted to nucleotides 160-211 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 97 or 98.
In certain embodiments, a target region is nucleotides 192-227 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 192-227 of SEQ ID NO: 5 is selected from Isis Nos: 299005 and 299006. In certain embodiments, an antisense compound targeted to nucleotides 192-227 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 98 or 99.
In certain embodiments, a target region is nucleotides 160-227 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 160-227 of SEQ ID NO: 5 is selected from Isis Nos: 299004, 299005 and 299006. In certain embodiments, an antisense compound targeted to nucleotides 160-227 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 97, 98 or 99.
In certain embodiments, a target region is nucleotides 254-273 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 254-273 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 254-273 of SEQ ID NO: 5 is Isis No: 299007. In certain embodiments, an antisense compound targeted to nucleotides 254-273 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 100.
In certain embodiments, a target region is nucleotides 278-297 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 278-297 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 278-297 of SEQ ID NO: 5 Isis No: 299008. In certain embodiments, an antisense compound targeted to nucleotides 278-297 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 101.
In certain embodiments, a target region is nucleotides 289-308 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 289-308 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 289-308 of SEQ ID NO: 5 is Isis No: 299009. In certain embodiments, an antisense compound targeted to nucleotides 289-308 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 102.
In certain embodiments, a target region is nucleotides 304-323 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 304-323 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 304-323 of SEQ ID NO: 5 is Isis No: 299010. In certain embodiments, an antisense compound targeted to nucleotides 304-323 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 103.
In certain embodiments, a target region is nucleotides 354-373 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 354-373 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 354-373 of SEQ ID NO: 5 is Isis No: 299012. In certain embodiments, an antisense compound targeted to nucleotides 354-373 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 104.
In certain embodiments, a target region is nucleotides 278-308 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 278-308 of SEQ ID NO: 5 is selected from Isis Nos: 299008 and 299009. In certain embodiments, an antisense compound targeted to nucleotides 278-308 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 101 or 102.
In certain embodiments, a target region is nucleotides 289-323 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 289-323 of SEQ ID NO: 5 is selected from Isis Nos: 299009 and 299010. In certain embodiments, an antisense compound targeted to nucleotides 289-323 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 102 or 103.
In certain embodiments, a target region is nucleotides 304-373 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 304-373 of SEQ ID NO: 5 is selected from Isis Nos: 299010 and 299012. In certain embodiments, an antisense compound targeted to nucleotides 304-373 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 103 or 104.
In certain embodiments, a target region is nucleotides 278-323 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 278-323 of SEQ ID NO: 5 is selected from Isis Nos: 299008, 299009 and 299010. In certain embodiments, an antisense compound targeted to nucleotides 278-323 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 101, 102, or 103.
In certain embodiments, a target region is nucleotides 289-373 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 289-373 of SEQ ID NO: 5 is selected from Isis Nos: 299009, 299010 and 299012. In certain embodiments, an antisense compound targeted to nucleotides 289-373 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 102, 103, or 104.
In certain embodiments, a target region is nucleotides 278-373 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 278-373 of SEQ ID NO: 5 is selected from Isis Nos: 299008, 299009, 299010 and 299012. In certain embodiments, an antisense compound targeted to nucleotides 278-373 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 101, 102, 103, or 104.
In certain embodiments, a target region is nucleotides 380-399 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 380-399 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 380-399 of SEQ ID NO: 5 is Isis No: 299013. In certain embodiments, an antisense compound targeted to nucleotides 380-399 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 105.
In certain embodiments, a target region is nucleotides 412-431 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 412-431 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 412-431 of SEQ ID NO: 5 is Isis No: 299014. In certain embodiments, an antisense compound targeted to nucleotides 412-431 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 106.
In certain embodiments, a target region is nucleotides 475-494 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 475-494 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 475-494 of SEQ ID NO: 5 is Isis No: 299015. In certain embodiments, an antisense compound targeted to nucleotides 475-494 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 107.
In certain embodiments, a target region is nucleotides 412-494 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 412-494 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 412-494 of SEQ ID NO: 5 is selected from Isis Nos: 299014 or 299015. In certain embodiments, an antisense compound targeted to nucleotides 412-494 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 106 or 107.
In certain embodiments, a target region is nucleotides 483-502 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 483-502 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 483-502 of SEQ ID NO: 5 is Isis No: 299016. In certain embodiments, an antisense compound targeted to nucleotides 483-502 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 108.
In certain embodiments, a target region is nucleotides 475-502 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 475-502 of SEQ ID NO: 5 is selected from Isis Nos: 299015 or 299016. In certain embodiments, an antisense compound targeted to nucleotides 475-502 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 107 or 108.
In certain embodiments, a target region is nucleotides 529-548 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 529-548 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 529-548 of SEQ ID NO: 5 is Isis No: 299017. In certain embodiments, an antisense compound targeted to nucleotides 529-548 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 109.
In certain embodiments, a target region is nucleotides 597-616 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 597-616 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 597-616 of SEQ ID NO: 5 is Isis No: 299018. In certain embodiments, an antisense compound targeted to nucleotides 597-616 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 110.
In certain embodiments, a target region is nucleotides 602-621 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 602-621 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 602-621 of SEQ ID NO: 5 is Isis No: 299019. In certain embodiments, an antisense compound targeted to nucleotides 602-621 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 111.
In certain embodiments, a target region is nucleotides 597-621 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 597-621 of SEQ ID NO: 5 is selected from Isis Nos: 299018 or 299019. In certain embodiments, an antisense compound targeted to nucleotides 597-621 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 110 or 111.
In certain embodiments, a target region is nucleotides 627-646 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 627-646 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 627-646 of SEQ ID NO: 5 is Isis No: 299020. In certain embodiments, an antisense compound targeted to nucleotides 627-646 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 112.
In certain embodiments, a target region is nucleotides 602-646 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 602-646 of SEQ ID NO: 5 is selected from Isis Nos: 299019 or 299020. In certain embodiments, an antisense compound targeted to nucleotides 602-646 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 111 or 112.
In certain embodiments, a target region is nucleotides 597-646 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 597-646 of SEQ ID NO: 5 is selected from Isis Nos: 299018, 299019, or 299020. In certain embodiments, an antisense compound targeted to nucleotides 597-646 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 110, 111 or 112.
In certain embodiments, a target region is nucleotides 711-730 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 711-730 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 711-730 of SEQ ID NO: 5 is Isis No: 299021. In certain embodiments, an antisense compound targeted to nucleotides 711-730 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 113.
In certain embodiments, a target region is nucleotides 727-746 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 727-746 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 727-746 of SEQ ID NO: 5 is Isis No: 299022. In certain embodiments, an antisense compound targeted to nucleotides 727-746 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 114.
In certain embodiments, a target region is nucleotides 739-758 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 739-758 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 739-758 of SEQ ID NO: 5 is Isis No: 299023. In certain embodiments, an antisense compound targeted to nucleotides 739-758 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 115.
In certain embodiments, a target region is nucleotides 757-776 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 757-776 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 757-776 of SEQ ID NO: 5 is Isis No: 299024. In certain embodiments, an antisense compound targeted to nucleotides 757-776 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 116.
In certain embodiments, a target region is nucleotides 711-746 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 711-746 of SEQ ID NO: 5 is selected from Isis Nos: 299021 and 299022. In certain embodiments, an antisense compound targeted to nucleotides 711-746 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 113 or 114.
In certain embodiments, a target region is nucleotides 727-758 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 727-758 of SEQ ID NO: 5 is selected from Isis Nos: 299022 and 299023. In certain embodiments, an antisense compound targeted to nucleotides 727-758 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 114 or 115.
In certain embodiments, a target region is nucleotides 739-776 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 739-776 of SEQ ID NO: 5 is selected from Isis Nos: 299023 and 299024. In certain embodiments, an antisense compound targeted to nucleotides 739-776 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 115 or 116.
In certain embodiments, a target region is nucleotides 711-758 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 711-758 of SEQ ID NO: 5 is selected from Isis Nos: 299021, 299022 and 299023. In certain embodiments, an antisense compound targeted to nucleotides 711-758 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 113, 114, or 115.
In certain embodiments, a target region is nucleotides 727-776 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 727-776 of SEQ ID NO: 5 is selected from Isis Nos: 299022, 299023 and 299024. In certain embodiments, an antisense compound targeted to nucleotides 727-776 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 114, 115, or 116.
In certain embodiments, a target region is nucleotides 711-776 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 711-776 of SEQ ID NO: 5 is selected from Isis Nos: 299021, 299022, 299023 and 299024. In certain embodiments, an antisense compound targeted to nucleotides 711-776 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 113, 114, 115, or 116.
In certain embodiments, a target region is nucleotides 785-804 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 785-804 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 785-804 of SEQ ID NO: 5 is Isis No: 299025. In certain embodiments, an antisense compound targeted to nucleotides 785-804 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 117.
In certain embodiments, a target region is nucleotides 833-852 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 833-852 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 833-852 of SEQ ID NO: 5 is Isis No: 299026. In certain embodiments, an antisense compound targeted to nucleotides 833-852 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 118.
In certain embodiments, a target region is nucleotides 964-983 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 964-983 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 964-983 of SEQ ID NO: 5 is Isis No: 299027. In certain embodiments, an antisense compound targeted to nucleotides 964-983 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 119.
In certain embodiments, a target region is nucleotides 969-988 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 969-988 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 969-988 of SEQ ID NO: 5 is Isis No: 299028. In certain embodiments, an antisense compound targeted to nucleotides 969-988 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 120.
In certain embodiments, a target region is nucleotides 785-852 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 785-852 of SEQ ID NO: 5 is selected from Isis Nos: 299025 and 299026. In certain embodiments, an antisense compound targeted to nucleotides 785-852 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 117 or 118.
In certain embodiments, a target region is nucleotides 833-983 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 833-983 of SEQ ID NO: 5 is selected from Isis Nos: 299026 and 299027. In certain embodiments, an antisense compound targeted to nucleotides 833-983 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 118 or 119.
In certain embodiments, a target region is nucleotides 964-988 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 964-988 of SEQ ID NO: 5 is selected from Isis Nos: 299027 and 299028. In certain embodiments, an antisense compound targeted to nucleotides 964-988 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 119 or 120.
In certain embodiments, a target region is nucleotides 785-983 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 785-983 of SEQ ID NO: 5 is selected from Isis Nos: 299025, 299026 and 299027. In certain embodiments, an antisense compound targeted to nucleotides 785-983 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 117, 118, or 119.
In certain embodiments, a target region is nucleotides 833-988 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 833-988 of SEQ ID NO: 5 is selected from Isis Nos: 299026, 299027 and 299028. In certain embodiments, an antisense compound targeted to nucleotides 833-988 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 118, 119, or 120.
In certain embodiments, a target region is nucleotides 785-988 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 785-988 of SEQ ID NO: 5 is selected from Isis Nos: 299025, 299026, 299027 and 299028. In certain embodiments, an antisense compound targeted to nucleotides 785-988 of SEQ ID NO: 5 has the sequence of SEQ ID NOs: 117, 118, 119, or 120.
In certain embodiments, a target region is nucleotides 1027-1046 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1027-1046 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1027-1046 of SEQ ID NO: 5 is Isis No: 299029. In certain embodiments, an antisense compound targeted to nucleotides 1027-1046 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 36.
In certain embodiments, a target region is nucleotides 1032-1051 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1032-1051 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1032-1051 of SEQ ID NO: 5 is Isis No: 299030. In certain embodiments, an antisense compound targeted to nucleotides 1032-1051 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 121.
In certain embodiments, a target region is nucleotides 1027-1051 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1027-1051 of SEQ ID NO: 5 is selected from Isis Nos: 299029 or 299030. In certain embodiments, an antisense compound targeted to nucleotides 1027-1051 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 36 or 121.
In certain embodiments, a target region is nucleotides 1076-1095 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1076-1095 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1076-1095 of SEQ ID NO: 5 is Isis No: 299031. In certain embodiments, an antisense compound targeted to nucleotides 1076-1095 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 122.
In certain embodiments, a target region is nucleotides 1090-1109 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1090-1109 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1090-1109 of SEQ ID NO: 5 is Isis No: 299032. In certain embodiments, an antisense compound targeted to nucleotides 1090-1109 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 123.
In certain embodiments, a target region is nucleotides 1076-1109 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1076-1109 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1076-1109 of SEQ ID NO: 5 is selected from Isis Nos: 299031 or 299032. In certain embodiments, an antisense compound targeted to nucleotides 1076-1109 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 122 or 123
In certain embodiments, a target region is nucleotides 1095-1114 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1095-1114 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1095-1114 of SEQ ID NO: 5 is Isis No: 299033. In certain embodiments, an antisense compound targeted to nucleotides 1095-1114 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 124.
In certain embodiments, a target region is nucleotides 1121-1140 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1121-1140 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1121-1140 of SEQ ID NO: 5 is Isis No: 299034. In certain embodiments, an antisense compound targeted to nucleotides 1121-1140 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 125.
In certain embodiments, a target region is nucleotides 1181-1200 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1181-1200 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1181-1200 of SEQ ID NO: 5 is Isis No: 299035. In certain embodiments, an antisense compound targeted to nucleotides 1181-1200 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 126.
In certain embodiments, a target region is nucleotides 1207-1226 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1207-1226 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1207-1226 of SEQ ID NO: 5 is Isis No: 299036. In certain embodiments, an antisense compound targeted to nucleotides 1207-1226 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 39.
In certain embodiments, a target region is nucleotides 1121-1200 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1121-1200 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1121-1200 of SEQ ID NO: 5 is selected from Isis Nos: 299034 or 299035. In certain embodiments, an antisense compound targeted to nucleotides 1121-1200 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 125 or 126.
In certain embodiments, a target region is nucleotides 1181-1226 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1181-1226 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1181-1226 of SEQ ID NO: 5 is selected from Isis Nos: 299035 or 299036. In certain embodiments, an antisense compound targeted to nucleotides 1181-1226 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 126 or 39.
In certain embodiments, a target region is nucleotides 1121-1226 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1121-1226 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1121-1226 of SEQ ID NO: 5 is selected from Isis Nos: 299034, 299035 or 299036. In certain embodiments, an antisense compound targeted to nucleotides 1121-1226 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 125, 126 or 39.
In certain embodiments, a target region is nucleotides 1235-1254 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1235-1254 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1235-1254 of SEQ ID NO: 5 is Isis No: 299037. In certain embodiments, an antisense compound targeted to nucleotides 1235-1254 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 127.
In certain embodiments, a target region is nucleotides 1326-1345 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1326-1345 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1326-1345 of SEQ ID NO: 5 is Isis No: 299038. In certain embodiments, an antisense compound targeted to nucleotides 1326-1345 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 128.
In certain embodiments, a target region is nucleotides 1235-1345 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1235-1345 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1235-1345 of SEQ ID NO: 5 is selected from Isis Nos: 299037 or 299038. In certain embodiments, an antisense compound targeted to nucleotides 1235-1345 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 127 or 128.
In certain embodiments, a target region is nucleotides 1428-1447 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1428-1447 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1428-1447 of SEQ ID NO: 5 is Isis No: 299039. In certain embodiments, an antisense compound targeted to nucleotides 1428-1447 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 129.
In certain embodiments, a target region is nucleotides 1447-1466 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1447-1466 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1447-1466 of SEQ ID NO: 5 is Isis No: 299040. In certain embodiments, an antisense compound targeted to nucleotides 1447-1466 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 130.
In certain embodiments, a target region is nucleotides 1452-1471 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1452-1471 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1452-1471 of SEQ ID NO: 5 is Isis No: 299041. In certain embodiments, an antisense compound targeted to nucleotides 1452-1471 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 131.
In certain embodiments, a target region is nucleotides 1428-1466 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1428-1466 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1428-1466 of SEQ ID NO: 5 is selected from Isis Nos: 299039 or 299040. In certain embodiments, an antisense compound targeted to nucleotides 1428-1466 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 129 or 130.
In certain embodiments, a target region is nucleotides 1447-1471 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1447-1471 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1447-1471 of SEQ ID NO: 5 is selected from Isis Nos: 299040 or 299041. In certain embodiments, an antisense compound targeted to nucleotides 1447-1471 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 130 or 131.
In certain embodiments, a target region is nucleotides 1428-1471 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1428-1471 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1428-1471 of SEQ ID NO: 5 is selected from Isis Nos: 299039, 299040 or 299041. In certain embodiments, an antisense compound targeted to nucleotides 1428-1471 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 129, 130 or 131.
In certain embodiments, a target region is nucleotides 1555-1574 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1555-1574 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1555-1574 of SEQ ID NO: 5 is Isis No: 299042. In certain embodiments, an antisense compound targeted to nucleotides 1555-1574 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 132.
In certain embodiments, a target region is nucleotides 1607-1626 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1607-1626 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1607-1626 of SEQ ID NO: 5 is Isis No: 299043. In certain embodiments, an antisense compound targeted to nucleotides 1607-1626 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 133.
In certain embodiments, a target region is nucleotides 1656-1675 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1656-1675 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1656-1675 of SEQ ID NO: 5 is Isis No: 299044. In certain embodiments, an antisense compound targeted to nucleotides 1656-1675 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 134.
In certain embodiments, a target region is nucleotides 1555-1626 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1555-1626 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1555-1626 of SEQ ID NO: 5 is selected from Isis Nos: 299042 or 299043. In certain embodiments, an antisense compound targeted to nucleotides 1555-1626 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 132 or 133.
In certain embodiments, a target region is nucleotides 1607-1675 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1607-1675 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1607-1675 of SEQ ID NO: 5 is selected from Isis Nos: 299043 or 299044. In certain embodiments, an antisense compound targeted to nucleotides 1607-1675 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 133 or 134.
In certain embodiments, a target region is nucleotides 1555-1675 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1555-1675 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1555-1675 of SEQ ID NO: 5 is selected from Isis Nos: 299042, 299043 or 299044. In certain embodiments, an antisense compound targeted to nucleotides 1555-1675 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 132, 133 or 134.
In certain embodiments, a target region is nucleotides 1326-1675 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1326-1675 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1326-1675 of SEQ ID NO: 5 is selected from Isis Nos: 299038, 299039, 299040, 299041, 299042, 299043 or 299044. In certain embodiments, an antisense compound targeted to nucleotides 1326-1675 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 128, 129, 130, 131, 132, 133 or 134.
In certain embodiments, a target region is nucleotides 1741-1760 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1741-1760 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1741-1760 of SEQ ID NO: 5 is Isis No: 299045. In certain embodiments, an antisense compound targeted to nucleotides 1741-1760 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 135.
In certain embodiments, a target region is nucleotides 1772-1791 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1772-1791 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1772-1791 of SEQ ID NO: 5 is Isis No: 299046. In certain embodiments, an antisense compound targeted to nucleotides 1772-1791 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 136.
In certain embodiments, a target region is nucleotides 1919-1938 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1919-1938 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1919-1938 of SEQ ID NO: 5 is Isis No: 299047. In certain embodiments, an antisense compound targeted to nucleotides 1919-1938 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 137.
In certain embodiments, a target region is nucleotides 1968-1987 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1968-1987 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1968-1987 of SEQ ID NO: 5 is Isis No: 299048. In certain embodiments, an antisense compound targeted to nucleotides 1968-1987 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 138.
In certain embodiments, a target region is nucleotides 1979-1998 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1979-1998 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1979-1998 of SEQ ID NO: 5 is Isis No: 299049. In certain embodiments, an antisense compound targeted to nucleotides 1979-1998 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 139.
In certain embodiments, a target region is nucleotides 1968-1998 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 1968-1998 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 1968-1998 of SEQ ID NO: 5 is Isis No: 299048 or 299049. In certain embodiments, an antisense compound targeted to nucleotides 1968-1998 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 138 or 139.
In certain embodiments, a target region is nucleotides 2268-2287 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2268-2287 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2268-2287 of SEQ ID NO: 5 is Isis No: 299050. In certain embodiments, an antisense compound targeted to nucleotides 2268-2287 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 140.
In certain embodiments, a target region is nucleotides 2313-2332 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2313-2332 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2313-2332 of SEQ ID NO: 5 is Isis No: 299051. In certain embodiments, an antisense compound targeted to nucleotides 2313-2332 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 141.
In certain embodiments, a target region is nucleotides 2394-2413 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2394-2413 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2394-2413 of SEQ ID NO: 5 is Isis No: 299052. In certain embodiments, an antisense compound targeted to nucleotides 2394-2413 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 64.
In certain embodiments, a target region is nucleotides 2416-2435 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2416-2435 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2416-2435 of SEQ ID NO: 5 is Isis No: 299053. In certain embodiments, an antisense compound targeted to nucleotides 2416-2435 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 142.
In certain embodiments, a target region is nucleotides 2481-2500 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2481-2500 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2481-2500 of SEQ ID NO: 5 is Isis No: 299054. In certain embodiments, an antisense compound targeted to nucleotides 2481-2500 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 143.
In certain embodiments, a target region is nucleotides 2497-2516 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2497-2516 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2497-2516 of SEQ ID NO: 5 is Isis No: 299055. In certain embodiments, an antisense compound targeted to nucleotides 2497-2516 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 144.
In certain embodiments, a target region is nucleotides 2503-2522 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2503-2522 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2503-2522 of SEQ ID NO: 5 is Isis No: 299056. In certain embodiments, an antisense compound targeted to nucleotides 2503-2522 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 145.
In certain embodiments, a target region is nucleotides 2557-2576 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2557-2576 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2557-2576 of SEQ ID NO: 5 is Isis No: 299057. In certain embodiments, an antisense compound targeted to nucleotides 2557-2576 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 146.
In certain embodiments, a target region is nucleotides 2565-2584 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2565-2584 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2565-2584 of SEQ ID NO: 5 is Isis No: 299058. In certain embodiments, an antisense compound targeted to nucleotides 2565-2584 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 147.
In certain embodiments, a target region is nucleotides 2629-2648 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2629-2648 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2629-2648 of SEQ ID NO: 5 is Isis No: 299059. In certain embodiments, an antisense compound targeted to nucleotides 2629-2648 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 148.
In certain embodiments, a target region is nucleotides 2698-2717 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2698-2717 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2698-2717 of SEQ ID NO: 5 is Isis No: 299060. In certain embodiments, an antisense compound targeted to nucleotides 2698-2717 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 149.
In certain embodiments, a target region is nucleotides 2738-2757 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2738-2757 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2738-2757 of SEQ ID NO: 5 is Isis No: 299061. In certain embodiments, an antisense compound targeted to nucleotides 2738-2757 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 150.
In certain embodiments, a target region is nucleotides 2752-2771 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2752-2771 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2752-2771 of SEQ ID NO: 5 is Isis No: 299062. In certain embodiments, an antisense compound targeted to nucleotides 2752-2771 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 151.
In certain embodiments, a target region is nucleotides 2851-2870 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2851-2870 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2851-2870 of SEQ ID NO: 5 is Isis No: 299063. In certain embodiments, an antisense compound targeted to nucleotides 2851-2870 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 152.
In certain embodiments, a target region is nucleotides 2497-2584 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2497-2584 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2497-2584 of SEQ ID NO: 5 is selected from Isis Nos: 299055, 299056, 299057, or 299058. In certain embodiments, an antisense compound targeted to nucleotides 2497-2584 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 144, 145, 146, or 147.
In certain embodiments, a target region is nucleotides 2738-2870 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2738-2870 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2738-2870 of SEQ ID NO: 5 is selected from Isis Nos: 299061, 299062, or 299063. In certain embodiments, an antisense compound targeted to nucleotides 2738-2870 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 150, 151, or 152.
In certain embodiments, a target region is nucleotides 2497-2870 of SEQ ID NO: 5. In certain embodiments, an antisense compound is targeted to nucleotides 2497-2870 of SEQ ID NO: 5. In certain such embodiments, an antisense compound targeted to nucleotides 2497-2870 of SEQ ID NO: 5 is selected from Isis Nos: 299055, 299056, 299057, 299058, 299059, 299060, 299061, 299062, or 299063. In certain embodiments, an antisense compound targeted to nucleotides 2497-2870 of SEQ ID NO: 5 has the sequence of SEQ ID NO: 144, 145, 146, 147, 148, 149, 150, 151, or 152.
In certain embodiments, a target region is nucleotides 308-327 of SEQ ID NO: 6. In certain embodiments, an antisense compound is targeted to nucleotides 308-327 of SEQ ID NO: 6. In certain such embodiments, an antisense compound targeted to nucleotides 308-327 of SEQ ID NO: 6 is Isis No: 299011. In certain embodiments, an antisense compound targeted to nucleotides 308-327 of SEQ ID NO: 6 has the sequence of SEQ ID NO: 153.
In certain embodiments, a target region is nucleotides 1204-1223 of SEQ ID NO: 6. In certain embodiments, an antisense compound is targeted to nucleotides 1204-1223 of SEQ ID NO: 6. In certain such embodiments, an antisense compound targeted to nucleotides 1204-1223 of SEQ ID NO: 6 is Isis No: 298992. In certain embodiments, an antisense compound targeted to nucleotides 1204-1223 of SEQ ID NO: 6 has the sequence of SEQ ID NO: 154.
In certain embodiments, a target region is nucleotides 423-442 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 423-442 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 423-442 of SEQ ID NO: 8 is Isis No: 299064. In certain embodiments, an antisense compound targeted to nucleotides 423-442 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 155.
In certain embodiments, a target region is nucleotides 460-479 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 460-479 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 460-479 of SEQ ID NO: 8 is Isis No: 299003. In certain embodiments, an antisense compound targeted to nucleotides 460-479 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 96.
In certain embodiments, a target region is nucleotides 583-602 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 583-602 of SEQ ID NO: 8.In certain such embodiments, an antisense compound targeted to nucleotides 583-602 of SEQ ID NO: 8 is Isis No: 298994. In certain embodiments, an antisense compound targeted to nucleotides 583-602 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 156.
In certain embodiments, a target region is nucleotides 1913-1932 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 1913-1932 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 1913-1932 of SEQ ID NO: 8 is Isis No: 298995. In certain embodiments, an antisense compound targeted to nucleotides 1913-1932 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 157.
In certain embodiments, a target region is nucleotides 3110-3129 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3110-3129 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3110-3129 of SEQ ID NO: 8 is Isis No: 299004. In certain embodiments, an antisense compound targeted to nucleotides 3110-3129 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 97.
In certain embodiments, a target region is nucleotides 3142-3161 of SEQ ID NO: 8. In certain embodiments, antisense compound is targeted to nucleotides 3142-3161 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3142-3161 of SEQ ID NO: 8 is Isis No: 299005. In certain embodiments, an antisense compound targeted to nucleotides 3142-3161 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 98.
In certain embodiments, a target region is nucleotides 3158-3177 of SEQ ID NO: 8. In certain embodiments, an antisense compound is tareted to nucleotides 3158-3177 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3158-3177 of SEQ ID NO: 8 is Isis No: 299006. In certain embodiments, an antisense compound targeted to nucleotides 3158-3177 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 99.
In certain embodiments, a target region is nucleotides 3199-3218 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3199-3218 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3199-3218 of SEQ ID NO: 8 is Isis No: 298996. In certain embodiments, an antisense compound targeted to nucleotides 3199-3218 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 158.
In certain embodiments, a target region is nucleotides 3924-3943 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3924-3943 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3924-3943 of SEQ ID NO: 8 is Isis No: 299008. In certain embodiments, an antisense compound targeted to nucleotides 3924-3943 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 101.
In certain embodiments, a target region is nucleotides 3935-3954 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3935-3954 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3935-3954 of SEQ ID NO: 8 is Isis No: 299009. In certain embodiments, an antisense compound targeted to nucleotides 3935-3954 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 102.
In certain embodiments, a target region is nucleotides 3950-3969 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3950-3969 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3950-3969 of SEQ ID NO: 8 is Isis No: 2990010, in certain embodiments, an antisense compound targeted to nucleotides 3950-3969 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 103.
In certain embodiments, a target region is nucleotides 3924-3954 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3924-3954 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3924-3954of SEQ ID NO: 8 is selected from Isis Nos: 299008 or 299009. In certain embodiments, an antisense compound targeted to nucleotides 3924-3954 of SEQ ID N0: 8 has the sequence of SEQ ID NO: 101 or 102.
In certain embodiments, a target region is nucleotides 3935-3969 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3935-3969 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3935-3969 of SEQ ID NO: 8 is selected from Isis Nos: 299009 or 299010. In certain embodiments, an antisense compound targeted to nucleotides 3935-3969 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 102 or 103.
In certain embodiments, a target region is nucleotides 3924-3969 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 3924-3969 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 3924-3969 of SEQ ID NO: 8 is selected from Isis Nos: 299008, 299009 or 299010. In certain embodiments, an antisense compound targeted to nucleotides 3924-3969 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 101, 102 or 103.
In certain embodiments, a target region is nucleotides 4000-4019 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4000-4019 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4000-4019 of SEQ ID NO: 8 is Isis No: 299012. In certain embodiments, an antisense compound targeted to nucleotides 4000-4019 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 104.
In certain embodiments, a target region is nucleotides 4026-4045 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4026-4045 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4026-4045 of SEQ ID NO: 8 is Isis No: 299013. In certain embodiments, an antisense compound targeted to nucleotides 4026-4045 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 105.
In certain embodiments, a target region is nucleotides 4058-4077 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4058-4077 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4058-4077 of SEQ ID NO: 8 is Isis No: 299014. In certain embodiments, an antisense compound targeted to nucleotides 4058-4077 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 106.
In certain embodiments, a target region is nucleotides 4121-4140 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4121-4140 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4121-4140 of SEQ ID NO: 8 is Isis No: 299015. In certain embodiments, an antisense compound targeted to nucleotides 4121-4140 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 107.
In certain embodiments, a target region is nucleotides 4129-4148 of SEQ ID NO: 8.In certain embodiments, an antisense compound is targeted to nucleotides 4129-4148 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4129-4148 of SEQ ID NO: 8 is Isis No: 299016. In certain embodiments, an antisense compound targeted to nucleotides 4129-4148 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 108.
In certain embodiments, a target region is nucleotides 4121-4148 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4121-4148 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4121-4148 of SEQ ID NO: 8 is selected from Isis Nos: 299015 or 299016. In certain embodiments, an antisense compound targeted to nucleotides 4121-4148 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 107 or 108.
In certain embodiments, a target region is nucleotides 4058-4148 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4058-4148 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4058-4148 of SEQ ID NO: 8 is selected from Isis Nos: 299014, 299015 or 299016. In certain embodiments, an antisense compound targeted to nucleotides 4058-4148 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 106, 107 or 108.
In certain embodiments, a target region is nucleotides 4174-4193 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4174-4193 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4174-4193 of SEQ ID NO: 8 is Isis No: 299068. In certain embodiments, an antisense compound targeted to nucleotides 4174-4193 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 159.
In certain embodiments, a target region is nucleotides 4250-4269 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4250-4269 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4250-4269 of SEQ ID NO: 8 is Isis No: 298997. In certain embodiments, an antisense compound targeted to nucleotides 4250-4269 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 160.
In certain embodiments, a target region is nucleotides 4266-4285 or SEQ ID NO: 8. In certain embodiments, an antisense compound is tareted to nucleotides 4266-4285 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4266-4285 of SEQ ID NO: 8 is Isis No: 299017. In certain embodiments, an antisense compound targeted to nucleotides 4266-4285 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 109.
In certain embodiments, a target region is nucleotides 4174-4285 of SEQ ID NO: 8. In certain embodiments, antisense compound is targeted to nucleotides 4174-4285 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4174-4285 of SEQ ID NO: 8 is selected from Isis Nos: 299068, 298997, or 299017. In certain embodiments, an antisense compound targeted to nucleotides 4174-4285 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 159, 160, or 109.
In certain embodiments, a target region is nucleotides 4058-4285 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4058-4285 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4058-4285 of SEQ ID NO: 8 is selected from Isis Nos: 2999014, 299015, 299016, 299068, 298997, or 299017. In certain embodiments, an antisense compound targeted to nucleotides 4058-4285 of SEQ ID NO: 8 has the sequence of SEQ ID NOs: 106, 107, 108, 159, 160, or 109.
In certain embodiments, a target region is nucleotides 4451-4470 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4451-4470 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4451-4470 of SEQ ID NO: 8 is Isis No: 299019. In certain embodiments, an antsense compound targeted to nucleotides 4451-4470 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 111.
In certain embodiments, a target region is nucleotides 4476-4495 or SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4476-4495 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4476-4495 of SEQ ID NO: 8 is Isis No: 299020. In certain embodiments, an antisense compound targeted to nucleotides 4476-4495 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 112.
In certain embodiments, a target region is nucleotides 4560-4579 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4560-4579 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4560-4579 of SEQ ID NO: 8 is Isis No: 299021. In certain embodiments, an antisense compound targeted to nucleotides 4560-4579 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 113.
In certain embodiments, a target region is nucleotides 4576-4595 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4576-4595 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4576-4595 SEQ ID NO: 8 is Isis No: 299022. In certain embodiments, an antisense compound targeted to nucleotides 4576-4595 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 114.
In certain embodiments, a target region is nucleotides 4588-4607 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4588-4607 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4588-4607 of SEQ ID NO: 8 is Isis No: 299023. In certain embodiments, an antisense compound targeted to nucleotides 4588-4607 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 115.
In certain embodiments, a target region is nucleotides 4560-4595 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4560-4595 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4560-4595 of SEQ ID NO: 8 is selected from Isis Nos: 299021 or 299022. In certain embodiments, an antisense compound targeted to nucleotides 4560-4595 of SEQ ID NO; 8 has the sequence of SEQ ED NO: 113 or 114.
In certain embodiments, a target region is nucleotides 4576-4607 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4576-4607 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4576-4607 of SEQ ID NO: 8 is selected from Isis Nos: 299022 or 299023. In certain embodiments, an antisense compound targeted to nucleotides 4576-4607 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 114 or 115.
In certain embodiments, a target region is nucleotides 4560-4607 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 4560-4607 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 4560-4607 of SEQ ID NO: 8 is selected from Isis Nos: 299021, 299022, or 299023. In certain embodiments, an antisense compound targeted to nucleotides 4560-4607 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 113, 114, or 115.
In certain embodiments. a taret region is nucleotides 5214-5233 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5214-5233 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5214-5233 of SEQ ID NO: 8 is Isis No: 299025. In certain embodiments, an antisense compound targeted to nucleotides 5214-5233 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 117.
In certain embodiments, a target region is nucleotides 5262-5281 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5262-5281 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5262-5281 of SEQ ID NO: 8 is Isis No: 299026. In certain embodiments, an antisense compound targeted to nucleotides 5262-5281 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 118.
In certain embodiments, a target region is nucleotides 5214-5281 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5214-5281 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5214-5281 of SEQ ID NO: 8 is selected from Isis Nos: 299025 or 299026. In certain embodiments, an antisense compound targeted to nucleotides 5214-5281 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 117 or 118.
In certain embodiments, a target region is nucleotides 5905-5924 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5905-5924 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5905-5924 of SEQ ID NO: 8 is Isis No: 299027. In certain embodiments, an antisense compound targeted to nucleotides 5905-5924 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 119.
In certain embodiments, a target region is nucleotides 5910-5929 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5910-5929 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5910-5929 of SEQ ID NO: 8 is Isis. No: 299028. In certain embodiments, an antisense compound targeted to nucleotides 5910-5929 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 120.
In certain embodiments, a target region is nucleotides 5905-5929 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5905-5929 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5905-5929 of SEQ ID NO: 8 is Isis Nos 299027 or 299028. In certain embodiments, an antisense compound targeted to nucleotides 5905-5929 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 119 or 120.
In certain embodiments, a target region is nucleotides 5968-5987 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5968-5987 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5968-5987 of SEQ ID NO: 8 is Isis No: 299029. In certain embodiments, an antisense compound targeted to nucleotides 5968-5987 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 36.
In certain embodiments, a target region is nucleotides 5910-5987 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5910-5987 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5910-5987 of SEQ ID NO: 8 is Isis Nos 299028 or 299029. In certain embodiments, an antisense compound targeted to nucleotides 5910-5987 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 120 or 36.
In certain embodiments, a target region is nucleotides 5905-5987 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5905-5987 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5905-5987 of SEQ ID NO: 8 is Isis Nos 299027, 299028 or 299029. In certain embodiments, an antisense compound targeted to nucleotides 5905-5987 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 119, 120 or 36.
In certain embodiments, a target region is nucleotides 5973-5992 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5973-5992 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5973-5992 of SEQ ID NO: 8 is Isis No: 299030. In certain embodiments, an antisense compound targeted to nucleotides 5973-5992 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 121.
In certain embodiments, a target region is nucleotides 5968-5992 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5968-5992 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5968-5992 SEQ ID NO: 8 is Isis Nos 299029 or 299030. In certain embodiments, an antisense compound targeted to nucleotides 5968-5992 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 36 or 121.
In certain embodiments, a target region is nucleotides 5910-5992 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5910-5992 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5910-5992 of SEQ ID NO: 8 is Isis Nos 299028, 299029 or 299030. In certain embodiments, an antisense compound targeted to nucleotides 5910-5992 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 120, 36 or 121.
In certain embodiments, a target region is nucleotides 5905-5992 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 5905-5992 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 5905-5992 of SEQ ID NO: 8 is Isis Nos 299027, 299028, 299029 or 299030. In certain embodiments, an antisense compound targeted to nucleotides 5905-5992 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 119, 120, 36 or 121.
In certain embodiments, a target region is nucleotides 6165-6184 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6165-6184 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6165-6184 of SEQ ID NO: 8 is Isis No: 299032. In certain embodiments, an antisense compound targeted to nucleotides 6165-6184 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 123.
In certain embodiments, a target region is nucleotides 6170-6189 of SEQ ID NO: 8. In certain embodiments, an antisense compound is tareeted to nucleotides 6170-6189 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6170-6189 of SEQ ID NO: 8 is Isis No: 299033. In certain embodiments, an antisense compound targeted to nucleotides 6170-6189 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 124.
In certain embodiments, a target region is nucleotides 6165-6189 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6165-6189 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6165-6189 of SEQ ID NO: 8 is Isis Nos: 299032 or 299033. In certain embodiments, an antisense compound targeted to nucleotides 6165-6189 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 123 or 124.
In certain embodiments, a target region is nucleotides 6196-6215 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6196-6215 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6196-6215 of SEQ ID NO: 8 is Isis No: 299034. In certain embodiments, an antisense compound targeted to nucleotides 6196-6215 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 125.
In certain embodiments, a target region is nucleotides 6170-6215 of SEQ NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6170-6215 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6170-6215 of SEQ ID NO: 8 is selected from Isis Nos: 299033 or 299034. In certain embodiments, an antisense compound targeted to nucleotides 6170-6215 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 124 or 125.
In certain embodiments, a target region is nucleotides 6165-6215 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6165-6215 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6165-6215 of SEQ ID NO: 8 is selected from Isis Nos: 299032, 299033, or 299034. In certain embodiments, an antisense compound targeted to nucleotides 6165-6215 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 123, 124, or 125.
In certain embodiments, a target region is nucleotides 6256-6275 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6256-6275 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6256-6275 of SEQ ID NO: 8 is Isis No: 299035. In certain embodiments, an antisense compound targeted to nucleotides 6256-6275 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 126.
In certain embodiments, a target region is nucleotides 6663-6682 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6663-6682 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6663-6682 of SEQ ID NO: 8 is Isis No: 299037. In certain embodiments, an antisense compound targeted to nucleotides 6663-6682 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 127.
In certain embodiments, a target region is nucleotides 6754-6773 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6754-6773 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6754-6773 of SEQ ID NO: 8 is Isis No: 299038. In certain embodiments, an antisense compound targeted to nucleotides 6754-6773 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 128.
In certain embodiments, a target region is nucleotides 6868-6887 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6868-6887 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6868-6887 of SEQ ID NO: 8 is Isis No: 298993. In certain embodiments, an antisense compound targeted to nucleotides 6868-6887 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 161.
In certain embodiments, a target region is nucleotides 6930-6949 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6930-6949 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6930-6949 of SEQ ID NO: 8 is Isis No: 299039. In certain embodiments, an antisense compound targeted to nucleotides 6930-6949 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 129.
In certain embodiments, a target region is nucleotides 6949-6968 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6949-6968 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6949-6968 of SEQ ID NO: 8 is Isis No: 299040. In certain embodiments, an antisense compound targeted to nucleotides 6949-6968 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 130.
In certain embodiments, a target region is nucleotides 6930-6968 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6930-6968 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6930-6968 of SEQ ID NO: 8 is selected from Isis Nos: 299039 or 299040. In certain embodiments, an antisense compound targeted to nucleotides 6930-6968 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 129 or 130.
In certain embodiments, a target region is nucleotides 6954-6973 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6954-6973 of SEQ NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6954-6973 of SEQ ED NO: 8 is Isis No: 299041. In certain embodiments, an antisensc compound targeted to nucleotides 6954-6973 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 131.
In certain embodiments, a target region is nucleotides 6949-6973 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6949-6973 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6949-6973 of SEQ ID NO: 8 is selected from Isis Nos: 299040 or 299041. In certain embodiments, an antisense compound targeted to nucleotides 6949-6973 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 130 or 131.
In certain embodiments, a target region is nucleotides 6930-6973 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 6930-6973 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 6930-6973 of SEQ ID NO: 8 is selected from Isis Nos: 299039, 299040 or 299041. In certain embodiments, an antisense compound targeted to nucleotides 6930-6973 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 129, 130 or 131.
In certain embodiments, a target region is nucleotides 7211-7230 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 7211-7230 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 7211-7230 of SEQ ID NO: 8 is Isis No: 299043. In certain embodiments, an antisense compound targeted to nucleotides 7211-7230 of SEQ ID NO: 8 has the sequence of SFQ ID NO: 133.
In certain embodiments, a target region is nucleotides 7260-7279 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 7260-7279 of SEQ ID NO: 8. In certain such embodiments, an antisensc compound targeted to nucleotides 7260-7279 of SEQ ID NO: 8 is Isis No: 299044. In certain embodiments, an antisense compound targeted to nucleotides 7260-7279 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 134.
In certain embodiments, a target region is nucleotides 7211-7279 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 7211-7279 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 7211-7279 of SEQ ID NO: 8 is selected from Isis Nos: 299043 or 299044. In certain embodiments, an antisense compound targeted to nucleotides 7211-7279 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 133 or 134.
In certain embodiments, a target region is nucleotides 7654-7673 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 7654-7673 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 7654-7673 of SEQ ID NO: 8 is Isis No: 298998. In certain embodiments, an antisense compound targeted to nucleotides 7654-7673 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 162.
In certain embodiments, a target region is nucleotides 8267-8286 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8267-8286 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8267-8286 of SEQ ID NO: 8 is Isis No: 298999. In certain embodiments, an antisense compound targeted to nucleotides 8267-8286 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 163.
In certain embodiments, a target region is nucleotides 8899-8918 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8899-8918 of SEQ ID NO: 8. In certain such embodiments, an antisense compound tareted to nucleotides 8899-8918 of SEQ ID NO: 8 is Isis No: 299045. In certain embodiments, an antisense compound targeted to nucleotides 8899-8918 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 135.
In certain embodiments, a target region is nucleotides 8930-8949 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8930-8949 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8930-8949 of SEQ ID NO: 8 is Isis No: 299046. In certain embodiments, an antisense compound targeted to nucleotides 8930-8949 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 136.
In certain embodiments, a target region is nucleotides 8899-8949 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8899-8949 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8899-8949 of SEQ ID NO: 8 is selected from Isis Nos: 299045 or 299046. In certain embodiments, an antisense compound targeted to nucleotides 8899-8949 of SEQ NO: 8 has the sequence of SEQ ID NO: 135 or 136.
In certain embodiments, a target region is nucleotides 8971-8990 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8971-8990 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8971-8990 of SEQ ID NO: 8 is Isis No: 299000. In certain embodiments, an antisense compound targeted to nucleotides 8971-8990 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 164.
In certain embodiments, a target region is nucleotides 8930-8990 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8930-8990 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8930-8990 of SEQ ID NO: 8 is selected from Isis Nos: 299046 or 299000. In certain embodiments, an antisense compound taraeted to nucleotides 8930-8990 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 136 or 164.
In certain embodiments, a target region is nucleotides 8899-8990 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8899-8990 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8899-8990 of SEQ ID NO: 8 is selected from Isis Nos: 299045, 299046 or 299000. In certain embodiments, an antisense compound targeted to nucleotides 8899-8990 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 135, 136 or 164.
In certain embodiments, a target region is nucleotides 9169-9188 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 9169-9188 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 9169-9188 of SEQ ID NO: 8 is selected from Isis Nos: 299047. In certain embodiments, an antisense compound targeted to nucleotides 9169-9188 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 137.
In certain embodiments, a target region is nucleotides 8899-9188 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 8899-9188 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 8899-9188 of SEQ ID NO: 8 is selected from Isis Nos: 299045, 299046, 299000 or 299047. In certain embodiments, an antisense compound targeted to nucleotides 8899-9188 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 135, 136, 164 or 137.
In certain embodiments, a target region is nucleotides 9218-9237 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 9218-9237 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 9218-9237SEQ ID NO: 8 is Isis No: 299048. In certain embodiments, an antisense compound targeted to nucleotides 9218-9237 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 138.
In certain embodiments, a target region is nucleotides 9169-9237 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 9169-9237 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 9169-9237 of SEQ ID NO: 8 is selected from Isis Nos: 299047 or 299048. In certain embodiments, an antisense compound targeted to nucleotides 9169-9237 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 137 or 138.
In certain embodiments, a target region is nucleotides 9863-9882 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 9863-9882 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 9863-9882 of SEQ ID NO: 8 is Isis No: 299001. In certain embodiments, an antisense compound targeted to nucleotides 9863-9882 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 165.
In certain embodiments, a target region is nucleotides 10204-10233 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 10204-10233 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 10204-10233 of SEQ ID NO: 8 is Isis No: 299050. In certain embodiments, an antisense compound targeted to nucleotides 10204-10233 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 140.
In certain embodiments, a target region is nucleotides 10797-10816 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 10797-10816 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 10797-10816 of SEQ ID NO: 8 is Isis No: 299002. In certain embodiments, an antisense compound targeted to nucleotides 10797-10816 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 166.
In certain embodiments, a target region is nucleotides 10880-10899 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 10880-10899 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 10880-10899 of SEQ ID NO: 8 is Isis No: 299052. In certain embodiments, an antisense compound targeted to nucleotides 10880-10899 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 64.
In certain embodiments, a target region is nucleotides 10797-10899 SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 10880-10899 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 10797-10899 of SEQ ID NO: 8 is selected from Isis Nos: 299002 or 299052. In certain embodiments, an antisense compound targeted to nucleotides 10797-10899 SEQ ID NO: 8 has the sequence of SEQ ID NO: 166 or 64.
In certain embodiments, a target region is nucleotides 11096-11115 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11096-11115 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to 11096-11115 of SEQ ID NO: 8 is Isis No: 299054. In certain embodiments, an antisense compound targeted to nucleotides 11096-11115 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 143.
In certain embodiments, a target region is nucleotides 11112-11131 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11112-11131 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to 11112-11131 of SEQ ID NO: 8 is Isis No: 299055. In certain embodiments, an antisense compound targeted to nucleotides 11112-11131 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 144.
In certain embodiments, a target region is nucleotides 11096-11131 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11096-11131 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to 11096-11131 of SEQ ID NO: 8 is selected from Isis Nos: 299054 or 299055. In certain embodiments, an antisense compound targeted to nucleotides 11096-11131 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 143 or 144.
In certain embodiments, a target region is nucleotides 11118-11137 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11118-11137 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to 11118-11137 of SEQ ID NO: 8 is Isis No: 299056. In certain embodiments, an antisense compound targeted to nucleotides 11118-11137 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 145.
In certain embodiments, a target region is nucleotides 11112-11137 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11112-11137 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to 11112-11137 of SEQ ID NO: 8 is selected from Isis Nos: 299055 or 299056. In certain embodiments, an antisense compound targeted to nucleotides 11112-11137 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 144 or 145.
In certain embodiments, a target region is nucleotides 11096-11137 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11096-11137 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11096-11137 of SEQ ID NO: 8 is selected from Isis Nos: 299054, 299055, or 299056. In certain embodiments, an antisense compound targeted to nucleotides 11096-11137 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 143, 144, or 145.
In certain embodiments, a target region is nucleotides 11172-11191 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11172-11191 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11172-11191 of SEQ ID NO: 8 is Isis No: 299057. In certain embodiments, an antisense compound targeted to nucleotides 11172-11191 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 146.
In certain embodiments, a target region is nucleotides 11118-11191 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11172-11191 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11118-11191 of SEQ ID NO: 8 is selected from Isis Nos: 299056 or 299057. In certain embodiments, an antisense compound targeted to nucleotides 11118-11191 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 145 or 146.
In certain embodiments, a target region is nucleotides 11112-11191 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11112-11191 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11112-11191 of SEQ ID NO: 8 is selected from Isis Nos: 299055, 299056, or 299057. In certain embodiments, an antisense compound targeted to nucleotides 11112-11191 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 144, 145, or 146.
In certain embodiments, a target region is nucleotides 11096-11191 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 1109611191 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11096-11191 of SEQ ID NO: 8 is selected from Isis Nos: 299054, 299055, 299056, or 299057. In certain embodiments, an antisense compound targeted to nucleotides 11096-11191 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 143, 144, 145, or 146.
In certain embodiments, a target region is nucleotides 11180-11199 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11180-11199 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11180-11199 of SEQ ID NO: 8 is Isis No: 299058. In certain embodiments, an antisense compound targeted to nucleotides 11180-11199 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 147.
In certain embodiments, a target region is nucleotides 11172-11199 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11172-11199 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11172-11199 of SEQ ID NO: 8 is selected from Isis Nos: 299057 or 299058. In certain embodiments, an antisense compound targeted to nucleotides 11172-11199 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 146 or 147.
In certain embodiments, a target region is nucleotides 11118-11199 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11118-11199 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11118-11199 of SEQ ID NO: 8 is selected from Isis Nos: 299056, 299057 or 299058. In certain embodiments, an antisense compound targeted to nucleotides 11118-11199 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 145, 146 or 147.
In certain embodiments, a target region is nucleotides 11112-11199 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11112-11199 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11112-11199 of SEQ ID NO: 8 is selected from Isis Nos: 299055, 299056, 299057 or 299058. In certain embodiments, an antisense compound targeted to nucleotides 11112-11199 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 144, 145, 146 or 147.
In certain embodiments, a target region is nucleotides 11096-11199 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11096-11199 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11096-11199 of SEQ ID NO: 8 is selected from Isis Nos: 299054, 299055, 299056, 299057 or 299058. In certain embodiments, an antisense compound targeted to nucleotides 11096-11199 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 143, 144, 145, 146 or 147.
In certain embodiments, a target region is nucleotides 11244-11263 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11244-11263 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11244-11263 of SEQ ID NO: 8. is Isis No: 299059. In certain embodiments, an antisense compound targeted to nucleotides 11244-11263 of SEQ ID NO: 8. has the sequence of SEQ ID NO: 148.
In certain embodiments, a target region is nucleotides 11313-11332 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11313-11332 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11313-11332 of SEQ ID NO: 8 is Isis No: 299060. In certain embodiments, an antisense compound targeted to nucleotides 11313-11332 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 149.
In certain embodiments, a target region is nucleotides 11353-11372 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11353-11372 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11353-11372 of SEQ ID NO: 8 is Isis No: 299061. In certain embodiments, an antisense compound targeted to nucleotides 11353-11372 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 150.
In certain embodiments, a target region is nucleotides 11367-11386 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11367-11386 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11367-11386 of SEQ ID NO: 8 is Isis No: 299062. In certain embodiments, an antisense compound targeted to nucleotides 11367-11386 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 151
In certain embodiments, a target region is nucleotides 11353-11386 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11353-11386 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11353-11386 of SEQ ID NO: 8 is selected from Isis Nos: 299061 or 299062. In certain embodiments, an antisense compound targeted to nucleotides 11353-11386 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 150 or 151.
In certain embodiments, a target region is nucleotides 11466-11485 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11466-11485 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11466-11485 of SEQ ID NO: 8 is Isis No: 299063. In certain embodiments, an antisense compound targeted to nucleotides 11466-11485 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 152.
In certain embodiments, a target region is nucleotides 11367-11485 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11367-11485 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11367-11485 of SEQ ID NO: 8 is selected from Isis Nos: 299062 or 299063. In certain embodiments, an antisense compound targeted to nucleotides 11367-11485 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 151 or 152.
In certain embodiments, a target region is nucleotides 11353-11485 of SEQ ID NO: 8. In certain embodiments, an antisense compound is targeted to nucleotides 11353-11485 of SEQ ID NO: 8. In certain such embodiments, an antisense compound targeted to nucleotides 11353-11485 of SEQ ID NO: 8 is selected from Isis Nos: 299061, 299062 or 299063. In certain embodiments, an antisense compound targeted to nucleotides 11353-11485 of SEQ ID NO: 8 has the sequence of SEQ ID NO: 150, 151 or 152.
In certain embodiments, the desired effect is a reduction in mRNA target nucleic acid levels. In other embodiments, the desired effect is reduction of levels of protein encoded by the target nucleic acid or a phenotypic change associated with the target nucleic acid.
In one embodiment, a target region is a structurally defined region of the nucleic acid. For example, a target region may encompass a 3′ UTR, a 5′ UTR, an exon, an intron, a coding region, a translation initiation region, translation termination region, or other defined nucleic acid region. In other embodiments, a target region may encompass the sequence from a 5′ target site of one target segment within the target region to a 3′ target site of another target segment within the target region.
Targeting includes determination of at least one target segment to which an antisense compound hybridizes, such that a desired effect occurs. A target region may contain one or more target segments. Multiple target segments within a target region may be overlapping. Alternatively, they may be non-overlapping. In one embodiment, target segments within a target region are separated by no more than about 10 nucleotides on the target nucleic acid. In another embodiment, target segments within a target region are separated by no more than about 5 nucleotides on the target nucleic acid. In additional embodiments, target segments are contiguous.
Suitable target segments may be found within a 5′ UTR, a coding region, a 3′ UTR, an intron, or an exon. Target segments containing a start codon or a stop codon are also suitable target segments.
The determination of suitable target segments may include a comparison of the sequence of a target nucleic acid to other sequences throughout the genome. For example, the BLAST algorithm may be used to identify regions of similarity amongst different nucleic acids. This comparison can prevent the selection of antisense compound sequences that may hybridize in a non-specific manner to sequences other than a selected target nucleic acid (i.e., non-target or off-target sequences).
There may be variation in activity (e.g., as defined by percent reduction of target nucleic acid levels) of the antisense compounds within an active target region. In one embodiment, reductions in FGFR4 mRNA levels are indicative of inhibition of FGFR4 expression. Reductions in levels of an FGFR4 protein are also indicative of inhibition of target FGFR4 expression. Further, phenotypic changes are indicative of inhibition of FGFR4 expression. For example, a decrease in body fat content is indicative of inhibition of FGFR4 expression.
In certain embodiments, the compound comprises an antisense nucleic acid molecule that is specifically hybridizable with a region of a nucleic acid molecule encoding FGFR4 selected from a 5′-untranslated region (5′UTR), a start region, a coding region, a stop region, or a 3′-untranslated region (3′UTR).
In certain other embodiments, the antisense compound is targeted to nucleotides 26-45 in the (5′UTR), nucleotides 160-179, 192-227, 254-323, 354-399, 412-431, 475-502, 529-548, 597-646, 711-776, 785-804, 833-852, 964-988, 1027-1051, 1076-1140, 1181-1226, 1235-1254, 1326-1345, 1428-1471, 1555-1574, 1607-1626, 1656-1675, 1742-1760, 1772-1791, 1919-1938, 1968-1998, 2268-2287, 2313, 2332, 2394-2435, 2481-2522 in the coding region of SEQ ID NO: 5; nucleotides 2557-2584, 2629-2648, 2698-2717, 2738-2757, 2752-2771, 2851-2870 in the 3′ UTR, all of SEQ ID NO: 5; (exon2) nucleotides 115-258, (exon3) nucleotides 259-522, (exon4) nucleotides 523-603, (exon5) nucleotides 604-770, (exon6) nucleotides 771-894, (exon7) nucleotides 895-1085, (exon8) nucleotides 1086-1224, (exon9) nucleotides 1225-1418, (exon10) nucleotides 1419-1564, (exon11) nucleotides 1565-1696, (exon12) nucleotides 1687-1797, (exon13) nucleotides 1798-1988, (exon14) nucleotides 1989-2111, (exon15) nucleotides 2112-2182, (exon16) nucleotides 2183-2320, (exon17) nucleotides 2321-2426, (exon18) nucleotides 2427-3026, and nucleotides 26-45, 160-179, 192-211, 160-211, 208-227, 160-227, 192-227, 254-273, 278-297, 289-308, 289-323, 278-308, 304-323, 278-323, 289-373, 278-373, 354-373, 380-399, 412-431, 475-494, 412-494, 483-502, 475-502, 529-548, 597-616, 602-621, 597-621, 627-646, 711-730, 727-746, 739-758, 757-776, 711-746, 711-758, 711-776, 727-746, 727-758, 739-758, 727-776, 739-776, 757-776, 785-804, 833-852, 785-852, 833-983, 964-983, 785-983, 833-988, 785-988, 969-988, 964-988, 1027-1046, 1032-1051, 1027-1051, 1076-1096, 1090-1109, 1095-1114, 1076-1109, 1076-1114, 1090-1114, 1121-1040, 1181-1200, 1121-1200, 1121-1226, 1181-1226, 1235-1345, 1428-1447, 1447-1466, 1428-1466, 1452-1471, 1428-1471, 1555-1574, 1607-1626, 1656-1675, 155-1626, 1607-1675, 1555-1675, 1326-1675, 1741-1760, 1772-1791, 1919-1938, 1968-1987, 1979-1998, 1968-1998, 2268-2287, 2313-2332, 2394-2413, 2481-2500, 2497-2516, 2503-2522, 2557-2576, 2565-2584, 2629-2648, 2738-2757, 2752-2771, 2497-2584, 2738-2870, 2497-2870, or 2313-2413 of SEQ ID NO: 5.
In certain other embodiments, the antisense compound is targeted to nucleotides 26-45 in the (5′UTR), nucleotides 3118-3120 of the start codon, nucleotides 11192-111642 of the 3′ UTR, (exon1) nucleotides 379-548, (exon1a) nucleotides 538-592, (exon2) nucleotides 3065-3208, (exon3) nucleotides 3905-4168, (exon4) nucleotides 4260-4340, (exon4a) nucleotides 4260-4611, (exon5) nucleotides 4453-4619, (exon6) nucleotides 5200-5323, (exon7) nucleotides 5836-6026, (exon8) nucleotides 6161-6299, (exon9) nucleotides 6653-6846, (exon10a) nucleotides 6847-7066, (exon10) nucleotides 6291-7066, (exon11) nucleotides 7169-7290, (exon12) nucleotides 8845-8955, (exon13) nucleotides 9048-9238, (exon14) nucleotides 9572-9694, (exon15) nucleotides 9802-9872, (exon16) nucleotides 10119-10256, (exon17) nucleotides 10807-10912, (exon18) nucleotides 11042-11641, (intron1) nucleotides 549-3064, (intron1a) nucleotides 593-3064, (intron2) nucleotides 3209-3904, (intron3) nucleotides 4169-4259, (intron4) nucleotides 4941-4452, (intron5) nucleotides 4620-5199, (intron6) nucleotides 5324-5835, (intron1) nucleotides 6027-6160, (intron8) nucleotides 6300-6652, (intron9) nucleotides 6847-6920, (intron10) nucleotides 7067-7168, (intron11) nucleotides 7291-8844, (intron12) nucleotides 8956-9047, (intron13) nucleotides 9239-9571, (intron14) nucleotides 9695-9801, (intron15) nucleotides 9873-10118, (intron16) nucleotides 10257-10806, and (intron17) nucleotides 10913-11041, nucleotides 432-442, 460-479, 538-602, 1913-1932, 3110-3129, 3142-3161, 3158-3177, 3199-3218, 3924-3943, 3935-3954, 3950-3969, 3924-3954, 3935-3969, 3924-3969, 4000-4019, 4026-4045, 4058-4077, 4121-4140, 4129-4148, 4121-4148, 4058-4148, 4174-4193, 4250-4269, 4266-4285, 4174-4285, 4058-4285, 4451-4470, 4476-4495, 4560-4579, 4576-4595, 4588-4607, 4560-4595, 4576-4607, 4560-4607, 5214-5233, 5262-5281, 5214-5281, 5905-5924, 5910-5929, 5905-5929, 5968-5987, 5910-5987, 5905-5987, 5973-5992, 5968-5992, 5910-5992, 6165-6184, 6170-6189, 6165-6189, 6196-6215, 6170-6215, 6256-6275, 6663-6682, 6754-6773, 6868-6887, 6930-6949, 6949-6968, 6930-6968, 6954-6973, 6949-6973, 6930-6973, 7211-7230, 7260-7279, 7211-7279, 7654-7673, 8267-8286, 8899-8918, 8930-8948, 8899-8948, 8971-8990, 8930-8990, 8899-8990, 9169-9188, 8899-9188, 9218-9237, 9169-9237, 9863-9882, 10204-10233, 10797-10816, 10880-10899, 10797-10899, 10880-10899, 11096-11115, 11112-11131, 11096-11131, 11118-11137, 11112-11137, 11096-11137, 11172-11191, 11118-11191, 11112-11191, 11096-11191, 11172-11199, 11180-11199, 11118-11199, 11112-11199, 11096-11199, 11244-11265, 11313-11332, 11353-11372, 11369-11386, 11466-11485, 11367-11485, or 11353-11485 of SEQ ID NO: 8.
Hybridization
For example, hybridization may occur between an antisense compound disclosed herein and a FGFR4 nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.
Hybridization can occur under varying conditions. Stringent conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.
Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In one embodiment, the antisense compounds provided herein are specifically hybridizable with an FGFR4 nucleic acid.
Complementarity
An antisense compound and a target nucleic acid are complementary to each other when a sufficient number of nucleobases of the antisense compound can hydrogen bond with the corresponding nucleobases of the target nucleic acid, such that a desired effect will occur (e.g., antisense inhibition of a target nucleic acid, such as an FGFR4 nucleic acid).
Non-complementary nucleobases between an antisense compound and an FGFR4 nucleic acid may be tolerated provided that the antisense compound remains able to specifically hybridize to a target nucleic acid. Moreover, an antisense compound may hybridize over one or more segments of an FGFR4 nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).
In some embodiments, the antisense compounds provided herein are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% complementary to an FGFR4 nucleic acid. Percent complementarity of an antisense compound with a target nucleic acid can be determined using routine methods.
In other embodiments, the antisense compounds provided herein are fully complementary (i.e., 100% complementary) to a target nucleic acid. For example, antisense compound may be fully complementary to an FGFR4 nucleic acid. As used herein, “fully complementary” means each nucleobase of an antisense compound is capable of precise base pairing with the corresponding nucleobases of a target nucleic acid.
The location of a non-complementary nucleobase may be at the 5′ end or 3′ end of the antisense compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the antisense compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.
In one embodiment, antisense compounds up to 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2 or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as an FGFR4 nucleic acid.
In another embodiment, antisense compounds up to 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2 or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as an FGFR4 nucleic acid.
The antisense compounds provided herein also include those which are complementary to a portion of a target nucleic acid. As used herein, “portion” refers to a defined number of contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A “portion” can also refer to a defined number of contiguous nucleobases of an antisense compound. In one embodiment, the antisense compounds are complementary to at least an 8 nucleobase portion of a target segment. In another embodiment, the antisense compounds are complementary to at least a 12 nucleobase portion of a target segment. In yet another embodiment, the antisense compounds are complementary to at least a 15 nucleobase portion of a target segment.
Identity
The antisense compounds provided herein may also have a defined percent identity to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific Isis number. As used herein, an antisense compound is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, an RNA which contains uracil in place of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the antisense compounds described herein as well as compounds having non-identical bases relative to the antisense compounds provided herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the antisense compound. Percent identity of an antisense compound is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared.
In one embodiment, the antisense compounds are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% identical to one or more of the antisense compounds disclosed herein.
Modifications
A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2′, 3′ or 5′ hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.
Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.
Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.
Modified Internucleoside Linkages
The naturally occurring internucleoside linkage of RNA and DNA is a 3′ to 5′ phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.
Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.
In one embodiment, antisense compounds targeted to an FGFR4 nucleic acid comprise one or more modified internucleoside linkages. In some embodiments, the modified internucleoside linkages are phosphorothioate linkages. In other embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.
Modified Sugar Moieties
Antisense compounds targeted to an FGFR4 nucleic acid may contain one or more nucleotides having modified sugar moieties. Sugar modifications may impart nuclease stability, binding affinity or some other beneficial biological property to the antisense compounds. The furanosyl sugar ring of a nucleoside can be modified in a number of ways including, but not limited to: addition of a substituent group, particularly at the 2′ position; bridging of two non-geminal ring atoms to form a bicyclic nucleic acid (BNA); and substitution of an atom or group such as —S—, —N(R)— or —C(R1)(R2) for the ring oxygen at the 4′-position. Modified sugars include, but are not limited to: substituted sugars, especially 2′-substituted sugars having a 2′-F, 2′-OCH2 (2′-OMe) or a 2′-O(CH2)2—OCH3 (2′-O-methoxyethyl or 2′-MOE) substituent group; and bicyclic modified sugars (BNAs), having a 4′-(CH2)n—O-2′ bridge, where n=1 or n=2. Methods for the preparations of modified sugars are well known to those skilled in the art.
In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified or a combination thereof) are maintained for hybridization with an appropriate nucleic acid target.
In one embodiment, antisense compounds targeted to an FGFR4 nucleic acid comprise one or more nucleotides having modified sugar moieties. In a suitable embodiment, the modified sugar moiety is 2′-MOE. In other embodiments, the 2′-MOE modified nucleotides are arranged in a gapmer motif.
Modified Nucleobases
Nucleobase (or base) modifications or substitutions are structurally distinguishable from, yet functionally interchangeable with, naturally occurring or synthetic unmodified nucleobases. Both natural and modified nucleobases are capable of participating in hydrogen bonding. Such nucleobase modifications may impart nuclease stability, binding affinity or some other beneficial biological property to antisense compounds. Modified nucleobases include synthetic and natural nucleobases such as, for example, 5-methylcytosine (5-me-C). Certain nucleobase substitutions, including 5-methylcytosine substitutions, are particularly useful for increasing the binding affinity of an antisense compound for a target nucleic acid. For example, 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278).
Additional unmodified nucleobases include 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡C—CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.
Heterocyclic base moieties may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Nucleobases that are particularly useful for increasing the binding affinity of antisense compounds include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
In one embodiment, antisense compounds targeted to an FGFR4 nucleic acid comprise one or more modified nucleobases. In an additional embodiment, gapmer antisense oligonucleotides targeted to an FGFR4 nucleic acid comprise one or more modified nucleobases. In some embodiments, the modified nucleobase is 5-methylcytosine. In further embodiments, each cytosine is a 5-methylcytosine.
Compositions and Methods for Formulating Pharmaceutical Compositions
Antisense oligonucleotides may be admixed with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.
An antisense compound targeted to an FGFR4 nucleic acid can be utilized in pharmaceutical compositions by combining the antisense compound with a suitable pharmaceutically acceptable diluent or carrier. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS). PBS is a diluent suitable for use in compositions to be delivered parenterally. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising an antisense compound targeted to an FGFR4 nucleic acid and a pharmaceutically acceptable diluent. In one embodiment, the pharmaceutically acceptable diluent is PBS. In other embodiments, the antisense compound is an antisense oligonucleotide.
Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.
A prodrug can include the incorporation of additional nucleosides at one or both ends of an antisense compound which are cleaved by endogenous nucleases within the body, to form the active antisense compound.
In certain embodiments, pharmaceutical compositions of the present invention comprise one or more oligonucleotides and one or more excipients. In certain such embodiments, excipients are selected from water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulosem and polyvinylpyrrolidone.
In certain embodiments, a pharmaceutical composition of the present invention is prepared using known techniques, including, but not limited to mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.
In certain embodiments, a pharmaceutical composition of the present invention is a liquid (e.g., a suspension, elixir and/or solution). In certain of such embodiments, a liquid pharmaceutical composition is prepared using ingredients known in the art, including, but not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
In certain embodiments, a pharmaceutical composition of the present invention is a solid (e.g., a powder, tablet, and/or capsule). In certain of such embodiments, a solid pharmaceutical composition comprising one or more oligonucleotides is prepared using ingredients known in the art, including, but not limited to, starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents.
In certain embodiments, a pharmaceutical composition of the present invention is formulated as a depot preparation. Certain such depot preparations are typically longer acting than non-depot preparations. In certain embodiments, such preparations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, depot preparations are prepared using suitable polymeric or hydrophobic materials (for example an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
In certain embodiments, a pharmaceutical composition of the present invention comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.
In certain embodiments, a pharmaceutical composition of the present invention comprises one or more tissue-specific delivery molecules designed to deliver the one or more pharmaceutical agents of the present invention to specific tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody.
In certain embodiments, a pharmaceutical composition of the present invention comprises a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80TM; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
In certain embodiments, a pharmaceutical composition of the present invention comprises a sustained-release system. A non-limiting example of such a sustained-release system is a semi-permeable matrix of solid hydrophobic polymers. In certain embodiments, sustained-release systems may, depending on their chemical nature, release pharmaceutical agents over a period of hours, days, weeks or months.
In certain embodiments, a pharmaceutical composition of the present invention is prepared for oral administration. In certain of such embodiments, a pharmaceutical composition is formulated by combining one or more oligonucleotides with one or more pharmaceutically acceptable carriers. Certain of such carriers enable pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject. In certain embodiments, pharmaceutical compositions for oral use are obtained by mixing oligonucleotide and one or more solid excipient. Suitable excipients include, but are not limited to, fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certain embodiments, such a mixture is optionally ground and auxiliaries are optionally added. In certain embodiments, pharmaceutical compositions are formed to obtain tablets or dragee cores. In certain embodiments, disintegrating agents (e.g., cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate) are added.
In certain embodiments, dragee cores are provided with coatings. In certain such embodiments, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to tablets or dragee coatings.
In certain embodiments, pharmaceutical compositions for oral administration are push-fit capsules made of gelatin. Certain of such push-fit capsules comprise one or more pharmaceutical agents of the present invention in admixture with one or more filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In certain embodiments, pharmaceutical compositions for oral administration are soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In certain soft capsules, one or more pharmaceutical agents of the present invention are be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
In certain embodiments, pharmaceutical compositions are prepared for buccal administration. Certain of such pharmaceutical compositions are tablets or lozenges formulated in conventional manner.
In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also contain suitable stabilizers or agents that increase the solubility of the phaiinaceutical agents to allow for the preparation of highly concentrated solutions.
In certain embodiments, a pharmaceutical composition is prepared for transmucosal administration. In certain of such embodiments penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
In certain embodiments, a pharmaceutical composition is prepared for administration by inhalation. Certain of such pharmaceutical compositions for inhalation are prepared in the form of an aerosol spray in a pressurized pack or a nebulizer. Certain of such pharmaceutical compositions comprise a propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In certain embodiments using a pressurized aerosol, the dosage unit may be determined with a valve that delivers a metered amount. In certain embodiments, capsules and cartridges for use in an inhaler or insufflator may be formulated. Certain of such formulations comprise a powder mixture of a pharmaceutical agent of the invention and a suitable powder base such as lactose or starch.
In certain embodiments, a pharmaceutical composition is prepared for rectal administration, such as a suppositories or retention enema. Certain of such pharmaceutical compositions comprise known ingredients, such as cocoa butter and/or other glycerides.
In certain embodiments, a pharmaceutical composition is prepared for topical administration. Certain of such pharmaceutical compositions comprise bland moisturizing bases, such as ointments or creams. Exemplary suitable ointment bases include, but are not limited to, petrolatum, petrolatum plus volatile silicones, lanolin and water in oil emulsions such as EucerinTM, available from Beiersdorf (Cincinnati, Ohio). Exemplary suitable cream bases include, but are not limited to, NiveaTM. Cream, available from Beiersdorf (Cincinnati, Ohio), cold cream (USP), Purpose CreamTM, available from Johnson & Johnson (New Brunswick, N.J.), hydrophilic ointment (USP) and LubridermTM, available from Pfizer (Morris Plains, N.J.).
In certain embodiments, a pharmaceutical composition of the present invention comprises an oligonucleotide in a therapeutically effective amount. In certain embodiments, the therapeutically effective amount is sufficient to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.
In certain embodiments, one or more oligonucleotides of the present invention is formulated as a prodrug. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically more active form of the oligonucleotide. In certain embodiments, prodrugs are useful because they are easier to administer than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., through oral administration) than is the corresponding active form. In certain instances, a prodrug may have improved solubility compared to the corresponding active form. In certain embodiments, prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, a prodrug is an ester. In certain such embodiments, the ester is metabolically hydrolyzed to carboxylic acid upon administration. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is cleaved upon administration to form the corresponding active form.
In certain embodiments, a prodrug is produced by modifying a pharmaceutically active compound such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, e.g., Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392).
In certain embodiments, a pharmaceutical composition comprising one or more pharmaceutical agents of the present invention is useful for treating a conditions or disorders in a mammalian, and particularly in a human, subject. Suitable administration routes include, but are not limited to, oral, rectal, transmucosal, intestinal, enteral, topical, suppository, through inhalation, intrathecal, intraventricular, intraperitoneal, intranasal, intraocular and parenteral (e.g., intravenous, intramuscular, intramedullary, and subcutaneous). In certain embodiments, pharmaceutical intrathecals are administered to achieve local rather than systemic exposures. For example, pharmaceutical compositions may be injected directly in the area of desired effect (e.g., in the renal or cardiac area).
In certain embodiments, a pharmaceutical composition of the present invention is administered in the form of a dosage unit (e.g., tablet, capsule, bolus, etc.). In certain embodiments, such pharmaceutical compositions comprise an oligonucleotide in a dose selected from 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 270 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 mg, 495 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 595 mg, 600 mg, 605 mg, 610 mg, 615 mg, 620 mg, 625 mg, 630 mg, 635 mg, 640 mg, 645 mg, 650 mg, 655 mg, 660 mg, 665 mg, 670 mg, 675 mg, 680 mg, 685 mg, 690 mg, 695 mg, 700 mg, 705 mg, 710 mg, 715 mg, 720 mg, 725 mg, 730 mg, 735 mg, 740 mg, 745 mg, 750 mg, 755 mg, 760 mg, 765 mg, 770 mg, 775 mg, 780 mg, 785 mg, 790 mg, 795 mg, and 800 mg. In certain such embodiments, a pharmaceutical composition of the present invention comprises a dose of oligonucleotide selected from 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700 mg, and 800 mg. In certain embodiments, a pharmaceutical composition is comprises a dose of oligonucleotide selected from 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, and 400 mg. In certain embodiments the dose is administered at intervals ranging from more than once per day, once per day, once per week, twice per week, three times per week, four times per week, five times per week, 6 times per week, once per month to once per three months, for as long as needed to sustain the desired effect.
In a further aspect, a pharmaceutical agent is sterile lyophilized oligonucleotide that is reconstituted with a suitable diluent, e.g., sterile water for injection. The reconstituted product is administered as a subcutaneous injection or as an intravenous infusion after dilution into saline. The lyophilized drug product consists of the oligonucleotide which has been prepared in water for injection, adjusted to pH 7.0-9.0 with acid or base during preparation, and then lyophilized. The lyophilized oligonucleotide may be 25-800 mg of the oligonucleotide. It is understood that this encompasses 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, and 800 mg of lyophilized oligonucleotide. The lyophilized drug product may be packaged in a 2 mL Type I, clear glass vial (ammonium sulfate-treated), stoppered with a bromobutyl rubber closure and sealed with an aluminum FLIP-OFF® overseal. In one embodiment, the lyophilized pharmaceutical agent comprises ISIS 301012.
The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the oligonucleotide(s) of the formulation.
Conjugated Antisense Compounds
Antisense compounds may be covalently linked to one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the resulting antisense oligonucleotides. Typical conjugate groups include cholesterol moieties and lipid moieties. Additional conjugate groups include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.
Antisense compounds can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of antisense compounds to enhance properties such as, for example, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect the antisense compound having terminal nucleic acid from exonuclease degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5′-terminus (5′-cap), or at the 3′-terminus (3′-cap), or can be present on both termini. Cap structures are well known in the art and include, for example, inverted deoxy abasic caps. Further 3′ and 5′-stabilizing groups that can be used to cap one or both ends of an antisense compound to impart nuclease stability include those disclosed in WO 03/004602 published on Jan. 16, 2003.
Cell Culture and Antisense Compounds Treatment
The effects of antisense compounds on the level, activity or expression of mDICT nucleic acids can be tested in vitro in a variety of cell types. Cell types used for such analyses are available from commerical vendors (e.g. American Type Culture Collection, Manassus, Va.; Zen-Bio, Inc., Research Triangle Park, N.C.; Clonetics Corporation, Walkersville, Md.) and cells are cultured according to the vendor's instructions using commercially available reagents (e.g. Invitrogen Life Technologies, Carlsbad, Calif.). Illustrative cell types include, but are not limited to, HepG2 cells, Hep3B cells, and primary hepatocytes.
In Vitro Testing of Antisense Oligonucleotides
Described herein are methods for treatment of cells with antisense oligonucleotides, which can be modified appropriately for treatment with other antisense compounds.
In general, cells are treated with antisense oligonucleotides when they cells reach approximately 60-80% confluency in culture.
One reagent commonly used to introduce antisense oligonucleotides into cultured cells includes the cationic lipid transfection reagent LIPOFECTIN® (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotides are mixed with LIPOFECTIN® in OPTI-MEM® 1 (Invitrogen, Carlsbad, Calif.) to achieve the desired final concentration of antisense oligonucleotide and a LIPOFECTIN® concentration that typically ranges 2 to 12 ug/mL per 100 nM antisense oligonucleotide.
Another reagent used to introduce antisense oligonucleotides into cultured cells includes LIPOFECTAMINE® (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotide is mixed with LIPOFECTAMINE® in OPTI-MEM® 1 reduced serum medium (Invitrogen, Carlsbad, Calif.) to achieve the desired concentration of antisense oligonucleotide and a LIPOFECTAMINE® concentration that typically ranges 2 to 12 ug/mL per 100 nM antisense oligonucleotide.
Cells are treated with antisense oligonucleotides by routine methods. Cells are typically harvested 16-24 hours after antisense oligonucleotide treatment, at which time RNA or protein levels of target nucleic acids are measured by methods known in the art and described herein. In general, when treatments are performed in multiple replicates, the data are presented as the average of the replicate treatments.
The concentration of antisense oligonucleotide used varies from cell line to cell line. Methods to determine the optimal antisense oligonucleotide concentration for a particular cell line are well known in the art. Antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300 nM.
RNA Isolation
RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in the art. RNA is prepared using methods well known in the art, for example, using the TRIZOL® Reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer's recommended protocols.
Analysis of Inhibition of Target Levels or Expression
Inhibition of levels or expression of an FGFR4 nucleic acid can be assayed in a variety of ways known in the art. For example, target nucleic acid levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or quantitaive real-time PCR. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in the art. Northern blot analysis is also routine in the art. Quantitative real-time PCR can be conveniently accomplished using the commercially available ABI PRISM® 7600, 7700, or 7900 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions.
Quantitative Real-Time PCR Analysis of Target RNA Levels
Quantitation of target RNA levels may be accomplished by quantitative real-time PCR using the ABI PRISM® 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. Methods of quantitative real-time PCR are well known in the art.
Prior to real-time PCR, the isolated RNA is subjected to a reverse transcriptase (RT) reaction, which produces complementary DNA (cDNA) that is then used as the substrate for the real-time PCR amplification. The RT and real-time PCR reactions are performed sequentially in the same sample well. RT and real-time PCR reagents are obtained from Invitrogen (Carlsbad, Calif.). RT, real-time-PCR reactions are carried out by methods well known to those skilled in the art.
Gene (or RNA) target quantities obtained by real time PCR are normalized using either the expression level of a gene whose expression is constant, such as GAPDH, or by quantifying total RNA using RIBOGREEN® (Invetrogen, Inc. Carlsbad, Calif.). GAPDH expression is quantified by real time PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RIBOGREEN® RNA quantification reagent (Invetrogen, Inc. Eugene, Oreg.). Methods of RNA quantification by RIBOGREEN® are taught in Jones, L. J., et al, (Analytical Biochemistry, 1998, 265, 368-374). A CYTOFLUOR® 4000 instrument (PE Applied Biosystems) is used to measure RIBOGREEN® fluorescence.
Probes and primers are designed to hybridize to an mDICT nucleic acid. Methods for designing real-time PCR probes and primers are well known in the art, and may include the use of software such as PRIMER EXPRESS® Software (Applied Biosystems, Foster City, Calif.).
Analysis of Protein Levels
Antisense inhibition of FGFR4 nucleic acids can be assessed by measuring FGFR4 protein levels. Protein levels of FGFR4 can be evaluated or quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme-linked immunosorbent assay (ELISA), quantitative protein assays, protein activity assays (for example, caspase activity assays), immunohistochemistry, immunocytochemistry or fluorescence-activated cell sorting (FACS). Antibodies directed to a target can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional monoclonal or polyclonal antibody generation methods well known in the art. Antibodies useful for the detection of human and rat FGFR4 are commercially available.
In Vivo Testing of Antisense Compounds
Antisense compounds, for example, antisense oligonucleotides, are tested in animals to assess their ability to inhibit expression of FGFR4 and produce phenotypic changes, such as decreases in body weight. Testing may be performed in normal animals, or in experimental disease models. For administration to animals, antisense oligonucleotides are formulated in a pharmaceutically acceptable diluent, such as phosphate-buffered saline. Administration includes parenteral routes of administration, such as intraperitoneal, intravenous, and subcutaneous. Calculation of antisense oligonucleotide dosage and dosing frequency is within the abilities of those skilled in the art, and depends upon factors such as route of administration and animal body weight. Following a period of treatment with antisense oligonucleotides, RNA is isolated from various tissues and changes in FGFR4 nucleic acid expression are measured. Changes in FGFR4 protein levels may also be measured.
Animal Models of Obesity


    
    
        Non-Limiting Disclosure and Incorporation by Reference
    
    


The following examples serve only to illustrate the methods, antisense oligonucleotides, and compositions provided and are not intended to limit the same. Each of the references, GENBANK® accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety. By incorporation of GENBANK® Accession Nos., associated sequence and structural data pertaining to such sequences including gene organization and structural elements that may be found in sequence databases such as the National Center for Biotechnology Information (NCBI) by searching such GENBANK® Accession Nos. are incorporated herein by reference in their entirety.
EXAMPLES
Example 1
Antisense Inhibition of Mus musculus FGFR4: Primary Hepatocytes
Antisense oligonucleotides targeted to a FGFR4 nucleic acid were tested for their effects on) FGFR4 mRNA expression in vitro. Cultured primary hepatocytes plated in a 96-well plate were treated with 60 nM of antisense oligonucleotide. Transfection was carried out using CytofectinTM (Genlantis, San Diego, Calif.). After a treatment period of approximately 24 hours, RNA was isolated from the cells and FGFR4 mRNA levels were measured by quantitative real-time PCR, as described herein using the primer/probe set shown in Table 4. Probes and primers to mouse FGFR4 were designed to hybridize to a mouse FGFR4 sequence, using published sequence information (GenBank® accession number BC033313.1 incorporated herein as SEQ ID NO: 10).







TABLE 4







Gene Target-specific mouse Primers and Probes for Use in Real-Time PCR















Target



SEQ


Target

Seq ID
Sequence


ID


Name
Species
No
Description
Sequence (5′ to 3′)
Length
NO





mFGFR4
Mouse
10
Forward
CCTTATGCCCCCATCTCAG
19
167





Primer





 


mFGFR4
Mouse
10
Reverse
TCCCAAGGCCTCTAGGTTG
19
168





Primer





 


mFGFR4
Mouse
10
Probe
CTCTCCGGGACTAGCTGCAA
50
169






AACTTATGCTCTAAACATTT








CTAGTTCCCC









The FGFR4 mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN®. Results are presented as percent inhibition of FGFR4, relative to untreated control cells. Antisense oligonucleotides that exhibited at least 30% inhibition of FGFR4 expression are shown in Table 5.
The oligonucleotides of Table 5, have a 5-10-52′-MOE gapmer motif. The heading “5′ target site” indicates the 5′-most nucleotide corresponding to the first base to which the antisense oligonucleotide is targeted on the indicated GENBANK® Accession No.
All antisense compounds in Table 5 are gapmers having 20 linked nucleobases and composed of a central “gap” segment consisting of 2′-deoxynucleotides, which are flanked on both sides (5′ and 3′ directions) by wing segments having 2′-modifications. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytosine nucleobases are 5-methylcytosines.







TABLE 5







Inhibition of Gene Target mRNA Levels by Chimeric Oligonucleotides 


with 2′-MOE Wings and Deoxy Gap (mus musculus)














Target
5′
3′


SEQ



SEQ ID
Target
Target

%
ID


ISIS #
 NO
Site
Site
Sequence (5′ to 3′)
Inhibition
NO





393247
10
  228
  247
GGGCTGGCACACTCACCCGC
91
15


 


393248
10
  238
  257
GATCCCGGCAGGGCTGGCAC
87
16


 


393249
10
  244
  263
GGTCACGATCCCGGCAGGGC
83
17


 


393250
10
  337
  356
GCCACATTTCCTTCCAGCTG
95
18


 


393251
10
  346
  365
CCAAGAGCAGCCACATTTCC
68
19


 


393252
10
  355
  374
TCAACAGGGCCAAGAGCAGC
71
20


 


393253
10
  402
  421
TTCCTCAGAGGCCTCAAGGG
88
21


 


393254
10
  600
  619
AGGAAGGAAGCTGGCGATCT
59
22


 


393255
10
  610
  629
CAGCATCCTCAGGAAGGAAG
52
23


 


393256
10
  635
  654
CCACGGGCCAGGCAGAGGTA
93
24


 


393257
10
  644
  663
GTCATGGAGCCACGGGCCAG
87
25


 


393258
10
  682
  701
AGGAGTCATCCATAAGCAAC
79
26


 


393259
10
  687
  706
GGTTAAGGAGTCATCCATAA
85
27


 


393260
10
  694
  713
TGATGGAGGTTAAGGAGTCA
75
28


 


393261
10
  773
  792
TGTGTCCAGTAGGGTGCTTG
72
29


 


393262
10
  873
  892
CCAGTGGATGGTAGGCATGG
97
30


 


393263
10
  878
  897
TTGAGCCAGTGGATGGTAGG
87
31


 


393264
10
  996
 1015
AAGGCATGTGTATGTGCCAC
57
32


 


393265
10
 1001
 1020
TCCACAAGGCATGTGTATGT
79
33


 


393266
10
 1020
 1039
AATGCTACCCAGAGAGTTCT
80
34


 


393267
10
 1048
 1067
CCAGCACATCCAGGAGATAG
61
35


 


299029
10
 1200
 1219
GCTGCTGCCGTTGATGACGA
95
36


 


393268
10
 1245
 1264
TGTTGTCTTCAGGACTTGTA
74
37


 


393269
10
 1364
 1383
AGCCACGCTGACTGGTAGGA
85
38


 


299036
10
 1380
 1399
CTCTGGCAGCACCGTGAGCC
90
39


 


393270
10
 1446
 1465
TGATACATACAGGATGATAT
37
40


 


393271
10
 1466
 1485
ACAAGCAGAACCAGTGAGCC
64
41


 


393272
10
 1471
 1490
GGAGCACAAGCAGAACCAGT
74
42


 


393273
10
 1490
 1509
TACACCCCGGCCAGCAGCAG
74
43


 


393274
10
 1604
 1623
GACTTGCCAGAGGACCTCGA
88
44


 


393275
10
 1615
 1634
GGGACAAACTTGACTTGCCA
79
45


 


393276
10
 1625
 1644
CCTCGCACCAGGGACAAACT
62
46


 


393277
10
 1670
 1689
ACAAGGCCCGTGAGCAAGGG
64
47


 


393278
10
 1756
 1775
CAAAGCAGCCCTCACCCAGG
50
48


 


393279
10
 1775
 1794
TCTGCACGAACCACTTGCCC
79
49


 


393280
10
 1796
 1815
GAGGGATCCATACCAAAGGC
93
50


 


393281
10
 1850
 1869
GAGGCATTGTCTTTCAGCAT
77
51


 


393282
10
 1870
 1889
GGTCTGCCAAATCCTTGTCG
86
52


 


393283
10
 1910
 1929
TGTCTTCCGATTAGCTTCAT
61
53


 


393284
10
 1939
 1958
AGACACCCAGCAGGTTGATG
56
54


 


393285
10
 1945
 1964
GAGTGCAGACACCCAGCAGG
76
55


 


393286
10
 1956
 1975
GGGCCCTTCCTGAGTGCAGA
72
56


 


393287
10
 2048
 2067
CCATCAGGGCTGAGATCAGG
70
57


 


322160
10
 2131
 2150
CCAGATACTGCATGCCTCGG
88
58


 


393288
10
 2150
 2169
TGGATGCACTTCCGAGACTC
61
59


 


393289
10
 2380
 2399
CCCCGAGGGTGAAGATTTCC
73
60


 


393290
10
 2440
 2459
TGTGCCCCTCTCGCAGCAGT
81
61


 


393291
10
 2490
 2509
CCTCATTAGCCCATACAGCT
44
62


 


393292
10
 2555
 2574
TTGTCCAGAGCTTCCACCAG
65
63


 


299052
10
 2567
 2586
GCCAGCAGGACCTTGTCCAG
85
64


 


393293
10
 2580
 2599
CTCTTCAGAGACAGCCAGCA
54
65


 


393294
10
 2600
 2619
GTCAGGCGGAGGTCAAGGTA
75
66


 


393295
10
 2616
 2635
AGAAAAGGGTCCAAAGGTCA
75
67


 


393296
10
 2628
 2647
CCCATTGGAGGGAGAAAAGG
65
68


 


393297
10
 2635
 2654
TGGCATCCCCATTGGAGGGA
83
69


 


393298
10
 2641
 2660
TGCTGCTGGCATCCCCATTG
87
70


 


393299
10
 2880
 2899
CAGGGCCAGAGAGAGGATCT
90
71


 


393300
10
 2935
 2954
TGGAACAGAAGGCCTCAACT
80
72


 


393301
10
 2994
 3013
CCAAGGGCAAGGCCATGATC
76
73


 


393302
10
 3000
 3019
ATGAGTCCAAGGGCAAGGCC
80
74


 


393303
10
 3005
 3024
TGAGGATGAGTCCAAGGGCA
83
75


 


393304
10
 3085
 3104
TAGAGCATAAGTTTTGCAGC
79
76


 


393305
10
 3090
 3109
ATGTTTAGAGCATAAGTTTT
51
77


 


393306
10
 3095
 3114
TAGAAATGTTTAGAGCATAA
72
78


 


393307
10
 3120
 3139
AGGCCTCTAGGTTGTTTGGG
79
79


 


393308
10
 3277
 3296
TTTATAAAAATGCCATGTTC
61
80


 


393310
14
 3566
 3585
TTCCATGCCCAGTTTGGGAC
74
81


 


393311
14
 4800
 4819
GGAGTCATTGATACCCATAG
80
82


 


393312
14
 6049
 6068
GTCAGAGTGGAGGCAGGTTA
77
83


 


393313
14
 7448
 7467
TTGATTCCCAGCAAATACAT
49
84


 


393314
14
 7805
 7824
ACCCAGCACATCCAGGAGAT
68
85


 


393315
14
 8295
 8314
CCCCACAAATGTTGCACCCA
73
86


 


393316
14
10349
10368
GCCCAGGTTGCCATGTGTAC
84
87


 


393317
14
12504
12523
GGTTTTGTTATGCATTAGAG
80
88


 


393318
14
14115
14134
GATCAGGAAGCATAGAAGGA
66
89


 


393319
14
15655
15674
GACAGTGGTGTGAGTAGTAT
50
90


 


393320
14
16387
16406
GAACAGGTCAAAGAGGTTTG
54
91









Antisense oligonucleotides with the following Isis Nos. exhibited at least 75% inhibition of FGFR4 mRNA levels: 299029, 299036, 299052, 322160, 393247, 393248, 393249, 393250, 393253, 393256, 393257, 393258, 393259, 393260, 393262, 393263, 393265, 393266, 393269, 393274, 393275, 393279, 393280, 393281, 393282, 393285, 393290, 393294, 393295, 393297, 393298, 393299, 393300, 393301, 393302, 393303, 393304, 393307, 393311, 393312, 393316, and 393317. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Antisense oligonucleotides with the following Isis Nos. exhibited at least 80% inhibition of FGFR4 mRNA levels: 299029, 299036, 299052, 322160, 393247, 393248, 393249, 393250, 393253, 393256, 393257, 393259, 393262, 393263, 393266, 393269, 393274, 393280, 393282, 393290, 393297, 393298, 393299, 393300, 393302, 393303, 393311, 393316, and 393317. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Antisense oligonucleotides with the following Isis Nos. exhibited at least 85% inhibition of FGFR4 mRNA levels: 299029, 299036, 299052, 322160, 393247, 393248, 393250, 393253, 393256, 393257, 393259, 393262, 393263, 393269, 393274, 393280, 393282, 393298, and 393299. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Antisense oligonucleotides with the following Isis Nos. exhibited at least 90% inhibition of FGFR4 mRNA levels: 299036, 299029, 393247, 393250, 393256, 393262, 393280, and 393299. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions
Antisense oligonucleotides with the following Isis Nos. exhibited at least 95% inhibition of FGFR4 mRNA levels: 299029, 393250, and 393262. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Example 2
Antisense Inhibition of Human FGFR4: A459 Cells
Antisense oligonucleotides targeted to a FGFR4 nucleic acid were tested for their effects on FGFR4 mRNA expression in vitro. Cultured A459 Cells in a 96-well plate were treated with 160 nM of antisense oligonucleotide. Transfection was carried out using CytofectinTM (Genlantis, San Diego, Calif.). After a treatment period of approximately 24 hours, RNA was isolated from the cells and FGFR4 mRNA levels were measured by quantitative real-time PCR, as described herein using the primer/probe set shown in Table 6. Probes and primers to human FGFR4 were designed to hybridize to a human FGFR4 sequence, using published sequence information (GenBank® accession number NM—002011.3, incorporated herein as SEQ ID NO: 5).







TABLE 6







Gene Target-specific human Primers and Probes for Use in Real-Time PCR















Target



SEQ


Target

SEQ ID
Sequence


ID


Name
Species
 NO
Description
Sequence (5′ to 3′)
Length
NO





FGFR4
Human
5
Forward
GTTCTGCTCGGCTTCTTGG
19
170





Primer





 


FGFR4
Human
5
Reverse
AGGCTTCCAGCTTCTCTGG
19
171





Primer





 


FGFR4
Human
5
Probe
GGCTGAGCCTGGCTGGAGAG
50
172






CTGCTATGCTAAACCTCCTGC








CTCCCAATA









The FGFR4 mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN®. Results are presented as percent inhibition of FGFR4, relative to untreated control cells. Antisense oligonucleotides that exhibited inhibition of human FGFR4 expression are shown in Table 7.
The oligonucleotides of Table 7, have a 5-10-52′-MOE gapmer motif. The heading “5′ target site” indicates the 5′-most nucleotide corresponding to the first base to which the antisense oligonucleotide is targeted on the indicated GENBANK® Accession No.
All antisense compounds in Table 7 are gapmers having 20 linked nucleobases and composed of a central “gap” segment consisting of 2′-deoxynucleotides, which are flanked on both sides (5′ and 3′ directions) by wing segments having 2′-modifications. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytosine nucleobases are 5-methylcytosines.







TABLE 7







Inhibition of Gene Target mRNA Levels by Chimeric Oligonucleotides 


with 2′-MOE Wings and Deoxy Gap (human)














Target
5′
3′


SEQ



SEQ ID
Target
Target

%
ID


ISIS # 
 NO
Site
Site
Sequence (5′ to 3′)
Inhibition
NO





299069
2
  455
  474
CAGCGGGACACAAGTCCTTG
52
 92


 


299067
3
   46
   65
AACTGCCTTCCTCGAGCCTG
59
 93


 


299065
4
  306
  325
GTCAAGGAGTCAAGCTCCAC
 2
 94


 


299066
4
  891
  910
GGTAGAGGGATGTCAACCAG
 5
 95


 


299003
5
   26
   45
GGCAGGGTCCGCAGACAGCC
60
 96


 


299004
5
  160
  179
CAGCAGCCGCATCTCCTTCT
86
 97


 


299005
5
  192
  211
GGCACACTCAGCAGGACCCC
80
 98


 


299006
5
  208
  227
CAAGACTGGAGGCCCAGGCA
82
 99


 


299007
5
  254
  273
GAGCCAGGCAGGGCTCAAGC
47
100


 


299008
5
  278
  297
CCTGCTCTTGCTGCTCCAGG
76
101


 


299009
5
  289
  308
TACTGTCAGCTCCTGCTCTT
75
102


 


299010
5
  304
  323
AGGCTGCCCAAGGGCTACTG
73
103


 


299012
5
  354
  373
TCCTTGTACCAGTGGCCACC
83
104


 


299013
5
  380
  399
GGCCAGCAGGTGCCAGGCGA
64
105


 


299014
5
  412
  431
AATCTCTAGGCGGCCCCTCC
79
106


 


299015
5
  475
  494
GACGATCATGGAGCCTCGTG
80
107


 


299016
5
  483
  502
TTCTGCAGGACGATCATGGA
63
108


 


299017
5
  529
  548
ATCATCGTTGCTGGAGGTCA
84
109


 


299018
5
  597
  616
GTCCAGTAGGGTGCTTGCTG
69
110


 


299019
5
  602
  621
GGTGTGTCCAGTAGGGTGCT
67
111


 


299020
5
  627
  646
TGCAGTTTCTTCTCCATGCG
69
112


 


299021
5
  711
  730
CCATCCTTAAGCCAGCGGAT
37
113


 


299022
5
  727
  746
CCCATGAAAGGCCTGTCCAT
82
114


 


299023
5
  739
  758
AATGCGGTTCTCCCCATGAA
55
115


 


299024
5
  757
  776
GCGCAGCCGAATGCCTCCAA
81
116


 


299025
5
  785
  804
TCTCCATCACGAGACTCCAG
76
117


 


299026
5
  833
  852
CGTTCTCTACCAGGCAGGTG
79
118


 


299027
5
  964
  983
CTTGCACAGCAGCTCCACGT
84
119


 


299028
5
  969
  988
TACACCTTGCACAGCAGCTC
79
120


 


299029
5
 1027
 1046
GCTGCTGCCGTTGATGACGA
69
 36


 


299030
5
 1032
 1051
CCGAAGCTGCTGCCGTTGAT
81
121


 


299031
5
 1076
 1095
TGTCTGCAGTCTTTAGGACT
65
122


 


299032
5
 1090
 1109
CTCTGAGCTATTGATGTCTG
69
123


 


299033
5
 1095
 1114
TCCACCTCTGAGCTATTGAT
65
124


 


299034
5
 1121
 1140
CTGACACGTTCCGCAGGTAC
71
125


 


299035
5
 1181
 1200
ACTGGTAGGAGAGGCCGATG
57
126


 


299036
5
 1207
 1226
CTCTGGCAGCACCGTGAGCC
81
 39


 


299037
5
 1235
 1254
GCGCTGCTGCGGTCCATGTG
61
127


 


299038
5
 1326
 1345
TGCCCTCGATACAGCCCGGC
86
128


 


299039
5
 1428
 1447
TTGCCGGAAGAGCCTGACTC
72
129


 


299040
5
 1447
 1466
TACCAGGGATGAGCTTGACT
84
130


 


299041
5
 1452
 1471
CCTCGTACCAGGGATGAGCT
85
131


 


299042
5
 1555
 1574
AAGCACCAGCCTGTCCCGGG
76
132


 


299043
5
 1607
 1626
AGGCCTCTGCACGTACTACC
89
133


 


299044
5
 1656
 1675
TTGACGGCCACAGTGCTGGC
78
134


 


299045
5
 1741
 1760
CTTGTGTCGGCCGATCAGCT
53
135


 


299046
5
 1772
 1791
GGGTGCAGACACCAAGCAGG
86
136


 


299047
5
 1919
 1938
AGACCAGGACTGGGAAGGAG
86
137


 


299048
5
 1968
 1987
TTCCGGGACTCCAGATACTG
61
138


 


299049
5
 1979
 1998
GGTGGATACACTTCCGGGAC
48
139


 


299050
5
 2268
 2287
CGATGTCCCTCCCGCAGCAG
66
140


 


299051
5
 2313
 2332
ATCAGCCCGTACAGCTCTGG
77
141


 


299052
5
 2394
 2413
GCCAGCAGGACCTTGTCCAG
74
 64


 


299053
5
 2416
 2435
GTCGAGGTACTCCTCAGAGA
62
142


 


299054
5
 2481
 2500
CTGGAGGAGCAGGTGCTGCT
 5
143


 


299055
5
 2497
 2516
GCTGAAGACAGAATCGCTGG
86
144


 


299056
5
 2503
 2522
GTCGTGGCTGAAGACAGAAT
71
145


 


299057
5
 2557
 2576
TCATGTCTGCACCCCAGACC
83
146


 


299058
5
 2565
 2584
AGCCTTGCTCATGTCTGCAC
81
147


 


299059
5
 2629
 2648
TGTGTCAGGCTGTGGCTGAG
64
148


 


299060
5
 2698
 2717
AAGGGCACGGCCCTTGGACA
57
149


 


299061
5
 2738
 2757
ATTTGGGCCATCAGGACACA
81
150


 


299062
5
 2752
 2771
AGCAGAACCCTGACATTTGG
88
151


 


299063
5
 2851
 2870
CCTGCTGGTATTGGGAGGCA
78
152


 


299011
6
  308
  327
ACAGCACAGCCGCACAGGCT
66
153


 


298992
6
 1204
 1223
CGCCCAGTACCTGGCAGCAC
11
154


 


299064
8
  423
  442
GGAGCGAGGAATGTACCCGC
52
155


 


299003
8
  460
  479
GGCAGGGTCCGCAGACAGCC
60
 96


 


298994
8
  583
  602
TCCGGCTCACCTCGAGCCTG
17
156


 


298995
8
 1913
 1932
GGAAACATCCTCTCCCTCGG
55
157


 


299004
8
 3110
 3129
CAGCAGCCGCATCTCCTTCT
86
 97


 


299005
8
 3142
 3161
GGCACACTCAGCAGGACCCC
80
 98


 


299006
8
 3158
 3177
CAAGACTGGAGGCCCAGGCA
82
 99


 


298996
8
 3199
 3218
GAAGCCATACCAAGCTCCAC
47
158


 


299008
8
 3924
 3943
CCTGCTCTTGCTGCTCCAGG
76
101


 


299009
8
 3935
 3954
TACTGTCAGCTCCTGCTCTT
75
102


 


299010
8
 3950
 3969
AGGCTGCCCAAGGGCTACTG
73
103


 


299012
8
 4000
 4019
TCCTTGTACCAGTGGCCACC
83
104


 


299013
8
 4026
 4045
GGCCAGCAGGTGCCAGGCGA
64
105


 


299014
8
 4058
 4077
AATCTCTAGGCGGCCCCTCC
79
106


 


299015
8
 4121
 4140
GACGATCATGGAGCCTCGTG
80
107


 


299016
8
 4129
 4148
TTCTGCAGGACGATCATGGA
63
108


 


299068
8
 4174
 4193
TTCACTCCCTGCTAGAGTCT
80
159


 


298997
8
 4250
 4269
GTCAAGGAGTCTACATCAGG
67
160


 


299017
8
 4266
 4285
ATCATCGTTGCTGGAGGTCA
84
109


 


299019
8
 4451
 4470
GGTGTGTCCAGTAGGGTGCT
67
111


 


299020
8
 4476
 4495
TGCAGTTTCTTCTCCATGCG
69
112


 


299021
8
 4560
 4579
CCATCCTTAAGCCAGCGGAT
37
113


 


299022
8
 4576
 4595
CCCATGAAAGGCCTGTCCAT
82
114


 


299023
8
 4588
 4607
AATGCGGTTCTCCCCATGAA
55
115


 


299025
8
 5214
 5233
TCTCCATCACGAGACTCCAG
76
117


 


299026
8
 5262
 5281
CGTTCTCTACCAGGCAGGTG
79
118


 


299027
8
 5905
 5924
CTTGCACAGCAGCTCCACGT
84
119


 


299028
8
 5910
 5929
TACACCTTGCACAGCAGCTC
79
120


 


299029
8
 5968
 5987
GCTGCTGCCGTTGATGACGA
69
 36


 


299030
8
 5973
 5992
CCGAAGCTGCTGCCGTTGAT
81
121


 


299032
8
 6165
 6184
CTCTGAGCTATTGATGTCTG
69
123


 


299033
8
 6170
 6189
TCCACCTCTGAGCTATTGAT
65
124


 


299034
8
 6196
 6215
CTGACACGTTCCGCAGGTAC
71
125


 


299035
8
 6256
 6275
ACTGGTAGGAGAGGCCGATG
57
126


 


299037
8
 6663
 6682
GCGCTGCTGCGGTCCATGTG
61
127


 


299038
8
 6754
 6773
TGCCCTCGATACAGCCCGGC
86
128


 


298993
8
 6868
 6887
AGTCAGGCTGTCACATGTGA
48
161


 


299039
8
 6930
 6949
TTGCCGGAAGAGCCTGACTC
72
129


 


299040
8
 6949
 6968
TACCAGGGATGAGCTTGACT
84
130


 


299041
8
 6954
 6973
CCTCGTACCAGGGATGAGCT
85
131


 


299043
8
 7211
 7230
AGGCCTCTGCACGTACTACC
89
133


 


299044
8
 7260
 7279
TTGACGGCCACAGTGCTGGC
78
134


 


298998
8
 7654
 7673
GTGAGCCCCTTCTATTAGTC
34
162


 


298999
8
 8267
 8286
AATGTGCATTTCTCAATCCC
70
163


 


299045
8
 8899
 8918
CTTGTGTCGGCCGATCAGCT
53
135


 


299046
8
 8930
 8949
GGGTGCAGACACCAAGCAGG
86
136


 


299000
8
 8971
 8990
AACGGCCCGTGCAGCCAGCC
71
164


 


299047
8
 9169
 9188
AGACCAGGACTGGGAAGGAG
86
137


 


299048
8
 9218
 9237
TTCCGGGACTCCAGATACTG
61
138


 


299001
8
 9863
 9882
CAGGACTCACACGTCACTCT
 0
165


 


299050
8
10204
10223
CGATGTCCCTCCCGCAGCAG
66
140


 


299002
8
10797
10816
CAGCCCGTACCTGCGAGAGG
55
166


 


299052
8
10880
10899
GCCAGCAGGACCTTGTCCAG
74
 64


 


299054
8
11096
11115
CTGGAGGAGCAGGTGCTGCT
 5
143


 


299055
8
11112
11131
GCTGAAGACAGAATCGCTGG
86
144


 


299056
8
11118
11137
GTCGTGGCTGAAGACAGAAT
71
145


 


299057
8
11172
11191
TCATGTCTGCACCCCAGACC
83
146


 


299058
8
11180
11199
AGCCTTGCTCATGTCTGCAC
81
147


 


299059
8
11244
11263
TGTGTCAGGCTGTGGCTGAG
64
148


 


299060
8
11313
11332
AAGGGCACGGCCCTTGGACA
57
149


 


299061
8
11353
11372
ATTTGGGCCATCAGGACACA
81
150


 


299062
8
11367
11386
AGCAGAACCCTGACATTTGG
88
151


 


299063
8
11466
11485
CCTGCTGGTATTGGGAGGCA
78
152









Antisense oligonucleotides with the following Isis Nos. exhibited at least 75% inhibition of FGFR4 mRNA levels: 299004, 299005, 299006, 299008, 299009, 299012, 299014, 299015, 299017, 299022, 299024, 299025, 299026, 299027, 299028, 299030, 299036, 299038, 299040, 299041, 299042, 299043, 299044, 299046, 299047, 299051, 299055, 299057, 299058, 299061, 299062, 299063, and 299068. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Antisense oligonucleotides with the following Isis Nos. exhibited at least 80% inhibition of FGFR4 mRNA levels: 299004, 299005, 299006, 299012, 299015, 299017, 299022, 299024, 299027, 299030, 299036, 299038, 299040, 299041, 299043, 299046, 299047, 299055, 299057, 299058, 299061, 299062, and 299068. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Antisense oligonucleotides with the following Isis Nos. exhibited at least 85% inhibition of FGFR4 mRNA levels: 299004, 299038, 299041, 299043, 299046, 299047, 299055, and 299062. The target segments to which these antisense oligonucleotides are targeted are active target segments. The target regions to which these antisense oligonucleotides are targeted are active target regions.
Example 3
Mus Musculus FGFR4Cross-Species Reactivity
The antisense compounds in Table 5 were designed to target different regions of the mouse FGFR4 RNA but have complementarity across species. Specifically, certain of the antisense compounds in table 5 are cross-reactive with rat mRNA. These include ISIS No's 299052, 322160, 393247, 393248, 393249, 393250, 393253, 393254, 393255, 393256, 393257, 393266, 393268, 393269, 393273, 393274, 393275, 393276, 393277, 393278, 393279, 393281, 393282, 393283, 393285, 393286, 393287, 393288, 393289, 393290, 393291, 393292, 393293, 393294, 393298, 393299, 393300, 393303, and 393307. Certain of the antisense compounds in Table 5 are cross-reactive with human FGFR4 sequences. Mouse FGFR4 antisense compounds that are cross reactive with human FGFR4 sequences are listed in Table 8.







TABLE 8







Mus Musculus Cross- species reactivity













Target
5′






SEQ ID
Target


SEQ ID


Isis #
NO
Site
Mismatches
Sequence (5′ to 3′)
 NO















393253
5
  229
1
TTCCTCAGAGGCCTCAAGGG
21


 


393254
5
  427
2
AGGAAGGAAGCTGGCGATCT
22


 


393255
5
  437
1
CAGCATCCTCAGGAAGGAAG
23


 


393256
5
  462
2
CCACGGGCCAGGCAGAGGTA
24


 


393260
5
  521
2
TGATGGAGGTTAAGGAGTCA
28


 


393261
5
  600
0
TGTGTCCAGTAGGGTGCTTG
29


 


393269
5
 1191
2
AGCCACGCTGACTGGTAGGA
38


 


393273
5
 1317
1
TACACCCCGGCCAGCAGCAG
43


 


393278
5
 1583
2
CAAAGCAGCCCTCACCCAGG
48


 


393281
5
 1677
2
GAGGCATTGTCTTTCAGCAT
51


 


393284
5
 1766
1
AGACACCCAGCAGGTTGATG
54


 


393285
5
 1772
2
GAGTGCAGACACCCAGCAGG
55


 


393286
5
 1783
1
GGGCCCTTCCTGAGTGCAGA
56


 


322160
5
 1958
0
CCAGATACTGCATGCCTCGG
58


 


393288
5
 1977
2
TGGATGCACTTCCGAGACTC
59


 


393289
5
 2207
1
CCCCGAGGGTGAAGATTTCC
60


 


393292
5
 2382
2
TTGTCCAGAGCTTCCACCAG
63


 


393293
5
 2407
2
CTCTTCAGAGACAGCCAGCA
65


 


393294
5
 2427
1
GTCAGGCGGAGGTCAAGGTA
66


 


393253
8
 3179
1
TTCCTCAGAGGCCTCAAGGG
21


 


393254
8
 4073
2
AGGAAGGAAGCTGGCGATCT
22


 


393255
8
 4083
1
CAGCATCCTCAGGAAGGAAG
23


 


393256
8
 4108
2
CCACGGGCCAGGCAGAGGTA
24


 


393261
8
 4449
1
TGTGTCCAGTAGGGTGCTTG
29


 


393269
8
 6266
2
AGCCACGCTGACTGGTAGGA
38


 


393273
8
 6745
1
TACACCCCGGCCAGCAGCAG
43


 


393278
8
 7187
2
CAAAGCAGCCCTCACCCAGG
48


 


393284
8
 8924
1
AGACACCCAGCAGGTTGATG
54


 


393285
8
 8930
2
GAGTGCAGACACCCAGCAGG
55


 


322160
8
 9208
0
CCAGATACTGCATGCCTCGG
58


 


393289
8
10143
1
CCCCGAGGGTGAAGATTTCC
60


 


393292
8
10868
2
TTGTCCAGAGCTTCCACCAG
63


 


393293
8
10893
2
CTCTTCAGAGACAGCCAGCA
65


 


393294
8
11042
1
GTCAGGCGGAGGTCAAGGTA
66









In Vivo Pharmacology (Prevention Study)
Example 4
Antisense Inhibition of FGFR4Levels In Vivo Studies in a Diet-Induced Model of Obesity (Prevention Study)
The C57BL/6 mouse strain is reported to be susceptible to weight gain when fed a high-fat diet. Accordingly, these mice (8 weeks old) were fed a high-fat diet for 14 days prior to administration of FGFR4 antisense oligonucleotides. They were then used in the following studies to evaluate the effects of FGFR4 antisense oligonucleotides on mRNA expression in liver and fat tissues in a diet-induced model of obesity.
Male C57BL/6 mice at 8 weeks of age were placed on a high-fat diet containing 58% calories from fat (Research Diet D12492, Research Diets Inc., New Brunswick, N.J.) 14 days prior to the initial dosing administration. The mice were divided into three treatment groups. One group received subcutaneous injections of ISIS 393250 (SEQ ID NO: 18) at a dose of 25 mg/kg twice per week for 12 weeks. The second group received subcutaneous injections of ISIS 141923, CCTTCCCTGAAGGTTCCTCC (SEQ ID NO: 173), at a dose of 25 mg/kg twice per week for 12 weeks. Oligonucleotides were dissolved in 0.9% saline for injection. A group of mice fed normal chow also received subcutaneous injections of saline twice weekly for 12 weeks. The saline-injected group fed the high-fat diet served as the control group to which the oligonucleotide-treated groups were compared.
After the 12 week treatment period, the mice were sacrificed and FGFR4 mRNA levels were evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT). mRNA levels were quantitated by real-time PCR as described in other examples herein. The results are presented in Table 9 and are expressed as percent inhibition relative to saline-treated mice receiving a high fat diet.







TABLE 9







Antisense inhibition of FGFR4 mRNA expression in liver and


fat tissues (Prevention study)


% Inhibition of FGFR4 mRNAs














Brown
White



ISIS #
Liver
Fat tissue
Fat tissue















Saline-58% HF
0
0
0



FGFR4 393250
−68.9
−56.65
−69.57









FGFR4 antisense oligonucleotide treatment, but not control antisense oligonucleotide treatment, reduced FGFR4 mRNA levels by  ̃69%, 57% and 70% in liver, brown adipose tissue and white adipose tissue, respectively. The data demonstrate that FGFR4 antisense oligonucleotide treatment can effectively reduce target mRNA levels in liver, brown adipose tissue and white adipose tissue.
Example 5
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Body Weight (Prevention Study)
Male C57BL/6J mice (age 10 weeks at time 0) were fed 58% high-fat diet for 14 days and were then divided into matched groups (n=6) based on body weight and body composition, and treated by subcutaneous injections twice a week with saline, ISIS 141923 (SEQ ID NO: 173, a control oligonucleotide) or ISIS 393250 (SEQ ID NO: 18, FGFR4 antisense oligonucleotide). The mice were treated at a dose of 25 mg/kg twice a week of ISIS 141923 or ISIS 393250, or saline, twice a week. A group of mice fed normal chow also received subcutaneous injections of saline twice weekly as normal controls. Treatment was continued for 12 weeks. At the end of the study, mice were sacrificed and tissues where collected and weighed. The results are presented in Table 10.







TABLE 10







Antisense inhibition of FGFR4 on total body


weight in Diet-induced Obese mice


(Prevention study)


Body Weight (g)










Mean










Weeks:





















0
1
2
3
4
5
6
7
8
9
10
11
12
























Saline
26.1
27.8
29.0
30.0
31.2
32.1
32.4
33.2
34.2
35.5
35.5
36.6
36.5


141923- Control
26.1
27.7
29.9
30.2
31.3
32.3
32.1
32.3
33.1
33.2
32.9
33.6
34.0


393250 - FGFR4
26.3
27.7
28.6
29.3
30.0
30.1
30.2
29.9
30.3
30.4
29.9
30.4
30.4


Chow-saline
23.9
24.2
24.8
25.3
25.7
25.9
25.7
26.0
26.8
26.8
26.5
27.3
27.5









Treatment of C57BL/6J mice with ISIS 393250 (SEQ ID NO: 18) resulted in a decrease in body weight gain, with animals gaining an average of 4.1 grams while saline treated controls gained 10.4 grams. Animals treated with the control oligonucleotide gained an average of 7.9 grams of body weight.
Saline-chow littermate animals gained 3.6 grams of body weight compared to a gain of 10.4 grams for the saline high-fat fed controls.
There was no appreciable change in food intake among the treatment groups.
Example 6
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Body Fat Content (Prevention Study)
Male C57BL/6J mice (age 10 weeks at time 0) were divided into matched groups (n=6) based on body weight and body composition, and treated by subcutaneous injections twice a week with saline, ISIS 141923, (SEQ ID NO: 173, a control oligonucleotide) or ISIS 393250 (SEQ ID NO: 18, FGFR4 antisense oligonucleotide). The mice were treated at a dose of 25 mg/kg twice a week of ISIS 141923 or 25 mg/kg ISIS 393250, or with volume of saline. A group of mice fed normal chow also received subcutaneous injections of saline twice weekly. Treatment was continued for 12 weeks. Body fat content was measured at weeks 0, 6, 9.5 and 11. The results are presented in Table 11 and 12.







TABLE 11







Antisense inhibition of FGFR4 on total body fat content (g)


(Prevention study)


Body fat content (g)









weeks:














mean







0
6
9.5
11
















saline
4.66
8.93
11.20
11.93



141923 -
4.55
7.69
8.15
8.21



Control







393250 -
4.28
5.25
4.91
4.67



FGFR4







chow-saline

3.16
3.35
3.54









The mice on the high fat diet treated with ISIS 393250 (SEQ ID NO: 18) showed no increase in body fat content (maintained body fat at a constant level), starting at 4.28 g at week 0 and ending at 4.67 g at week 11. Saline treated animals on the high fat diet showed a significant increase in body fat content starting at 4.66 g at week 0 and ending at 11.93 g at week 11. The mice on the high fat diet treated with the control antisense oligonucleotide, ISIS 141923, demonstrated a similar increase in body fat content to that in the saline treated mice, starting at 4.55 g at week 0 and ending at 8.21 g at week 11. The lean body mass remained relatively unchanged. The mice on the chow diet showed no significant change in body fat content starting at 3.16 g at week 6 and ending at 3.54 g at week 11.







TABLE 12







Antisense inhibition of FGFR4 on total body fat content (%)


Percentage body fat content (%)









weeks:














mean







0
6
9.5
11
















saline
17.7
27.1
31.0
32.0



141923-
17.3
23.6
24.0
23.8



Control







393250-
16.1
17.3
16.1
15.3



FGFR4







chow-saline

12.2
12.6
12.9









Mice on the high fat diet treated with ISIS 393250 showed a decrease in percent body fat content starting at 16.1% at week 0 and ending at 15.3% at week 11. Saline treated animals on the high fat diet showed a significant increase in percent body fat content starting at 17.7% at week 0 and ending at 32.0% at week 11. Mice on the high fat diets treated with the control ASO, ISIS 141923, demonstrated an increase in percent body fat content starting at 17.3% at week 0 and ending at 23.8% at week 11. Mice on the chow diet showed no significant change body fat content starting at 12.2% at week 6 and ending at 12.9% at week 11.
In Vivo Pharmacology (Reversal Study)
Example 7
Antisense Inhibition of FGFR4 Levels: In Vivo Studies in a Diet-Induced Model of Obesity (Reversal Study)
The C57BL/6 mouse strain is reported to be susceptible to weight gain when fed a high-fat diet. Accordingly, these mice were fed a high-fat diet for 3 months and then used in the following studies to evaluate the effects of FGFR4 antisense oligonucleotides on mRNA expression in liver and fat tissues in a diet-induced model of obesity.
Male C57BL/6 mice at 4 weeks of age were placed on a high-fat diet containing 58% calories from fat (Research Diet D12492, Research Diets Inc., New Brunswick, N.J.) for 3 months. The mice were divided into three treatment groups. One group received subcutaneous injections of ISIS 393250 (SEQ ID NO: 18) at a dose of 25 mg/kg twice per week for 9.5 weeks. The second group received subcutaneous injections of ISIS 141923 (SEQ ID NO: 173) at a dose of 25 mg/kg twice per week for 9.5 weeks. Oligonucleotides were dissolved in 0.9% saline for injection. The third group of mice received subcutaneous injections of saline twice weekly for 9.5 weeks. The saline-injected group served as the control group to which the oligonucleotide-treated groups were compared.
After the 9.5 week treatment period, the mice were sacrificed and FGFR4 mRNA levels were evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT). mRNA expression levels were quantitated by real-time PCR as described in other examples herein. The results are presented in Table 13 and are expressed as percent inhibition relative to saline-treated mice receiving a high fat diet.







TABLE 13







Antisense inhibition of FGFR4 mRNA expression in liver and


fat tissues (Reversal study)









% Inhibition of



FGFR4 mRNA














Brown
White



ISIS #
Liver
Fat tissue
Fat tissue















Saline-58% HF
0
0
0



FGFR4 393250
−77.6
−69.2
−44.5



Control 141923
−7.7
−18.2
−11.2









FGFR4 antisense oligonucleotide treatment, but not control antisense oligonucleotide treatment, reduced FGFR4 mRNA levels by  ̃80%, 70% and 45% in liver, brown adipose tissue and white adipose tissue, respectively. The data demonstrate that FGFR4 antisense oligonucleotide treatment can effectively inhibit target mRNA expression in liver, brown adipose tissue and white adipose tissue.
Example 8
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Body Weight (Reversal Study)
Male C57BL/6J mice, 4 weeks of age, were placed on a high-fat diet containing 58% calories from fat (Research Diet D12492, Research Diets Inc., New Brunswick, N.J.) for 3 months. The mice were divided into three groups (n=6) with the same starting average blood glucose levels, body weight, and body composition and treated by subcutaneous injection twice a week with saline, ISIS 141923 (the control oligonucleotide) or ISIS 393250. The mice were treated at a dose of 25 mg/kg of ISIS 141923 or ISIS 393250, or similar volume of saline. Treatment was continued for 9.5 weeks. At day 84 mice were sacrificed and the tissues were collected and weighed. The results are presented in Table 14.







TABLE 14







Effect of Antisense inhibition of FGFR4 gene expression on total


body weight in Diet-induced Obese mice (Reversal study)


Body weight (g)










mean










Weeks:


















0
1
2
3
4
5
6
7
8
9





















saline
39.7
40.7
41.1
40.9
39.7
39.9
40.4
40.2
40.4
40.1


141923-
41.3
43.2
43.8
43.4
41.7
41.7
41.2
40.4
39.9
38.8


control


393250-
40.8
42.6
42.9
42.5
40.7
40.1
39.3
37.4
36.6
35.2


FGFR4









Treatment of C57BL/6J mice with ISIS 393250 resulted in a decrease in body weight, with animals losing an average of 5.6 grams while saline treated controls remained relatively unchanged (gained 0.4 grams). Animals treated with the control oligonucleotide lost an average of 2.5 grams of body weight.
Therefore, FGFR4 antisense oligonucleotide treatment lowered body weight by  ̃10% (35.2±0.7 vs. 40.1±1.8 g in saline group; P<0.05), but it did not change lean body mass.
Example 9
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Body Fat Content (Reversal Study)
Male C57BL/6J mice (4 weeks of age weeks at time 0) were fed a 58% high-fat diet for 3 months and then divided into matched groups (n=6) with the same average blood glucose levels, body weight, and body composition, and treated by subcutaneous injections twice a week with saline, or 25 mg/kg twice a week of ISIS 141923 or ISIS 393250. Treatment was continued for 9.5 weeks. Body fat content was measured at weeks 0, 3.5, 7.5 and 9.5. The results are presented in Table 15 and 16.







TABLE 15







Antisense inhibition of FGFR4 on total body fat content (g)


(Reversal study)


Whole body fat content (g)









Weeks:














mean







0
3.5
7.5
9.5
















saline
14.63
15.74
15.60
15.26



141923-control
14.94
16.38
14.14
12.15



393250-FGFR4
14.81
14.86
10.88
8.21









The mice on the high fat diet treated with ISIS 393250 showed a significant decrease in body fat content, starting at 14.81 g at week 0 and ending at 8.21 g at week 9.5. Saline treated animals on the high fat diet showed no decrease in body fat content starting at 14.63 g at week 0 and ending at 15.26 g at week 9.5. The mice on the high fat diet treated with the control ASO, ISIS 141923, demonstrated a slight decrease in body fat content, starting at 14.94 g at week 0 and ending at 12.15 at week 9.5.
FGFR4 antisense oligonucleotide treatment lowered epididymal fat pad weight by  ̃40% (1.41±0.06 vs. 2.37±0.15 g in saline group; P<0.001), peri-renal fat pad weight by  ̃62% (0.40±0.03 vs. 1.06±0.09 g in saline group; P<0.001) and whole body fat content by  ̃44% (8.21±0.55 vs. 15.25±1.12 g in saline group; P<0.001), but did not change lean body mass.







TABLE 16







Effect of Antisense inhibition of FGFR4 on total body fat content (%)


(Reversal study)


fat/BW (%)









Weeks:














mean







0
3.5
7.5
9.5
















saline
36.5
37.7
37.9
37.0



141923-
36.1
37.1
34.5
30.9



control







393250-
36.1
34.6
29.1
23.0



FGFR4









Mice on the high fat diet treated with ISIS 393250 showed a decrease in body fat content starting at 36.1% at week 0 and ending at 23% at week 9.5. Saline treated animals showed no decrease in body fat content starting at 36.5% at week 0 and ending at 37.0% at week 9.5. Mice on the high fat diet treated with the control antisense oligonucleotide, ISIS 141923, demonstrated a slight decrease in body fat content starting at 36.1% at week 0 and ending at 30.9% at week 9.5. FGFR4 antisense oligonucleotide treated animals demonstrated a significant decrease in body fat content after 9.5 weeks showing almost a 13% reduction.

Example 10
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Blood Glucose Levels (Reversal Study)
A glucose tolerance test in medical practice is the administration of glucose to determine how quickly it is cleared from the blood and is used to test for diabetes. Blood was obtained from the Diet Induced Obese (DIO) C57BL/6J mice and analyzed for glucose concentration. The results are shown in Table 17, illustrating changes in fasting plasma glucose levels at Week 6. For the Insulin Tolerance Test (ITT), food was withdrawn at 9:15 am and ITT was started from 1:30 pm. The Insulin dose was 0.5 U/kg. For the Intraperitoneal Glucose Treatment test (IPGTT), mice were fasted overnight and IPGTT was started from 8:30 am. The Glucose dose was 1.00 g/kg. The results are shown in Tables 18.







TABLE 17







IPGTT to determine glucose tolerance at


Week 6 in DIO mice (Reversal study)


Glucose mg/dL














mean







ISIS #
0 mins
20 mins
40 mins
70 mins
100 mins
130 mins
















saline
112.5
292.4
359.8
249.1
205.8
166.3


141923-
96.0
244.4
265.0
173.5
136.3
117.3


control


393250-
109.3
222.0
184.6
138.3
135.3
119.1


FGFR4









In response to glucose challenge, animals treated with ISIS 393250 show improved glucose tolerance. Peak plasma glucose level at the 30 minute time point was decreased by over 50% from the saline treated control and the subsequent drop in glucose was enhanced compared to controls, indicating that inhibition of FGFR4 by antisense improved glucose tolerance. The results indicated that glucose was cleared much more quickly from the blood of mice treated with ISIS 393250 relative to the control groups. This indicates that inhibition of FGFR4 by antisense may increase glucose tolerance and, therefore, may be useful for treating, preventing and/or ameliorating disorders of or associated with glucose intolerance and/or insulin resistance, such as, obesity, metabolic syndrome, diabetes, and hyperglycemia. See also FIG. 3.







TABLE 18







ITT to determine insulin sensitivity at Week


5.5 in DIO Mice (Reversal study)


Glucose mg/dL













mean






ISIS #
0 mins
30 mins
60 mins
90 mins
120 mins















saline
128.1
95.3
85.1
115.6
134.1


141923-
119.6
87.4
91.4
109.4
133.3


control


393250-
116.9
74.8
71.1
96.3
126.3


FGFR4









An insulin tolerance test was also completed. There was an increase in rate and magnitude of glucose lowering after injecting insulin in the animals treated with ISIS 393250. Glucose levels are reduced during ITT in mice treated with ISIS 393250 compared to saline treated control, indicating an increase in insulin sensitivity. See also FIG. 2.

Example 11
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Metabolic Rate (Reversal Study)
Male C57BL/6J mice were subjected to measurements of metabolic rates at the 8 week time point by known methods. The metabolic rate (as measured by oxygen consumption rate, VO2-ml/hr/kg) was measured in both light and dark phases as shown in Table 19.







TABLE 19







Metabolic rates VO2 (ml/hr/kg) at Week 8


Metabolic rate - (VO2-ml/hr/kg) at week 8












mean





dark
light














Saline
3082.8
2686.0



141923-control
3090.4
2709.7



393250-FGFR4
3459.3
2865.0









As shown in Table 19, treatment with ISIS 393250 caused an increase in the metabolic rate in both light and dark phases compared to either the saline treated or ISIS 141923 treated controls. The data indicate that the mice treated with ISIS 393250 had a higher metabolic rate than the mice of the control groups. Specifically, ISIS 393250 increased metabolic rate by about 11% (dark) and 7% (Light) at 8 weeks compared to saline treated controls, while the respiratory quotient remained relatively unchanged (See FIG. 1). This indicates that ISIS 393250 may be useful for increasing metabolic rates and, in turn, reducing body weight and body fat. For the animals treated with ISIS 393250 in this example, a reduction in body weight and body fat (data shown in Examples 7 and 8) can be seen at 7.5 weeks of treatment. The compounds provided herein are therefore useful in the treatment, prevent and/or amelioration of obesity, metabolic syndrome and related disorders.
Example 12
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Adipose Tissue Weight (Reversal Study)
Male C57BL/6J mice were subjected to measurement of tissue weight by known methods. The tissue weight of epididymal white adipose tissue (epiWAT), perirenal white adipose tissue (periWAT), and brown adipose tissue (BAT) were measured, as shown in Table 20.







TABLE 20







Tissue weight (g)


Tissue wt (g):











Mean





epididymal
peri-renal




WAT
WAT
BAT















saline
2.37
1.06
0.22



141923-
1.93
0.74
0.20



control






393250-
1.41
0.40
0.17



FGFR4









The data indicate that the antisense oligonucleotides are effective at reducing adipose tissue weight. The tissue weight of epididymal white adipose tissue (epiWAT), perirenal white adipose tissue (periWAT), and brown adipose tissue (BAT) were all lowered with the treatment of Isis 393250-FGFR4 antisense oligonucleotide compared to the saline counterpart within each adipose tissue type. The epididymal white adipose tissue (epiWAT) weight treated with Isis 393250-FGFR4 antisense oligonucleotide was decreased by  ̃40% compared to the saline treated control group. The peri-renal white adipose tissue (periWAT) weight treated with Isis 393250-FGFR4 antisense oligonucleotide was decreased by  ̃62% compared to the saline treated control group. The brown adipose tissue (BAT) weight treated with Isis 393250-FGFR4 antisense oligonucleotide was decreased by  ̃23% compared to the saline treated control group.
Example 13
Effects of Antisense Inhibition of FGFR4 with ISIS 393250 on Differentiation and Proliferation and Cell Size in White Adipose Tissue (Reversal Study)
Obesity is characterized by an excess of subcutaneous fat in proportion to lean body mass. In obesity, adipose tissue, as opposed to most tissues in the body, will continue to grow. Growth of the adipose tissue results from both the enlargement of mature adipocytes and the formation of new adipocytes from adipocyte precursor cells (preadipocytes). Thus, fat accumulation is associated with increase in the size (hypertrophy) as well as the number (hyperplasia) of adipose tissue cells.
As indicated by the description of fat accumulation above, the lowered body fat content is partially due to a decrease in adipocyte size (see FIG. 4). ISIS 393250 caused a reduction in white adipose tissue cell size compared to the saline and ISIS 141923 treated white adipose tissue, indicating a potential effect on adipocyte proliferation or differentiation.
Example 14
Dose Response Antisense Inhibition of Human FGFR4 in A549 Cells, Primer Probe Set RTS1325
Several antisense oligonucleotides exhibiting at least 80% in vitro inhibition of FGFR4 were tested at various doses in A549 cells. Cells were plated at densities of 5500 cells per well and treated with nM concentrations of antisense oligonucleotide as indicated in Table 21. After a treatment period of approximately 24 hours, RNA was isolated from the cells and FGFR4 mRNA levels were measured by quantitative real-time PCR, as described herein. Human FGFR4 primer probe set RTS1325 was used to measure mRNA levels. FGFR4 mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN®. Results are presented as percent inhibition of FGFR4, relative to untreated control cells. As illustrated in Table 21, FGFR4 mRNA levels were reduced in a dose-dependent manner.







TABLE 21







Antisense Inhibition of human FGFR4 in A549 cells,


Primer Probe Set RTS1325















ISIS No
2.4 nM
4.7 nM
9.4 nM
18.8 nM
37.5 nM
75.0 nM
150.0 nM
300.0 nM


















299043
6
5
28
28
48
63
68
76


299062
8
40
44
53
78
84
94
97


299004
8
33
48
71
84
95
96
95


299038
6
35
34
42
73
84
87
85


299046
13
34
35
40
60
79
81
78


299055
11
19
37
52
71
88
91
92


299047
20
31
42
56
62
81
86
83


141923
33
14
8
5
0
3
8
18


(control)

## Claims

1. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising a portion which consists of at least 8 contiguous nucleobases complementary to an equal-length portion of nucleobases 192 to 227 of SEQ ID NO: 5.

2. The compound of claim 1, wherein the modified oligonucleotide is a single-stranded oligonucleotide.

3. The compound of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO 5.

4. The compound of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to SEQ ID NO 5.

5. The compound of claim 1, wherein at least one internucleoside linkage is a modified internucleoside linkage.

6. The compound of claim 5, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

7. The compound of claim 1, wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.

8. The compound of claim 7, wherein the at least one modified sugar is a bicyclic sugar.

9. The compound of claim 8, wherein at least one modified sugar comprises a 2′-O-methoxyethyl.

10. The compound of claim 1, wherein at least one nucleoside comprises a modified nucleobase.

11. The compound of claim 10, wherein the modified nucleobase is a 5-methylcytosine.

12. The compound of claim 7, wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

13. The compound of claim 1, consisting of a single-stranded modified oligonucleotide.

14. A method comprising administering to an animal the compound of claim 1.

15. The method of claim 14, wherein the animal is a human.

16. The method of claim 15 wherein administering the compound slows progression and/or ameliorates diabetes, obesity or metabolic syndrome.

17. The method of claim 16, wherein diabetes is Type 2 diabetes.

18. The method of claim 14, comprising co-administering the compound and an anti-obesity agent, glucose-lowering agent, or anti-psychotic agent.

19. The method of claim 18, wherein the compound and an anti-obesity agent, glucose-lowering agent, or anti-psychotic agent are administered concomitantly.

20. The method of claim 14, wherein the administering is parenteral administration.

21. A method comprising administering to a human with diabetes, obesity or metabolic syndrome a therapeutically effective amount of the compound of claim 1.

22. The method of claim 21, wherein administering results in a reduction of obesity, body weight, body fat content, glucose, insulin resistance or an increase in metabolic rate or insulin sensitivity or any combination thereof.

23. The method of claim 22, wherein the reduction in body fat content is a reduction in adipocyte size or adipocyte proliferation or a combination thereof.

24. The method of claim 23, comprising co-administering the compound and an anti-obesity agent, glucose-lowering agent, or anti-psychotic agent.

25. The method of claim 21, wherein administering the compound slows progression and/or ameliorates obesity, diabetes, or metabolic syndrome.